<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antiplatelet agents for preventing pre‐eclampsia and its complications - Duley, L - 2019 | Cochrane Library</title> <meta content="Antiplatelet agents for preventing pre‐eclampsia and its complications - Duley, L - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004659.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antiplatelet agents for preventing pre‐eclampsia and its complications - Duley, L - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004659.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004659.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Antiplatelet agents for preventing pre‐eclampsia and its complications" name="citation_title"/> <meta content="Lelia Duley" name="citation_author"/> <meta content="Nottingham Health Science Partners" name="citation_author_institution"/> <meta content="lelia.duley@nottingham.ac.uk" name="citation_author_email"/> <meta content="Shireen Meher" name="citation_author"/> <meta content="Birmingham Women's Hospital" name="citation_author_institution"/> <meta content="Kylie E Hunter" name="citation_author"/> <meta content="University of Sydney" name="citation_author_institution"/> <meta content="Anna Lene Seidler" name="citation_author"/> <meta content="University of Sydney" name="citation_author_institution"/> <meta content="Lisa M Askie" name="citation_author"/> <meta content="University of Sydney" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD004659.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/10/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004659.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004659.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004659.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Aspirin [therapeutic use]; Gestational Age; Infant, Small for Gestational Age; Maternal Mortality; Platelet Aggregation Inhibitors [*therapeutic use]; Pre‐Eclampsia [drug therapy, *prevention &amp; control]; Premature Birth [prevention &amp; control]; Prenatal Care [*methods]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004659.pub3&amp;doi=10.1002/14651858.CD004659.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004659\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004659\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","th","ms","fa","fr","zh_HANS","de","zh_HANT","ko","pt","ja"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004659.pub3",title:"Antiplatelet agents for preventing pre\\u2010eclampsia and its complications",firstPublishedDate:"Oct 30, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004659.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004659.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004659.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004659.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004659.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004659.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004659.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004659.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004659.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004659.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>25321 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004659.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-sec-0148"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-sec-0090"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-sec-0142"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/appendices#CD004659-sec-0153"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/table_n/CD004659StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/table_n/CD004659StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antiplatelet agents for preventing pre‐eclampsia and its complications</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/information#CD004659-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Lelia Duley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/information#CD004659-cr-0003">Shireen Meher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/information#CD004659-cr-0004">Kylie E Hunter</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/information#CD004659-cr-0005">Anna Lene Seidler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004659.pub3/information#CD004659-cr-0006">Lisa M Askie</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/information/en#CD004659-sec-0163">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 October 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004659.pub3">https://doi.org/10.1002/14651858.CD004659.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004659-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004659-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004659-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004659-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004659-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD004659-abs-0017">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004659-abs-0019">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD004659-abs-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004659-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004659-abs-0001" lang="en"> <section id="CD004659-sec-0001"> <h3 class="title" id="CD004659-sec-0001">Background</h3> <p>Pre‐eclampsia is associated with deficient intravascular production of prostacyclin, a vasodilator, and excessive production of thromboxane, a vasoconstrictor and stimulant of platelet aggregation. These observations led to the hypotheses that antiplatelet agents, low‐dose aspirin in particular, might prevent or delay development of pre‐eclampsia. </p> </section> <section id="CD004659-sec-0002"> <h3 class="title" id="CD004659-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of antiplatelet agents, such as aspirin and dipyridamole, when given to women at risk of developing pre‐eclampsia. </p> </section> <section id="CD004659-sec-0003"> <h3 class="title" id="CD004659-sec-0003">Search methods</h3> <p>For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register, <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) (30 March 2018), and reference lists of retrieved studies. We updated the search in September 2019 and added the results to the awaiting classification section of the review. </p> </section> <section id="CD004659-sec-0004"> <h3 class="title" id="CD004659-sec-0004">Selection criteria</h3> <p>All randomised trials comparing antiplatelet agents with either placebo or no antiplatelet agent were included. Studies only published in abstract format were eligible for inclusion if sufficient information was available. We would have included cluster‐randomised trials in the analyses along with individually‐randomised trials, if any had been identified in our search strategy. Quasi‐random studies were excluded. Participants were pregnant women at risk of developing pre‐eclampsia. Interventions were administration of an antiplatelet agent (such as low‐dose aspirin or dipyridamole), comparisons were either placebo or no antiplatelet. </p> </section> <section id="CD004659-sec-0005"> <h3 class="title" id="CD004659-sec-0005">Data collection and analysis</h3> <p>Two review authors assessed trials for inclusion and extracted data independently. For binary outcomes, we calculated risk ratio (RR) and its 95% confidence interval (CI), on an intention‐to‐treat basis. For this update we incorporated individual participant data (IPD) from trials with this available, alongside aggregate data (AD) from trials where it was not, in order to enable reliable subgroup analyses and inclusion of two key new outcomes. We assessed risk of bias for included studies and created a 'Summary of findings' table using GRADE. </p> </section> <section id="CD004659-sec-0006"> <h3 class="title" id="CD004659-sec-0006">Main results</h3> <p>Seventy‐seven trials (40,249 women, and their babies) were included, although three trials (relating to 233 women) did not contribute data to the meta‐analysis. Nine of the trials contributing data were large (&gt; 1000 women recruited), accounting for 80% of women recruited. Although the trials took place in a wide range of countries, all of the nine large trials involved only women in high‐income and/or upper middle‐income countries. IPD were available for 36 trials (34,514 women), including all but one of the large trials. Low‐dose aspirin alone was the intervention in all the large trials, and most trials overall. Dose in the large trials was 50 mg (1 trial, 1106 women), 60 mg (5 trials, 22,322 women), 75mg (1 trial, 3697 women) 100 mg (1 trial, 3294 women) and 150 mg (1 trial, 1776 women). Most studies were either low risk of bias or unclear risk of bias; and the large trials were all low risk of bas. </p> <p><b>Antiplatelet agents versus placebo/no treatment</b> </p> <p>The use of antiplatelet agents reduced the risk of <b>proteinuric pre‐eclampsia</b> by 18% (36,716 women, 60 trials, RR 0.82, 95% CI 0.77 to 0.88; high‐quality evidence), number needed to treat for one women to benefit (NNTB) 61 (95% CI 45 to 92). There was a small (9%) reduction in the RR for <b>preterm birth &lt;37 weeks</b> (35,212 women, 47 trials; RR 0.91, 95% CI 0.87 to 0.95, high‐quality evidence), NNTB 61 (95% CI 42 to 114), and a 14% reduction in<b>fetal deaths, neonatal deaths or death before hospital discharge</b> (35,391 babies, 52 trials; RR 0.85, 95% CI 0.76 to 0.95; high‐quality evidence), NNTB 197 (95% CI 115 to 681). Antiplatelet agents slightly reduced the risk of <b>small‐for‐gestational age</b> babies (35,761 babies, 50 trials; RR 0.84, 95% CI 0.76 to 0.92; high‐quality evidence), NNTB 146 (95% CI 90 to 386), and <b>pregnancies with serious adverse outcome</b> (a composite outcome including maternal death, baby death, pre‐eclampsia, small‐for‐gestational age, and preterm birth) (RR 0.90, 95% CI 0.85 to 0.96; 17,382 women; 13 trials, high‐quality evidence), NNTB 54 (95% CI 34 to 132). Antiplatelet agents probably slightly increase <b>postpartum haemorrhage &gt; 500 mL</b> (23,769 women, 19 trials; RR 1.06, 95% CI 1.00 to 1.12; moderate‐quality evidence due to clinical heterogeneity), and they probably marginally increase the risk of <b>placental abruption</b>, although for this outcome the evidence was downgraded due to a wide confidence interval including the possibility of no effect (30,775 women; 29 trials; RR 1.21, 95% CI 0.95 to 1.54; moderate‐quality evidence). </p> <p>Data from two large trials which assessed children at aged 18 months (including results from over 5000 children), did not identify clear differences in development between the two groups. </p> </section> <section id="CD004659-sec-0007"> <h3 class="title" id="CD004659-sec-0007">Authors' conclusions</h3> <p>Administering low‐dose aspirin to pregnant women led to small‐to‐moderate benefits, including reductions in pre‐eclampsia (16 fewer per 1000 women treated), preterm birth (16 fewer per 1000 treated), the baby being born small‐for‐gestational age (seven fewer per 1000 treated) and fetal or neonatal death (five fewer per 1000 treated). Overall, administering antiplatelet agents to 1000 women led to 20 fewer pregnancies with serious adverse outcomes. The quality of evidence for all these outcomes was high. Aspirin probably slightly increased the risk of postpartum haemorrhage of more than 500 mL, however, the quality of evidence for this outcome was downgraded to moderate, due to concerns of clinical heterogeneity in measurements of blood loss. Antiplatelet agents probably marginally increase placental abruption, but the quality of the evidence was downgraded to moderate due to low event numbers and thus wide 95% CI. </p> <p>Overall, antiplatelet agents improved outcomes, and at these doses appear to be safe. Identifying women who are most likely to respond to low‐dose aspirin would improve targeting of treatment. As almost all the women in this review were recruited to the trials after 12 weeks' gestation, it is unclear whether starting treatment before 12 weeks’ would have additional benefits without any increase in adverse effects. While there was some indication that higher doses of aspirin would be more effective, further studies would be warranted to examine this. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004659-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004659-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD004659-abs-0015">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD004659-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004659-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004659-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD004659-abs-0021">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD004659-abs-0018">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004659-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004659-abs-0020">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004659-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD004659-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004659-abs-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004659-abs-0016">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004659-abs-0006" lang="en"> <h3>Antiplatelet agents for preventing pre‐eclampsia and its complications</h3> <p>We set out to assess the ability of antiplatelet agents, such as aspirin and dipyridamole, to prevent women from developing pre‐eclampsia during pregnancy and to improve health outcomes for them and their babies. We also wanted to find out whether these medicines had any undesirable effects for the mother or baby. </p> <p><b>What is the question?</b> </p> <p>Do low doses of aspirin help to prevent pre‐eclampsia, and reduce the number of preterm births before 37 weeks, small‐for‐gestational‐age babies, infant deaths and other unwanted effects? </p> <p><b>Why is this important?</b> </p> <p>Pre‐eclampsia is a condition experienced by some women during pregnancy and is evident as high blood pressure and protein in the urine. This condition can lead to serious complications for the mother and her baby (in fact, it is one of the leading causes of illness and death in pregnancy). The mother’s placenta may not be functioning properly, which limits the blood supply to the unborn baby so that it is at risk of poor growth and being born early as a result of preterm labour, or needing to be delivered early. Pre‐eclampsia affects the platelets in the women’s blood so that they are more ready to clump and cause the blood to clot. Antiplatelet drugs like aspirin prevent blood clotting and have a role in preventing pre‐eclampsia and its complications. </p> <p><b>What evidence did we find?</b> </p> <p>We searched for randomised controlled trials in March 2018. Our review includes 77 trials, involving 40,249 women and their babies, although it wasn't possible to include results form three of these trials (233 women) . We included information about the results for women and babies in two different formats: 36 trials (34,514 women) reported 'individual participant data' (IPD), where we received information about each of the individuals involved; all the other trials reported 'aggregate data' (AD), where each study reports the average information about the individuals involved in the study. By using IPD, we could conduct very thorough and accurate analyses; and by combining both the AD and the IPD, we could include all the available information on this question. </p> <p>Nine of the trials included more than 1000 women, and all of these large trials were at low risk of bias. Low‐dose aspirin alone was the intervention in all the large trials, and most trials overall. Almost all the women were recruited to the trials after 12 weeks' gestation. Most women were at risk of developing pre‐eclampsia, and the trials included women with normal blood pressure, existing long‐term high blood pressure or pregnancy‐induced high blood pressure. High‐quality evidence showed that the use of antiplatelet agents reduced the risk of pre‐eclampsia by 18%, or less than one sixth (36,716 women, 60 trials). This meant that 61 women had to be treated with an antiplatelet drug for one woman to benefit by avoiding pre‐eclampsia. The risk of preterm birth was reduced by 9% (35,212 women, 47 trials) and the number of infant deaths before or around the time of birth was reduced by 15% (35,391 women, 52 trials). Antiplatelet agents reduced the risk of small‐for‐gestational‐age babies (35,761 mothers, 50 trials) and pregnancies with serious adverse outcomes (17,382 mothers; 13 trials). Moderate‐quality evidence showed that only slightly more women lost more than 500 mL of blood immediately after birth, termed postpartum haemorrhage (23,769 mothers, 19 trials), indicating that aspirin is safe. Doses of aspirin less than 75 mg appear to be safe. Higher doses might be better, but we do not know whether they increase adverse effects. </p> <p><b>What does this mean?</b> </p> <p>Low doses of aspirin slightly reduce the risk of pre‐eclampsia and its complications. As most women in this review were in trials evaluating low‐dose aspirin, the reassurance about the safety of aspirin may not apply to higher doses or other antiplatelet agents. Further research should aim to identify women who are most likely to respond to low‐dose aspirin treatment. While it is possible that higher doses of aspirin may be more effective, further studies are needed to determine whether higher doses are both more effective and safe for women and babies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004659-sec-0148" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004659-sec-0148"></div> <h3 class="title" id="CD004659-sec-0149">Implications for practice</h3> <section id="CD004659-sec-0149"> <p>Administration of antiplatelet agents leads to a 17% reduction in the relative risk of developing pre‐eclampsia. For primary prevention of pre‐eclampsia, for every 64 women treated, one case of pre‐eclampsia will be prevented. For women who are at high risk, the results suggest that one case of pre‐eclampsia will be prevented for every 39 treated. There are also smaller risk reductions associated with the use of antiplatelet agents of preterm birth (9%), with 61 women needing to be treated to prevent one case, and of fetal or neonatal death (14%) with 213 women needing to be treated to prevent one case. Adverse effects appear to be low although data were not reported by all trials. The results suggest a slight increase in postpartum haemorrhage of &gt; 500 mL. Overall, there was a 10% reduction in pregnancies with serious adverse outcomes. </p> <p>As most women in this review were in trials evaluating low‐dose aspirin, the reassurance about safety may not apply to higher doses or other agents. However, there was some indication that higher doses may be more effective in preventing pre‐eclampsia. The evidence presented in this review may be summarised and made available to women at risk of pre‐eclampsia. The decision about whether to take aspirin during pregnancy may then be made in consultation between the woman and her doctor. As the reductions in risk are small to moderate, relatively large numbers of women will need to be treated to prevent pre‐eclampsia and its consequences. However, from a public health perspective these moderate benefits are likely to be worthwhile, and low‐dose aspirin may be worth considering for more widespread use. </p> </section> <h3 class="title" id="CD004659-sec-0150">Implications for research</h3> <section id="CD004659-sec-0150"> <p>Identifying women who are most likely to respond to low‐dose aspirin would allow improved targeting of treatment. As almost all the women in this review were recruited to the trials after 12 weeks' gestation, it is unclear whether starting treatment before 12 weeks would have additional benefits without any increase in adverse effects. While there was some indication that higher doses of aspirin would be more effective, further studies would be warranted to examine whether a higher dose would be more effective and safe. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004659-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004659-sec-0036"></div> <div class="table" id="CD004659-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antiplatelet agents compared with no antiplatelet agents/placebo for pre‐eclampsia prevention</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> pregnant women <i>considered to be at risk of developing pre‐eclampsia</i> </p> <p><b>Settings:</b> maternity hospitals, recruitment usually in ante natal clinics </p> <p><b>Intervention:</b><i>any antiplatelet agent (such as low‐dose aspirin or dipyridamole)</i> </p> <p><b>Comparison:</b><i>no treatment with antiplatelet agents/placebo</i> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo/no antiplatelet</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antiplatelet agents</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proteinuric pre‐eclampsia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>16 fewer per 1000</b> </p> <p>(22 fewer to 11 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> </p> <p>(0.77 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36,716<br/> (60 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any reported infant death (fetal, neonatal, or before hospital discharge</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>5 fewer per 1000</b> </p> <p>(9 fewer to 1 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> </p> <p>(0.76 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,391</p> <p>(52 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Preterm birth</b> </p> <p>(before 37 weeks' gestation)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>175 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>16 fewer per 1000</b> </p> <p>(23 fewer to 9 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b> </p> <p>(0.87 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,212<br/> (47 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Small‐for‐gestational age</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>7 fewer per 1000</b> </p> <p>(11 fewer to 3 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b> </p> <p>(0.76 to 0.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,761<br/> (50 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy with serious adverse outcome (composite including maternal death, baby death, pre‐eclampsia, small‐for‐gestational age, preterm birth) ‐ only trials with individual participant data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>197 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>20 fewer per 1000</b> </p> <p>(30 fewer to 8 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> </p> <p>(0.85 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,382</p> <p>(13 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Postpartum haemorrhage &gt; 500 mL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>9 more per 1000</b> </p> <p>(0 fewer to 19 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> </p> <p>(1.00 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,769</p> <p>(19 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placental abruption</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>2 more per 1000</b> </p> <p>(0 fewer to 4 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> </p> <p>(0.95 to 1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30,775</p> <p>(29 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Although this effect estimate did not meet our threshold for statistical heterogeneity (threshold i<sup>2</sup> = 40%), we downgraded due to concerns about clinical heterogeneity between trials in methods for measurement of blood loss (‐1). </p> <p>b. Wide confidence interval including appreciable harm for antiplatelet agents and crossing line of no effect (‐1). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004659-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004659-sec-0037"></div> <section id="CD004659-sec-0038"> <h3 class="title" id="CD004659-sec-0038">Description of the condition</h3> <p>Pre‐eclampsia is defined as high blood pressure (hypertension) associated with proteinuria (protein in the urine) (<a href="./references#CD004659-bbs2-0227" title="GiffordRWJr , AugustPA , CunninghamG , GreenLA , LindhemierMD , McNellisD , et al. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. American Journal of Obstetrics and Gynecology2000;183(Suppl):1‐22. ">Gifford 2000</a>). It occurs in the second half of pregnancy and complicates between 2% to 8% of pregnancies (<a href="./references#CD004659-bbs2-0210" title="AnanthCV , KeyesKM , WapnerRJ . Pre‐eclampsia rates in the United States, 1980–2010:age‐period‐cohort analysis. BMJ2013;347:f6564. ">Ananth 2013</a>; <a href="./references#CD004659-bbs2-0212" title="AugerN , LuoZC , NuytAM , KaufmanJS , NaimiAI , PlattRW , et al. Secular Trends in Preeclampsia Incidence and Outcomes in a Large Canada Database: A Longitudinal Study Over 24 Years. Canadian Journal of Cardiology2016;32:987.e15‐23. ">Auger 2016</a>; <a href="./references#CD004659-bbs2-0263" title="ThorntonC , DahlenH , KordaA , HennessyA . The incidence of preeclampsia and eclampsia and associated maternal mortality in Australia from population‐linked datasets: 2000‐2008. American Journal of Obstetrics and Gynecology2013;208:476.e1‐5. ">Thornton 2013</a>; <a href="./references#CD004659-bbs2-0271" title="World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Geographic variation in the incidence of hypertension in pregnancy. American Journal of Obstetrics and Gynecology1988;158:80‐3. ">WHO 1988</a>). Pre‐eclampsia can also affect other maternal organs, leading to problems in liver, kidneys and brain, and to abnormalities of the clotting system (<a href="./references#CD004659-bbs2-0241" title="MolBW , RobertsCT , ThangaratinamS , MageeLA , deGrootCJM , HofmeyrGJ . Pre‐eclampsia. Lancet2016;387(10022):999‐1011. ">Mol 2016</a>). As the placenta is also involved, there are increased risks for the baby (<a href="./references#CD004659-bbs2-0241" title="MolBW , RobertsCT , ThangaratinamS , MageeLA , deGrootCJM , HofmeyrGJ . Pre‐eclampsia. Lancet2016;387(10022):999‐1011. ">Mol 2016</a>). The most common are poor growth due to inadequate blood supply through the damaged placenta, and the problems of prematurity (related either to the spontaneous onset of preterm labour or to early delivery to protect the mother or the fetus) (<a href="./references#CD004659-bbs2-0258" title="SaigalS , DoyleLW . An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet2008;371(9608):261‐9. ">Saigal 2008</a>). Pre‐eclampsia is discussed in more detail in the generic protocol of interventions for preventing pre‐eclampsia (<a href="./references#CD004659-bbs2-0237" title="MeherS , DuleyL , Prevention of Pre‐eclampsia Cochrane ReviewAuthors . Interventions for preventing pre‐eclampsia and its consequences: generic protocol. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD005301] ">Meher 2005</a>). </p> <p>High blood pressure is common during pregnancy, and around 10% of women will have their blood pressure recorded as above normal at some point before delivery (<a href="./references#CD004659-bbs2-0242" title="National Collaborating Centre for Women's and Children's Health (UK). Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. London: RCOG Press, 2010. ">NICE 2010</a>). For women who develop raised blood pressure but have no proteinuria or any other complication, pregnancy outcome is similar to that for women who have normal blood pressure. Raised blood pressure alone occurring for the first time during pregnancy is known as gestational hypertension, or pregnancy‐induced hypertension (<a href="./references#CD004659-bbs2-0265" title="TranquilliAL , DekkerG , MageeL , RobertsJ , SibaiBM , SteynW , et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregancy Hypertension2014;4:97‐104. ">Tranquilli 2014</a>). One of the difficulties in caring for women with gestational hypertension is that it is so common, and there is no reliable way of predicting who will progress to more severe disease. Therefore, very large numbers of these women are admitted to hospital or to day‐care units for assessment, or receive antenatal care designed for high‐risk women. Women with gestational hypertension or mild pre‐eclampsia usually feel well. It is only when blood pressure is very high (greater than 160 mmHg systolic or greater than 110 mmHg diastolic) or they develop symptoms of severe pre‐eclampsia, such as headache, epigastric pain or visual disturbances, that they may feel unwell. </p> <p>Although the outcome following pre‐eclampsia or eclampsia (the rare occurrence of seizures superimposed on pre‐eclampsia) is good for most women, particularly in high‐income settings, these conditions remain major causes of maternal mortality (<a href="./references#CD004659-bbs2-0260" title="SayL , ChouD , GemmillA , TunçalpÖ , MollerAB , DanielsJ , et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health2014;2(6):e323‐e333. ">Say 2014</a>). A quarter of a million women die each year of pregnancy‐related causes, and 99% of these deaths occur in low‐ and middle‐income countries (<a href="./references#CD004659-bbs2-0233" title="MahlerH . The safe motherhood initiative: a call to action. Lancet1987;i:668‐70. ">Mahler 1987</a>; <a href="./references#CD004659-bbs2-0254" title="RosenfieldA , MaineD . Maternal mortality ‐ a neglected tragedy. Lancet1985;ii:83‐5. ">Rosenfield 1985</a>; <a href="./references#CD004659-bbs2-0273" title="World Health Organization. World Health Statistics 2014. Millennium Development Goals (MDGs). http://www.who.int/mediacentre/factsheets/fs290/en/ (accessed 11th September, 2014). ">WHO 2014</a>). An estimated 9% to 26% of the maternal deaths in low‐ and middle‐income countries are associated with hypertensive disorders of pregnancy (<a href="./references#CD004659-bbs2-0225" title="DuleyL . Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. British Journal of Obstetrics and Gynaecology1992;99:547‐53. ">Duley 1992a</a>; <a href="./references#CD004659-bbs2-0272" title="KhanKS , WojdylaD , SayL , GülmezogluAM , VanLookPF . WHO analysis of causes of maternal death: a systematic review. Lancet2006;367(6516):1066‐74. ">WHO 2006</a>), as are 18% of the direct obstetric deaths in the UK (<a href="./references#CD004659-bbs2-0218" title="Centre for Maternal and Child Enquiries (CMACE). Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer: 2006–08. The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG: an international journal of obstetrics and gynaecology2011;118(Suppl):1‐203. ">CMACE UK 2011</a>). Perinatal mortality is also increased (<a href="./references#CD004659-bbs2-0209" title="AnanthCV , SavitzDA , BowesWA . Hypertensive disorders of pregnancy and stillbirth in North Carolina, 1988‐1991. Acta Obstetricia et Gynecologica Scandinavica1995;74:788‐93. ">Ananth 1995</a>; <a href="./references#CD004659-bbs2-0224" title="Department of Health. Confidential Enquiry into Stillbirths and Deaths in Infancy: 3rd Annual Report. London: Department of Health, 1996. ">Dept of Health 1996</a>). There is little good quality information about morbidity for either mother or baby, but it is likely that this too is high. </p> </section> <section id="CD004659-sec-0039"> <h3 class="title" id="CD004659-sec-0039">Description of the intervention</h3> <p>Antiplatelet drugs act by decreasing platelet aggregation and inhibiting thrombus formation. The most common antiplatelet agent is aspirin, which is also known as acetylsalicylic acid. It is widely available without prescription, usually as 300 mg tablets, and used as an anti‐inflammatory drug for minor aches and pains, and to reduce fever. Aspirin has its antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damage to the wall of blood vessels (<a href="./references#CD004659-bbs2-0207" title="Committee on obstetric practice, Society for Maternal‐Fetal Medicine. Low‐dose aspirin use during pregnancy. Obstetrics &amp; Gynaecology2018;132(1):e44‐52. ">ACOG 2018</a>). Low‐dose aspirin (usually 75 mg) is used for long‐term therapy to help prevent heart attacks, strokes and blood clots (thrombosis) in people at high risk. It is also used after heart attacks, to prevent another happening. </p> <p>Aspirin does have side effects. When taken at higher doses and for prolonged periods (in doses up to 300 mg, for more than five years), it can lead to gastrointestinal and cerebral bleeding (<a href="./references#CD004659-bbs2-0222" title="DeBerardisG , LucisanonG , D'EttorreA , PellegriniF , LeporeV , TognoniG , et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA2012;307(21):2286‐94. ">De Berardis 2012</a>). However, as aspirin for prevention of pre‐eclampsia is prescribed at the lower end of this range of doses, and for limited duration, these more serious problems are unlikely. </p> </section> <section id="CD004659-sec-0040"> <h3 class="title" id="CD004659-sec-0040">How the intervention might work</h3> <p>Pre‐eclampsia is a complex condition, and the initial cause is faulty implantation of the placenta early in pregnancy (<a href="./references#CD004659-bbs2-0269" title="UzanJ , CarbonnelM , PiconneO , AsmarR , AyoubiJ‐M . Pre‐eclampsia: pathophysiology, diagnosis, and management. Vascular Health and Risk Management2011;7:467‐74. ">Uzan 2011</a>). The primary problem is thought to be deficient trophoblast invasion of the spiral arteries in the uterus during the second trimester, leading to underperfusion of the circulation between uterus and placenta, with consequent reduction in blood flow through the placenta (placental ischaemia) (<a href="./references#CD004659-bbs2-0246" title="RedmanC . Current topic: pre‐eclampsia and the placenta. Placenta1991;12:301‐8. ">Redman 1991</a>; <a href="./references#CD004659-bbs2-0269" title="UzanJ , CarbonnelM , PiconneO , AsmarR , AyoubiJ‐M . Pre‐eclampsia: pathophysiology, diagnosis, and management. Vascular Health and Risk Management2011;7:467‐74. ">Uzan 2011</a>). The resulting placental damage is thought to lead to release of factors into the maternal circulation, which are responsible for the maternal syndrome (<a href="./references#CD004659-bbs2-0253" title="RobertsJM , HubelCA . The two stage model of preeclampsia: variations on the theme. Placenta2009;30(Suppl 1):32‐7. ">Roberts 2009</a>). Activation of platelets and the clotting system may occur early in the course of the disease, before clinical symptoms develop (<a href="./references#CD004659-bbs2-0231" title="JanesS , KyleP , RedmanC , GoodallA . Flow cytometric detection of activated platelets in pregnant women prior to the development of pre‐eclampsia. Thrombosis and Haemostasis1995;74:1059‐63. ">Janes 1995</a>; <a href="./references#CD004659-bbs2-0245" title="RedmanC , BonnarJ , BeilinL . Early platelet consumption in pre‐eclampsia. BMJ1978;1:467‐9. ">Redman 1978</a>). Deficient intravascular production of prostacyclin, a vasodilator, with excessive production of thromboxane, a platelet‐derived vasoconstrictor and stimulant of platelet aggregation (<a href="./references#CD004659-bbs2-0217" title="BussolinoF , BenedettoC , MassobrioM , CamussiG . Maternal vascular prostacyclin activity in pre‐eclampsia. Lancet1980;ii:702. ">Bussolino 1980</a>) have also been demonstrated to occur in pre‐eclampsia. </p> <p>These observations led to the hypotheses that antiplatelet agents, and low‐dose aspirin in particular, might prevent or delay the development of pre‐eclampsia and that, for women who already have the disorder, the risk of adverse events might be reduced (<a href="./references#CD004659-bbs2-0223" title="DekkerGA , Sibai BahaM . Low‐dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms, and clinical trials. American Journal of Obstetrics and Gynecology1993;168:214‐27. ">Dekker 1993</a>). A further hypothesis is that the effect of antiplatelets may be different if treatment is started before placental implantation is complete (<a href="./references#CD004659-bbs2-0019" title="BarJ , HodM , PardoJ , FischB , RabinersonD , KaplanB , et al. Effect on fetal circulation of low‐dose aspirin for prevention and treatment of pre‐eclampsia and intrauterine growth restriction: Doppler flow study. Ultrasound in Obstetrics &amp; Gynaecology1997;9:262‐5. BarJ , PadoaA , HodM , SullivanMH , KaplanB , KidronD . Decreased pathological placental findings in aspirin‐treated pregnant women at risk of hypertensive complications. Hypertension in Pregnancy1997;16:435‐44. BowerSJ , HarringtonKF , SchuchterK , McGirrC , CampbellS . Prediction of pre‐eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. British Journal of Obstetrics and Gynaecology1996;103:625‐9. CLASP (Collaborative Low‐dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low‐dose aspirin for the prevention and treatment of pre‐eclampsia among 9364 pregnant women. Lancet1994;343:619‐29. CLASP Collaborative Group. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. British Journal of Obstetrics and Gynaecology1994;102:861‐8. KylePM , BuckleyD , KissaneJ , deSwietM , RedmanCW . The angiotensin sensitivity test and low‐dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. American Journal of Obstetrics and Gynecology1995;173:865‐72. MathaiM . Aspirin for pre‐eclampsia. National Medical Journal of India1995;8:23‐4. VikhlyaevaK , AsymbekovaGU , ZerdevVP . Aspirin in profilaxis and treatment of placental insufficiency: lessons from Russian aspirin experience. Hypertension in Pregnancy2000;19(Suppl 1):68. ">CLASP 1994</a>). If this hypothesis were correct, the greatest benefit should be seen in women who started treatment before 16 weeks' gestation, with the effect attenuating with later onset of treatment (<a href="./references#CD004659-bbs2-0211" title="AskieLM , DuleyL , Henderson‐SmartDJ , StewartLA . Antiplatelet agents for prevention of pre‐eclampsia: a meta‐analysis of individual patient data. Lancet2007;369:1791‐8. ">Askie 2007</a>; <a href="./references#CD004659-bbs2-0216" title="BujoldE , RobergeS , LacasseY , Bureau M, AudibertF , MarcouxS , et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta‐analysis. Obstetrics and Gynecology2010;116:402‐14. ">Bujold 2010</a>; <a href="./references#CD004659-bbs2-0244" title="Perinatal Antiplatelet Review of International Studies (PARIS) Collaboration Steering Group on behalf of the PARIS collaboration. Antiplatelet agents for prevention of pre‐eclampsia and its consequences: a systematic review and individual patient data meta‐analysis. BMC Pregnancy and Childbirth2005;5:7. ">PARIS 2005</a>). Similarly, it remains unclear as to the most appropriate dose of antiplatelet therapy for the prevention of pre‐eclampsia in order to maximise benefits whilst minimising harms (<a href="./references#CD004659-bbs2-0268" title="UzanS , BeaufilsM , DumontA , MervielP , ChallierJC , BreartG . Does aspirin still have a role in pregnancy?. Fetal Diagnosis and Therapy1998;13:131‐2. ">Uzan 1998</a>). Many of the large trials have evaluated 60 mg or 75 mg, whilst some trials have used the higher dose of 100 mg or 150 mg. It has been suggested that low doses of aspirin (&lt; 75 mg) may selectively inhibit the cyclo‐oxygenase pathway in platelet production but not in vessel wall endothelium, thereby diminishing the synthesis of thromboxane but not of prostacyclin. A higher dose may inhibit both thromboxane and prostacyclin, thereby neutralising the effect of the intervention (<a href="./references#CD004659-bbs2-0235" title="MasottiG , GalantiG , PoggesiL , AbbateR , Neri SerneriGG . Differentialinhibition of prostacyclin production and platelet aggregation by aspirin. Lanct1979;2:1213‐7. ">Masotti 1979</a>). However, there is also limited evidence from randomised trials that a higher dose of aspirin (75 mg or higher) may effect a greater reduction in the risk of pre‐eclampsia (<a href="./references#CD004659-bbs2-0280" title="DuleyL , Henderson‐SmartDJ , MeherS , KingJF . Antiplatelet agents for preventing pre‐eclampsia and its complications. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD004659.pub2] ">Duley 2007</a>). </p> </section> <section id="CD004659-sec-0041"> <h3 class="title" id="CD004659-sec-0041">Why it is important to do this review</h3> <p>The hypothesis that antiplatelet drugs, low‐dose aspirin in particular, might prevent pre‐eclampsia and its complications was first tested in several small randomised trials which reported striking benefits in terms of reducing the risk of hypertension and proteinuria (<a href="./references#CD004659-bbs2-0223" title="DekkerGA , Sibai BahaM . Low‐dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms, and clinical trials. American Journal of Obstetrics and Gynecology1993;168:214‐27. ">Dekker 1993</a>). The trials were too small to provide reliable information about other more substantive outcomes, such as perinatal mortality, although there were anecdotal reports of women exposed to aspirin which suggested promising benefits. In addition, there was no information about the potential hazards of this therapy, such as a possible increased risk of bleeding for both the woman and her baby, and possible adverse effects on infant and child development. The promising results of these early trials of low‐dose aspirin led to several large trials being conducted in various parts of the world. Before these results became available, however, the use of low‐dose aspirin had already become relatively widespread for women considered to be at increased risk of pre‐eclampsia. When the large trials were published, they led to widespread disappointment that low‐dose aspirin was not effective for prevention of pre‐eclampsia (<a href="./references#CD004659-bbs2-0213" title="BarthWJr . Low‐dose aspirin for preeclampsia‐‐the unresolved question. New England Journal of Medicine1998;338(11):756‐7. ">Barth 1998</a>; <a href="./references#CD004659-bbs2-0214" title="BeilinL . Aspirin and pre‐eclampsia. BMJ1994;308:1250‐1. ">Beilin 1994</a>; <a href="./references#CD004659-bbs2-0221" title="DarlingM . Low‐dose aspirin not for pre‐eclampsia. Lancet1998;352(9125):342. ">Darling 1998</a>). It was only when all trials were combined in a systematic review that it became clear that there were indeed modest reductions in the risk of pre‐eclampsia and some of its consequences associated with the use of antiplatelet agents (<a href="./references#CD004659-bbs2-0278" title="DuleyL , Henderson‐SmartD , KnightM , KingJ . Antiplatelet drugs for prevention of pre‐eclampsia and its consequences: systematic review. BMJ2001;322:329‐33. ">Duley 2001</a>; <a href="./references#CD004659-bbs2-0281" title="KnightM , DuleyL , Henderson‐SmartDJ , KingJF . Antiplatelet agents for preventing and treating pre‐eclampsia. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD000492] ">Knight 2000a</a>). None of the large trials had been powered to detect such modest effects, and so the differences only achieved statistical significance when combined within the meta‐analysis. </p> <p>Over 35,000 pregnant women have been entered into randomised trials evaluating low‐dose aspirin. In the past, several systematic reviews have attempted to summarise these results (<a href="./references#CD004659-bbs2-0276" title="CollinsR . Antiplatelet agents for IUGR and pre‐eclampsia. [revised 04 May 1994]. In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration; Issue 2, Oxford: Update Software; 1995. ">Collins 1995</a>; <a href="./references#CD004659-bbs2-0278" title="DuleyL , Henderson‐SmartD , KnightM , KingJ . Antiplatelet drugs for prevention of pre‐eclampsia and its consequences: systematic review. BMJ2001;322:329‐33. ">Duley 2001</a>; <a href="./references#CD004659-bbs2-0230" title="ImperialeTF , PetrulisAS . A meta‐analysis of low‐dose aspirin for the prevention of pregnancy‐induced hypertensive disease. JAMA1991;266:260‐4. ">Imperiale 1991</a>; <a href="./references#CD004659-bbs2-0232" title="LeitichH , EgarterC , HussleinP , KaiderA , SchemperM . A meta‐analysis of low dose aspirin for prevention of intrauterine growth retardation. British Journal of Obstetrics and Gynaecology1997;104:450‐9. ">Leitich 1997</a>; <a href="./references#CD004659-bbs2-0248" title="ReyE , DerderianF . [Efficacite de l'aspirine a faible dose au cours de al grossesse en fonction des facteurs de risque maternels et foetaux]. SOGC: journal of the Society of Obstetricians and Gynaecologists of Canada1996;18(10):51‐60. ">Rey 1996</a>; <a href="./references#CD004659-bbs2-0259" title="Sanchez‐RamosL , WearsR , DelValleGO , GaudierFL , AdairD . Low dose aspirin for the prevention of pregnancy‐induced hypertension: a meta‐analysis. American Journal of Obstetrics and Gynecology1994;170:408. ">Sanchez‐Ramos 1994</a>; <a href="./references#CD004659-bbs2-0262" title="Sharts‐EngelNC . Aspirin for prevention of pregnancy‐induced hypertension. MCN. The American Journal of Maternal Child Nursing1992;17(3):168. ">Sharts‐Engel 1992</a>), although none of these remain up to date. The previous update of this review concluded antiplatelet agents, largely low‐dose aspirin, have moderate benefits when used for prevention of pre‐eclampsia and its consequences; and that further information is required to assess which women are most likely to benefit, when treatment is best started, and at what dose (<a href="./references#CD004659-bbs2-0280" title="DuleyL , Henderson‐SmartDJ , MeherS , KingJF . Antiplatelet agents for preventing pre‐eclampsia and its complications. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD004659.pub2] ">Duley 2007</a>). </p> <p>Recent systematic reviews published elsewhere have focused on specific subgroups of women, for example based either on risk factors for development of pre‐eclampsia (<a href="./references#CD004659-bbs2-0219" title="CoomarasamyA , PapaioannouS , GeeH , KhanKS . Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta‐analysis. Obstetrics and Gynecology2001;98:861‐6. ">Coomarasamy 2001</a>; <a href="./references#CD004659-bbs2-0220" title="CoomarasamyA , HonestH , PapaioannouS , GeeH , KhanK . Aspirin for prevention of preeclampsia in women with historical risk factors : a systematic review. Obstetrics and Gynecology2003;101(6):1319–332. ">Coomarasamy 2003</a>; <a href="./references#CD004659-bbs2-0255" title="RossiAC , MullinPM . Prevention of pre‐eclampsia with low‐dose aspirin or vitamins C and E in women at high or low risk: a systematic review with meta‐analysis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2011;158:9‐16. ">Rossi 2011</a>; <a href="./references#CD004659-bbs2-0256" title="RuanoR , FontesRS , ZugaibM . Prevention of preeclampsia with low‐dose aspirin ‐‐ a systematic review and meta‐analysis of the main randomized controlled trials. Clinics2005;60:407–14. ">Ruano 2005</a>; <a href="./references#CD004659-bbs2-0266" title="TrivediNA . A meta‐analysis of low‐dose aspirin for prevention of preeclampsia. Journal of Postgraduate Medicine2011;57:91‐5. ">Trivedi 2011</a>) or gestation at randomisation when antiplatelet therapy is started (<a href="./references#CD004659-bbs2-0216" title="BujoldE , RobergeS , LacasseY , Bureau M, AudibertF , MarcouxS , et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta‐analysis. Obstetrics and Gynecology2010;116:402‐14. ">Bujold 2010</a>; <a href="./references#CD004659-bbs2-0250" title="RobergeS , NicolaidesKH , DemersS , VillaP , BujoldE . Prevention of perinatal death and adverse perinatal outcome using low‐dose aspirin: a meta‐analysis. Ultrasound in Obstetrics and Gynecology2013;41(5):491‐9. ">Roberge 2013</a>). Nevertheless, there is reasonable agreement that low‐dose aspirin appears to be safe, at least in the short term, and that it reduces the risk of pre‐eclampsia for a broad range of women. However, as the risk of pre‐eclampsia reduces the number of women who need to be treated to prevent one case of pre‐eclampsia grows. So whilst the public health benefits may be clear, it is less certain whether there is worthwhile benefit for individual women at low‐to‐moderate risk of developing pre‐eclampsia (<a href="./references#CD004659-bbs2-0211" title="AskieLM , DuleyL , Henderson‐SmartDJ , StewartLA . Antiplatelet agents for prevention of pre‐eclampsia: a meta‐analysis of individual patient data. Lancet2007;369:1791‐8. ">Askie 2007</a>; <a href="./references#CD004659-bbs2-0252" title="RobertsJM , CatovJM . Aspirin for pre‐eclampsia: compelling data on benefit and risk. Lancet2007;369:1765‐6. ">Roberts 2007</a>). Several issues remain controversial. These include whether dose, type of preparation, or starting treatment early in pregnancy are factors that substantially influence effectiveness. Also, there is concern about potential for publication bias, due to enthusiasm for the use of low‐dose aspirin, which may have led to speedy publication of small positive trials in high‐profile journals, with small negative trials taking far longer to appear, and then doing so only in more obscure publications (<a href="./references#CD004659-bbs2-0215" title="Broughton PipkinF , CrowtherC , deSwietM , DuleyL , JuddA , LilfordRJ , et al. Where next for prophylaxis against pre‐eclampsia?. British Journal of Obstetrics and Gynaecology1996;103:603‐7. ">Broughton Pipkin 1996</a>; <a href="./references#CD004659-bbs2-0281" title="KnightM , DuleyL , Henderson‐SmartDJ , KingJF . Antiplatelet agents for preventing and treating pre‐eclampsia. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD000492] ">Knight 2000a</a>). </p> <p>Since the last update of this Cochrane Review, the PARIS individual participant data (IPD) meta‐analysis of trials evaluating antiplatelet drugs for prevention of pre‐eclampsia and its complications has been published (<a href="./references#CD004659-bbs2-0211" title="AskieLM , DuleyL , Henderson‐SmartDJ , StewartLA . Antiplatelet agents for prevention of pre‐eclampsia: a meta‐analysis of individual patient data. Lancet2007;369:1791‐8. ">Askie 2007</a>). Overall, 63 trials were identified as potentially eligible (with 38,026 women). Data were obtained from 36 studies (34,288 women, 90% of randomised women). Of these, 31 trials recruited women for primary prevention of pre‐eclampsia (32,217 women and 32,819 babies). IPD from these 31 studies have been incorporated into this update. The methods used for the PARIS review (<a href="./references#CD004659-bbs2-0244" title="Perinatal Antiplatelet Review of International Studies (PARIS) Collaboration Steering Group on behalf of the PARIS collaboration. Antiplatelet agents for prevention of pre‐eclampsia and its consequences: a systematic review and individual patient data meta‐analysis. BMC Pregnancy and Childbirth2005;5:7. ">PARIS 2005</a>) have been added to the methods for this updated Cochrane Review. </p> <p>A wide variety of other interventions have been suggested for possible prevention of pre‐eclampsia. Other Cochrane Reviews cover calcium supplementation (<a href="./references#CD004659-bbs2-0229" title="HofmeyrGJ , LawrieTA , AtallahÁN , TorloniMR . Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database of Systematic Reviews2018, Issue 10. [DOI: 10.1002/14651858.CD001059.pub5] ">Hofmeyr 2018</a>), magnesium supplementation (<a href="./references#CD004659-bbs2-0234" title="MakridesM , CrosbyDD , ShepherdE , CrowtherCA . Magnesium supplementation in pregnancy. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD000937.pub2] ">Makrides 2014</a>), protein intake and nutritional advice (<a href="./references#CD004659-bbs2-0243" title="OtaE , HoriH , MoriR , Tobe‐GaiR , FarrarD . Antenatal dietary education and supplementation to increase energy and protein intake. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD000032.pub3] ">Ota 2015</a>), salt intake (<a href="./references#CD004659-bbs2-0226" title="DuleyL , Henderson‐SmartD . Reduced salt intake compared to normal dietary salt, or high intake, in pregnancy. Cochrane Database of Systematic Reviews1999, Issue 3. [DOI: 10.1002/14651858.CD001687] ">Duley 1999b</a>), omega‐3 fatty acid additions (<a href="./references#CD004659-bbs2-0240" title="MiddletonP , GomersallJC , GouldJF , ShepherdE , OlsenSF , MakridesM . Omega‐3 fatty acid addition during pregnancy. Cochrane Database of Systematic Reviews2018, Issue 11. [DOI: 10.1002/14651858.CD003402.pub3] ">Middleton 2018</a> and antioxidants (<a href="./references#CD004659-bbs2-0257" title="RumboldA , DuleyL , CrowtherCA , HaslamRR . Antioxidants for preventing pre‐eclampsia. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD004227.pub3] ">Rumbold 2008</a>). Although some of these interventions are promising, to date only aspirin and calcium have been shown to have clinically worthwhile benefits in prevention of pre‐eclampsia and its complications (<a href="./references#CD004659-bbs2-0236" title="MeadsCA , CnossenJS , MeherS , Juarez‐GarciaA , ter RietG , DuleyL , et al. Methods of prediction and prevention of pre‐eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technology Assessment2008;12(6):iii‐iv, 1‐270. [PUBMED: 18331705] ">Meads 2008</a>). </p> <p>The aims of this review are (i) to identify as many of both the published and unpublished antiplatelet trials as possible and (ii) to estimate the benefits and hazards of antiplatelet agents when used for the prevention of pre‐eclampsia. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004659-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004659-sec-0042"></div> <p>To assess the effectiveness and safety of antiplatelet agents, such as aspirin and dipyridamole, when given to women at risk of developing pre‐eclampsia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004659-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004659-sec-0043"></div> <section id="CD004659-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004659-sec-0045"> <h4 class="title">Types of studies</h4> <p>All randomised trials comparing antiplatelet agents with either placebo or no antiplatelet agent during pregnancy. Studies only published in abstract format were eligible for inclusion if sufficient information was available. Cluster‐randomised controlled trials were eligible (but none were identified). Quasi‐random studies were excluded. </p> </section> <section id="CD004659-sec-0046"> <h4 class="title">Types of participants</h4> <p>Pregnant women considered to be at risk of developing pre‐eclampsia. This included women with normal blood pressure and those with chronic hypertension, as well as women with pregnancy‐induced or gestational hypertension. </p> <p>For studies where IPD were available, individual women were classified into risk categories based on the criteria in the PARIS protocol (<a href="./references#CD004659-bbs2-0211" title="AskieLM , DuleyL , Henderson‐SmartDJ , StewartLA . Antiplatelet agents for prevention of pre‐eclampsia: a meta‐analysis of individual patient data. Lancet2007;369:1791‐8. ">Askie 2007</a>). They were classified as low risk if they had any one of the following risk factors: primiparity, family history of pre‐eclampsia, age greater than 40 years, or multiple pregnancy. Women were classified as moderate risk if they had any two of the previous risk factors. Women were classified as high risk if they had any one of the following risk factors: diabetes, chronic hypertension, renal disease, autoimmune disease, gestational hypertension, positive uterine artery Doppler, previous pre‐eclampsia or previous fetal/neonatal death associated with pre‐eclampsia. Women with no identifiable risk factor in the available IPD were grouped with the low‐risk women. Hence for studies where IPD were available, data from one trial could appear in more than one 'maternal risk' category and in more than one 'gestational age at randomisation' category, as individual women within each trial could be classified into different risk and gestational age subgroups. </p> <p>For studies where aggregate data (AD) only were available, inclusion criteria were used to group women into low, moderate, high or unclassified risk according to the same criteria outlined above, so that categorisation was consistent with IPD analyses. Women in a particular trial could be placed in one category only (unless appropriate subgroup data were available from the trial publication), as IPD were not available. </p> </section> <section id="CD004659-sec-0047"> <h4 class="title">Types of interventions</h4> <p>Comparisons of any antiplatelet agent (such as low‐dose aspirin or dipyridamole) with either placebo or no antiplatelet agent. This was regardless of dose and duration of therapy or mode of administration, and irrespective of whether in combination with another agent. </p> </section> <section id="CD004659-sec-0048"> <h4 class="title">Types of outcome measures</h4> <p>For trials with IPD, outcomes were defined using the <a href="./references#CD004659-bbs2-0244" title="Perinatal Antiplatelet Review of International Studies (PARIS) Collaboration Steering Group on behalf of the PARIS collaboration. Antiplatelet agents for prevention of pre‐eclampsia and its consequences: a systematic review and individual patient data meta‐analysis. BMC Pregnancy and Childbirth2005;5:7. ">PARIS 2005</a> definitions. For trials with only AD available, the trialists' own outcome definitions were used. </p> <section id="CD004659-sec-0049"> <h5 class="title">Primary outcomes</h5> <section id="CD004659-sec-0050"> <h6 class="title">For the women</h6> <p> <ul id="CD004659-list-0001"> <li> <p>Pre‐eclampsia (as reported by the trialist)</p> </li> </ul> </p> </section> <section id="CD004659-sec-0051"> <h6 class="title">For the children</h6> <p> <ul id="CD004659-list-0002"> <li> <p>Death (fetal, neonatal, or before hospital discharge)</p> </li> <li> <p>Preterm birth (all birth before 37 weeks)</p> </li> <li> <p>Small‐for‐gestational age (preferably using below the third centile of birthweight for gestational age, but otherwise the most extreme centile available) </p> </li> </ul> </p> </section> </section> <section id="CD004659-sec-0052"> <h5 class="title">Secondary outcomes</h5> <section id="CD004659-sec-0053"> <h6 class="title">For the women</h6> <p> <ul id="CD004659-list-0003"> <li> <p>Gestational hypertension (new hypertension with onset after 20 weeks' gestation)</p> </li> <li> <p>Death (secondary outcome as likely to be a rare event in the trials)</p> </li> <li> <p>Elective delivery (induction of labour or elective caesarean section)</p> </li> <li> <p>Caesarean section (emergency plus elective)</p> </li> </ul> </p> <section id="CD004659-sec-0054"> <p><b>Bleeding episodes</b></p> <p> <ul id="CD004659-list-0004"> <li> <p>Abruption of the placenta</p> </li> <li> <p>Antepartum haemorrhage</p> </li> <li> <p>Postpartum haemorrhage</p> </li> <li> <p>Complications of epidural anaesthesia</p> </li> <li> <p>Need for blood transfusion</p> </li> </ul> </p> </section> <section id="CD004659-sec-0055"> <p><b>Measures of serious maternal morbidity</b></p> <p> <ul id="CD004659-list-0005"> <li> <p>Eclampsia</p> </li> <li> <p>Liver failure</p> </li> <li> <p>Renal failure</p> </li> <li> <p>Disseminated intravascular coagulation</p> </li> </ul> </p> </section> <section id="CD004659-sec-0056"> <p><b>Rare adverse events</b></p> <p> <ul id="CD004659-list-0006"> <li> <p>Temporary blindness</p> </li> <li> <p>Major psychiatric disorders</p> </li> </ul> </p> </section> </section> <section id="CD004659-sec-0057"> <h6 class="title">For the children</h6> <p> <ul id="CD004659-list-0007"> <li> <p>Bleeding episodes (such as intraventricular haemorrhage)</p> </li> <li> <p>Infant and child development (such as cerebral palsy, cognitive delay, deafness, and blindness, as defined by the trialist) </p> </li> </ul> </p> </section> <section id="CD004659-sec-0058"> <h6 class="title">For the pregnancy (as defined in the PARIS protocol)</h6> <p> <ul id="CD004659-list-0008"> <li> <p>Serious adverse outcome (pregnancy where the woman dies or develops pre‐eclampsia, or the baby is preterm, small‐for‐gestational age, or dies before discharge from hospital) </p> </li> </ul> </p> </section> <section id="CD004659-sec-0059"> <h6 class="title">Use of health service resources</h6> <section id="CD004659-sec-0060"> <p><b>For the woman</b></p> <p> <ul id="CD004659-list-0009"> <li> <p>Antenatal hospital admission</p> </li> <li> <p>Visits to day care units</p> </li> <li> <p>Use of intensive care</p> </li> <li> <p>Ventilation</p> </li> <li> <p>Dialysis</p> </li> </ul> </p> </section> <section id="CD004659-sec-0061"> <p><b>For the children</b></p> <p> <ul id="CD004659-list-0010"> <li> <p>Admission to special care/intensive care nursery</p> </li> <li> <p>Duration of mechanical ventilation</p> </li> <li> <p>Length of stay in hospital</p> </li> <li> <p>Development and special needs after discharge</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section id="CD004659-sec-0062"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004659-sec-0063"> <h4 class="title">Electronic searches</h4> <p>For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register by contacting their Information Specialist (30 March 2018). We carried out an updated search in September 2019 and added 27 new trial reports to <a href="./references#CD004659-bbs1-0003" title="">Studies awaiting classification</a>. </p> <p>The Register is a database containing over 25,000 reports of controlled trials in the field of pregnancy and childbirth. It represents over 30 years of searching. For full current search methods used to populate Pregnancy and Childbirth’s Trials Register including the detailed search strategies for CENTRAL, MEDLINE, Embase and CINAHL; the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service, please follow this <a href="https://pregnancy.cochrane.org/pregnancy-and-childbirth-groups-trials-register" target="_blank">link</a> </p> <p>Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is maintained by their Information Specialist and contains trials identified from: </p> <p> <ul id="CD004659-list-0011"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>weekly searches of MEDLINE (Ovid);</p> </li> <li> <p>weekly searches of Embase (Ovid);</p> </li> <li> <p>monthly searches of CINAHL (EBSCO);</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ul> </p> <p>Search results are screened by two people and the full text of all relevant trial reports identified through the searching activities described above is reviewed. Based on the intervention described, each trial report is assigned a number that corresponds to a specific Pregnancy and Childbirth review topic (or topics), and is then added to the Register. The Information Specialist searches the Register for each review using this topic number rather than keywords. This results in a more specific search set that has been fully accounted for in the relevant review sections (<a href="./references#CD004659-bbs1-0001" title="">Included studies</a>; <a href="./references#CD004659-bbs1-0002" title="">Excluded studies</a>; <a href="./references#CD004659-bbs1-0003" title="">Studies awaiting classification</a>; <a href="./references#CD004659-bbs1-0004" title="">Ongoing studies</a>). </p> <p>In addition, we searched <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> and the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) for unpublished, planned and ongoing trial reports (30 March 2018) using the search methods detailed in <a href="./appendices#CD004659-sec-0154">Appendix 1</a>. </p> </section> <section id="CD004659-sec-0064"> <h4 class="title">Searching other resources</h4> <p>We asked trialists in the PARIS Collaboratio if they knew of any further studies.</p> <p>We searched the reference lists of retrieved studies.</p> <p>We did not apply any language or date restrictions</p> </section> </section> <section id="CD004659-sec-0065"> <h3 class="title" id="CD004659-sec-0065">Data collection and analysis</h3> <p>For the methods used when assessing the trials identified in the previous version of this review, see <a href="./references#CD004659-bbs2-0280" title="DuleyL , Henderson‐SmartDJ , MeherS , KingJF . Antiplatelet agents for preventing pre‐eclampsia and its complications. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD004659.pub2] ">Duley 2007</a>. </p> <p>For this update we used the following methods when assessing the reports identified by the updated search. </p> <section id="CD004659-sec-0066"> <h4 class="title">Selection of studies</h4> <p>At least two review authors independently assessed for inclusion each of the potential studies that we identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted a third review author. </p> </section> <section id="CD004659-sec-0067"> <h4 class="title">Data extraction and management</h4> <p>We designed a form to extract data. For eligible studies, at least two review authors extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted a third review author. We entered data into Review Manager software (<a href="./references#CD004659-bbs2-0247" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) and checked for accuracy. </p> <p>When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details. </p> <p>For this update we combined aggregate data (AD) with individual participant data (IPD). Meta‐analyses based on IPD allow more powerful and uniformly consistent analyses, whilst allowing better characterisation of subgroups and outcomes, compared to those based on AD (<a href="./references#CD004659-bbs2-0249" title="RileyRD , LambertPC , Abo‐ZaidG . Meta‐analysis of individual participant data: rationale, conduct, and reporting. BMJ2010;340:c221. [DOI: 10.1136/bmj.c221] ">Riley 2010</a>; <a href="./references#CD004659-bbs2-0267" title="Tudur SmithC , MarcucciM , NolanSJ , IorioA , SudellM , RileyR , et al. Individual participant data meta‐analyses compared with meta‐analyses based on aggregate data. Cochrane Database of Systematic Reviews2016, Issue 9. [DOI: 10.1002/14651858.MR000007.pub3] ">Tudur Smith 2016</a>). We included both AD and IPD in this update in order to combine all available information. The use of IPD supported more detailed and accurate analyses. It enabled us to classify participants by specific characteristics, supporting analyses subgrouped by maternal risk of developing pre‐eclampsia, and also provided new data on key outcomes. Combining IPD with AD meant that it was possible to bring together all eligible trials even where IPD was unavailable. </p> <p>IPD from trials within the PARIS Collaboration were collected according to the methods described in the <a href="./references#CD004659-bbs2-0211" title="AskieLM , DuleyL , Henderson‐SmartDJ , StewartLA . Antiplatelet agents for prevention of pre‐eclampsia: a meta‐analysis of individual patient data. Lancet2007;369:1791‐8. ">Askie 2007</a> paper as follows. Data to be collected were agreed after extensive consultation within the PARIS Collaborative Group. Anonymised data for each of the pre‐specified variables were requested for each woman randomised. Data were supplied in a variety of formats, re‐coded as necessary, and were checked for internal consistency, consistency with published reports, and for missing items. Information about the trials, e.g. randomisation method and antiplatelet dose, were cross‐checked with published reports, trial protocols, and data collection sheets. Quality and integrity of the randomisation processes were assessed by reviewing the chronological randomisation sequence and pattern of assignment, as well as the balance of baseline characteristics across treatment groups (taking into account stratification factors). Inconsistencies or missing data were discussed with relevant trialists and corrected when necessary. Finalised data for each study were verified with the relevant trialists before being combined into the final PARIS dataset. </p> <p>Where IPD were available from the PARIS dataset, these were extracted for use in the review, using the subgroup classifications and outcome definitions defined in this review. </p> </section> <section id="CD004659-sec-0068"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004659-bbs2-0228" title="HigginsJP , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved any disagreement by discussion or by involving a third assessor. </p> <p>During the collection of IPD for the PARIS Collaboration, additional information was sought from the authors of the studies included in this Collaboration to further clarify the 'Risk of bias' assessments. Additional information gained during this process (that was not available from the published data alone) is referred to as the ‘PARIS assessment’ in the text and tables of this review. </p> <section id="CD004659-sec-0069"> <h5 class="title">(1) Random sequence generation (checking for possible selection bias)</h5> <p>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the method as:</p> <p> <ul id="CD004659-list-0012"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004659-sec-0070"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. </p> <p>We assessed the methods as:</p> <p> <ul id="CD004659-list-0013"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004659-sec-0071"> <h5 class="title">(3) Blinding of participants, personnel and outcome assessment (checking for possible performance and detection bias) </h5> <p>We described for each included study the methods used, if any, to blind study participants, personnel and outcome assessors from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the methods as low, high or unclear risk of bias.</p> </section> <section id="CD004659-sec-0072"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </h5> <p>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we re‐included missing data in the analyses which we undertook. </p> <p>We assessed methods as:</p> <p> <ul id="CD004659-list-0014"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial departure of intervention received from that assigned at randomisation); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004659-sec-0073"> <h5 class="title">(5) Selective reporting (checking for reporting bias)</h5> <p>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found. </p> <p>We assessed the methods as:</p> <p> <ul id="CD004659-list-0015"> <li> <p>low risk of bias (where it is clear that all of the study’s pre‐specified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>high risk of bias (where not all the study’s pre‐specified outcomes have been reported; one or more reported primary outcomes were not pre‐specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004659-sec-0074"> <h5 class="title">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</h5> <p>We described for each included study any important concerns we had about other possible sources of bias. </p> <p>We assessed whether each study was free of other problems that could put it at risk of bias: </p> <p> <ul id="CD004659-list-0016"> <li> <p>low risk of other bias;</p> </li> <li> <p>high risk of other bias;</p> </li> <li> <p>unclear whether there is risk of other bias.</p> </li> </ul> </p> </section> <section id="CD004659-sec-0075"> <h5 class="title">(7) Overall risk of bias</h5> <p>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <i>Handbook</i> (<a href="./references#CD004659-bbs2-0228" title="HigginsJP , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it was likely to impact on the findings. We explored the impact of the level of bias through undertaking sensitivity analyses ‐ <i>see</i><a href="#CD004659-sec-0089">Sensitivity analysis</a>. </p> </section> <section id="CD004659-sec-0076"> <h5 class="title">Assessment of the quality of the evidence using the GRADE approach</h5> <p>For this update, we evaluated the quality of the evidence comparing antiplatelet agents with placebo/no antiplatelet for the outcomes proteinuric pre‐eclampsia, fetal or neonatal death, preterm birth, small‐for‐gestational‐age, pregnancy with serious adverse outcome, postpartum haemorrhage, and placental abruption using the GRADE approach as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE handbook</a>. The GRADE approach uses five considerations (trial limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for specific outcomes. The evidence can be downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, inconsistency, imprecision of effect estimates or publication bias. </p> </section> <section id="CD004659-sec-0077"> <h5 class="title">'Summary of findings' table</h5> <p>We used <a href="http://www.guidelinedevelopment.org/" target="_blank">GRADEpro</a> Guideline Development Tool to import data from Review Manager 5.3 (<a href="./references#CD004659-bbs2-0247" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) in order to create a 'Summary of findings’ table for the maternal and child outcomes listed above that were evaluated with the GRADE approach. The 'Summary of findings' table presents summaries of the intervention effect and measures of quality according to the GRADE approach. </p> </section> </section> <section id="CD004659-sec-0078"> <h4 class="title">Measures of treatment effect</h4> <section id="CD004659-sec-0079"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we presented results as summary risk ratio with 95% confidence intervals.  </p> </section> <section id="CD004659-sec-0080"> <h5 class="title">Continuous data</h5> <p>For continuous data, we used the mean difference as outcomes were measured in the same way between trials. We planned to use the standardised mean difference to combine trials that measured the same outcome, but used different methods.   </p> </section> </section> <section id="CD004659-sec-0081"> <h4 class="title">Unit of analysis issues</h4> <section id="CD004659-sec-0082"> <h5 class="title">Cluster‐randomised trials</h5> <p>We would have included cluster‐randomised trials in the analyses along with individually‐randomised trials, if any had been identified in our search strategy. If we had found any we would have adjusted their sample sizes using the methods described in the <i>Handbook</i> [Section 16.3.4] using an estimate of the intracluster correlation co‐efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we had used ICCs from other sources, we would have reported this and conducted sensitivity analyses to investigate the effect of variation in the ICC. If we had identified cluster‐randomised trials and individually‐randomised trials, we planned to synthesise the relevant information. We would have considered it reasonable to combine the results from both if there was little heterogeneity between the study designs and an interaction between the effect of intervention and the choice of randomisation unit was considered to be unlikely. </p> <p>We would also have acknowledged heterogeneity in the randomisation unit and performed a subgroup analysis to investigate the effects of the randomisation unit. </p> </section> <section id="CD004659-sec-0083"> <h5 class="title">Cross‐over trials and other unit of analysis issues</h5> <p>As a cross‐over design is not a valid study design for this review, we planned to exclude these studies. If we identified trials with more than two treatment groups, we planned to include them. For studies comparing two different antiplatelet regimens with placebo or no treatment, we planned to combine data for the two antiplatelet groups. For trials with three or more arms, we planned to combine data where possible, but split the arms by subgroup where necessary (e.g. trials administering different doses to different arms were split when analysing subgroups by dose). Each intervention arm was then compared to the full control group within its subgroup. This was the case for two trials with a total of 367 women (<a href="./references#CD004659-bbs2-0022" title="BeaufilsM , UzanS , BreartG , BazinB , ParisJ . Prevention of preeclampsia with low‐dose aspirin: results of the epreda trial. XIth International Congress of Nephrology; 1990 July 15‐20; Tokyo, Japan. 1990:319A. SureauC . Prevention of perinatal consequences of pre‐eclampsia with low‐dose aspirin: results of the EPREDA trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1991;41:71‐3. UzanM , BeaufilsM , BreartG , BazinB , CapitantC , ParisJ , et al. Prevention of pre‐eclampsia with low‐dose aspirin: results of the EPREDA trial. Journal of Perinatal Medicine1990;18 Suppl:116. UzanS , BeaufilsM , BreartG , BazinB , CapitantC , ParisJ . Prevention of fetal growth retardation with low‐dose aspirin: findings of the EPREDA trial. Lancet1991;337:1427‐31. UzanS , BeaufilsM , BreartG , BazinB , CapitantC , ParisJ . Prevention of pre‐eclampsia with low‐dose aspirin: results of the EPREDA trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;44:12. UzanS , BeaufilsM , BreartG , BazinB , ParisJ . Prevention of pre‐eclampsia with low‐dose aspirin: results of the EPREDA trial. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:34. UzanS , BeaufilsM , BreartG , UzanM , ParisJ . Prevention of intrauterine growth retardation and pre‐eclampsia by small doses of aspirin. Results of the French multicenter trial EPREDA and comparison with data in the literature; value of uterine Doppler [Prevention du retard de croissance intra‐uterin et de la preeclampsie par des petites doses d'Aspirine: resultats de l'essai multicentrique francais EPREDA et comparison avec les donnees de la litterature; interet du Doppler uterin]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1992;21(3):315‐8. ">EPREDA 1991</a>; <a href="./references#CD004659-bbs2-0060" title="RailtonA , DaveyA . Aspirin and dipyridamole in the prevention of pre‐eclampsia: effect on plasma prostanoids 6 keto PG1a and TXB2 and clinical outcome of pregnancy. Proceedings of the 6th International Congress of the International Society for the Study of Hypertension in Pregnancy; 1988 May 22‐26; Montreal, Quebec, Canada. 1988:60. RailtonA , DaveyDA . Aspirin and dipyridamole in the prevention of pre‐eclampsia: effect on plasma 6 keto PGF1alpha and TxB2 and clinical outcome of pregnancy. Proceedings of 1st European Congress on Prostaglandins in Reproduction; 1988 July 6‐9; Vienna, Austria. 1988:48. ">S Africa 1988</a>). </p> <p>The mother was the unit of analysis with an event being any baby having an event (e.g. any baby being small‐for‐gestational age) in case of multiple pregnancies. </p> </section> </section> <section id="CD004659-sec-0084"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, we noted levels of attrition. Where more than 20% of participants were lost to follow‐up, the study was excluded. For individual outcomes where more than 20% of data were missing, the trials were excluded from the meta‐analysis for that particular outcome. We explored the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. We included data for long‐term follow‐up of women and children where losses to follow‐up were greater than 20%, providing that substantive bias between the groups was unlikely. We documented completeness of follow‐up for these studies alongside any results. </p> <p>For all outcomes, we carried out analyses, as far as possible, on an intention‐to‐treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing. </p> </section> <section id="CD004659-sec-0085"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the T<sup>2</sup>, I² and Chi² statistics. We regarded heterogeneity as substantial if an I<sup>2</sup> was greater than 40% and either a T<sup>2</sup> was greater than zero or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. </p> </section> <section id="CD004659-sec-0086"> <h4 class="title">Assessment of reporting biases</h4> <p>For outcomes with 10 or more studies contributing events in the meta‐analysis, we investigated reporting biases (such as publication bias) using funnel plots. We assessed funnel plot asymmetry visually. If asymmetry was suggested by a visual assessment, we performed exploratory analyses to investigate it, including exploration of any apparent differences between results from IPD and AD in the funnel plots. </p> </section> <section id="CD004659-sec-0087"> <h4 class="title">Data synthesis</h4> <p>Data were synthesised using a two‐stage approach which involved calculating treatment effect estimates for both the individual participant and aggregate data separately, and then combining these for an overall effect estimate when appropriate. Individual participant and aggregate data were further subgrouped according to maternal risk, gestational age at trial entry, aspirin dosage and use of placebo (see section below). When the definition of the outcomes varied too strongly across types of data (individual participant versus aggregate), they were analysed separately. For some outcomes, only IPD were available, while for others, only AD were available. </p> <p>We carried out statistical analysis using the Review Manager software (<a href="./references#CD004659-bbs2-0247" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We used fixed‐effect meta‐analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials’ populations and methods were judged sufficiently similar. </p> <p>In future updates, If there is clinical heterogeneity sufficient to expect that the underlying treatment effects differ between trials, or if substantial statistical heterogeneity is detected, we will use random‐effects meta‐analysis to produce an overall summary if an average treatment effect across trials is considered clinically meaningful. The random‐effects summary will be treated as the average range of possible treatment effects and we will discuss the clinical implications of treatment effects differing between trials. If the average treatment effect is not clinically meaningful, we will not combine trials. If we use random‐effects analyses, the results will be presented as the average treatment effect with 95% confidence intervals, and the estimates of T² and I². </p> </section> <section id="CD004659-sec-0088"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If we identified substantial heterogeneity, we planned to investigate it using subgroup analyses and sensitivity analyses. We considered whether an overall summary was meaningful, and if it was, used random‐effects analysis to produce it. </p> <p>We planned to carry out the following subgroup analyses:</p> <p> <ul id="CD004659-list-0017"> <li> <p>maternal risk of pre‐eclampsia at trial entry (as defined under types of participant): low risk; moderate risk; or high risk; </p> </li> <li> <p>gestation at trial entry: before 20 weeks' gestation; at or after 20 weeks' gestation; unclear or unspecified; </p> </li> <li> <p>type of antiplatelet agent: low‐dose aspirin alone; all other types of antiplatelet agent and low‐dose aspirin combined with other antiplatelet agents; </p> </li> <li> <p>by dose of aspirin: less than 75 mg; greater than or equal to 75 mg; dose not known;</p> </li> <li> <p>by type of control group intervention: placebo; no placebo.</p> </li> </ul> </p> <p>Subgroup analyses were restricted to the primary outcomes.</p> <p>Since we had IPD and AD for most outcomes that were entered as separate subgroups, interaction tests available with RevMan (<a href="./references#CD004659-bbs2-0247" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) were not meaningful for the subgroups and were therefore not reported and interpreted. Instead, we visually inspected the forest plots to assess differences between subgroups. Furthermore, we conducted additional analyses for the most relevant outcomes (proteinuric pre‐eclampsia, fetal or neonatal death, preterm birth, small‐for‐gestational age), in which we combined IPD and AD to perform interaction tests available with RevMan (<a href="./references#CD004659-bbs2-0247" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) to test for maternal risk subgroup differences (<a href="./references#CD004659-fig-0040" title="">Analysis 1.5</a>; <a href="./references#CD004659-fig-0041" title="">Analysis 1.6</a>; <a href="./references#CD004659-fig-0042" title="">Analysis 1.7</a>; <a href="./references#CD004659-fig-0043" title="">Analysis 1.8</a>). Results of these subgroup analyses were reported quoting the Chi<sup>2</sup> statistic and P value, and the interaction test I² value. </p> </section> <section id="CD004659-sec-0089"> <h4 class="title">Sensitivity analysis</h4> <p>We planned sensitivity analyses (restricted to the primary outcomes) excluding studies with high risk of bias in three or more 'Risk of bias' domains. Since this was not the case for any of the studies, no sensitivity analyses were performed. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004659-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004659-sec-0090"></div> <section id="CD004659-sec-0091"> <h3 class="title">Description of studies</h3> <section id="CD004659-sec-0092"> <h4 class="title">Results of the search</h4> <p>See: <a href="#CD004659-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD004659-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD004659-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We assessed 160 new trial reports (146 from the new search and 16 that were awaiting classification in the previous version of the review (<a href="./references#CD004659-bbs2-0280" title="DuleyL , Henderson‐SmartDJ , MeherS , KingJF . Antiplatelet agents for preventing pre‐eclampsia and its complications. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD004659.pub2] ">Duley 2007</a>)). We also reassessed the previously excluded studies. We included two previously excluded studies (<a href="./references#CD004659-bbs2-0033" title="GroverV , SachdevaS , KumariS . Evaluation of dipyridamole and aspirin in prevention and management of intrauterine growth retardation. Journal of Perinatal Medicine1991;19(2):104. ">India 1991</a>; <a href="./references#CD004659-bbs2-0057" title="UzanS , BeaufilsM , BazinB , DanaysT . Idiopathic recurrent fetal growth retardation and aspirin‐dipyridamole therapy [letter]. American Journal of Obstetrics and Gynecology1989;160:763‐4. ">Pergar 1987</a>), and moved nine studies previously excluded to <a href="./references#CD004659-bbs1-0003" title="">Studies awaiting classification</a> as if further information became available they could potentially be included (<a href="./references#CD004659-bbs2-0175" title="NoortWA , RotmansN , KeirseMJ , WallenburgHC . Effect of low‐dose aspirin with and without dipyridamole on prostanoid biosynthesis in pregnancy. Proceedings of 2nd European Congress on Prostaglandins in Reproduction; 1991 April 30‐May 3; The Hague, Netherlands. 1991:182. WallenburgHC , RotmansN , NoortWA , KeirseMJ . Effect of low‐dose aspirin with and without dipyridamole on prevention of recurrent idiopathic fetal growth retardation. Proceedings of 2nd European Congress on Prostaglandins in Reproduction; 1991 April 30‐May 3; The Hague, Netherlands1991:92. ">Netherlands 1991</a>; <a href="./references#CD004659-bbs2-0174" title="KraavenbrinkA , GansR , vanGeijnH , DekkerG . Insulin resistance, vasoactive mediators and preeclampsia. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S26. KraayenbrinkAA , RobsonM , DekkerGA , PearceJM , vanGeijnHP . Prevention of preeclampsia and fetal growth retardation; allylestrenol vs aspirin, a two centered study. Proceedings of 9th International Congress, International Society for the Study of Hypertension in Pregnancy; 1994 March 15‐18; Sydney, Australia. 1994:125. ">Netherlands/UK 1994</a>; <a href="./references#CD004659-bbs2-0183" title="Sajina‐StritarB , Novak‐AntolicZ . Antiaggregational therapy in preventing EPH gestosis and its complications. Journal of Perinatal Medicine1992;20(Suppl 1):73. Sajina‐StritarB , Novak‐AntolicZ . Antiaggregational therapy in preventing EPH gestosis and its complications. Proceedings of 26th British Congress of Obstetrics and Gynaecology; 1992 July 7‐10; Manchester, UK. 1992:454. ">Slovenia 1992</a>; <a href="./references#CD004659-bbs2-0184" title="Sajina‐StritarB . Prevention of gestational hypertension and its complications with ASA and N‐3 fatty acids (comparative study). Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5‐8; Helsinki, Finland. 1994:182. ">Slovenia 1994</a>; <a href="./references#CD004659-bbs2-0185" title="RichardsA , MoodleyJ , NormanR . The use of low dose aspirin in pregnancy induced hypertension. 23rd South African Congress of Obstetrics and Gynaecology; 1986 September 23‐26; South Africa. 1986:16. ">South Africa 1986</a>; <a href="./references#CD004659-bbs2-0187" title="FerrierC , KoeferlU , DuerigP , SchneiderH . Effects of LMW‐heparin and low‐dose aspirin on renal uric acid handling in high‐risk pregnancies. Hypertension in Pregnancy2000;19(Suppl 1):O68. FerrierC , KoferlU , DurigP , SchneiderH . LMW heparin and low dose aspirin for prevention of preeclampsia: preliminary data of a randomised prospective study [abstract]. Hypertension in Pregnancy2000;19(1):82. ">Switzerland 2000</a>; <a href="./references#CD004659-bbs2-0188" title="LuleJ . [Personal communication] Trial of aspirin and methyldopa for moderate hypertension in pregnancy. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 3 June 1993. ">Uganda 1992</a>; <a href="./references#CD004659-bbs2-0189" title="O'Grady JP WilsonB . [Personal communication] Effects of low‐dose aspirin in improving fetal outcome in high risk pregnancies for intrauterine fetal growth retardation and/or preterm delivery. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 19 March 1991. ">USA 1988a</a>; <a href="./references#CD004659-bbs2-0147" title="RobertsCS , BeesonJH . Low dose aspirin in the prevention of preeclampsia in nulliparas. Preliminary results of a prospective, placebo‐controlled, double blind study. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 January 23‐27; Houston, Texas, USA. 1990:89. ">USA 1990</a>). </p> <p>Of the 160 reports, we included 17 new studies (42 reports) and excluded 27 studies (57 reports), A further 29 reports were additional publications for studies already included in the review. We added three new studies (four reports) to <a href="./references#CD004659-bbs1-0003" title="">Studies awaiting classification</a> and 13 studies (28 reports) are ongoing. </p> <p>We carried out an updated search in September 2019 and added 27 new trial reports to <a href="./references#CD004659-bbs1-0003" title="">Studies awaiting classification</a> for consideration at the next update. </p> </section> <section id="CD004659-sec-0093"> <h4 class="title">Included studies</h4> <p>There were 77 randomised trials involving 40,586 women included in this review.</p> <p>For the PARIS IPD review, the search was last updated in December 2005. At that time 63 trials (with 38,026 women) were eligible for inclusion (<a href="./references#CD004659-bbs2-0211" title="AskieLM , DuleyL , Henderson‐SmartDJ , StewartLA . Antiplatelet agents for prevention of pre‐eclampsia: a meta‐analysis of individual patient data. Lancet2007;369:1791‐8. ">Askie 2007</a>). Of these, we were unable to trace the investigators for seven trials, one trialist declined to participate, data were confirmed as lost or non‐retrievable for 17 trials, and although available, were not supplied for two small trials. Ultimately, data were therefore available from 36 trials and 34,288 women (90% of randomised women at that time). Of these, 31 trials recruited women in a primary prevention setting (total 32,217 women and 32,819 babies). </p> <p>Details for each trial are in the <a href="./references#CD004659-sec-0179" title="">Characteristics of included studies</a> table. </p> <section id="CD004659-sec-0094"> <h5 class="title">Methods</h5> <p>All included studies were randomised trials. Overall, methodological quality of these trials was good, with around half the trials having low risk of bias and relatively few having high risk of bias for any assessment (<a href="#CD004659-fig-0002">Figure 2</a>). The nine large trials (over 1000 women) were all high quality (<a href="#CD004659-fig-0003">Figure 3</a>). For sequence generation, all trials were low or unclear risk of bias (<a href="#CD004659-fig-0004">Figure 4</a>). Similarily, for concealment of allocation almost all studies were either low or unclear risk of bias, with all the large trials low risk, and only two small trials (<a href="./references#CD004659-bbs2-0037" title="SharmaN , SrinivasanKJ , NadhamuniK , SrinivasanS . Role of aspirin in high pulsatility index of uterine artery: a consort study. Journal of Obstetrics and Gynecology of India2017 [Epub ahead of print]. ">India 2017</a>, <a href="./references#CD004659-bbs2-0065" title="RamaiyaC , MgayaH . Low dose aspirin in prevention of pregnancy‐induced hypertension in primigravidae at the Muhimbili Medical Centre, Dar Es Salaam. Acta Obstetricia et Gynecologica Scandinavica1997;76(167):1. RamaiyaC , MgayaHN . Low dose aspirin in prevention of pregnancy‐induced hypertension in primigravidae at the Muhimbili Medical Centre, Dar es Salaam. East African Medical Journal1995;72:690‐3. RamaiyaCP . Low dosage of aspirin in prevention of pregnancy induced hypertension (PIH) in primigravidae at Muhimbili Medical Centre, Dar es Salaam [MD thesis]. Ethiopia: University of Dar es Salaam, 1992. ">Tanzania 1995</a>) high risk. High risk of bias was most common for blinding (performance and detection bias), which was usually associated with the trials with no placebo. </p> <div class="figure" id="CD004659-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004659-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph for the nine large trials: review authors' judgements about each risk of bias item presented as percentages across all studies." data-id="CD004659-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph for the nine large trials: review authors' judgements about each risk of bias item presented as percentages across all studies. </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias, summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004659-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias, summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD004659-sec-0095"> <h5 class="title">Sample size</h5> <p>Data were reported for less than 50 women in 19 trials, 50 to 99 women in 17 trials, for 100 to 999 women in 32 trials, and over 1000 women in nine trials. Sample size for the nine large trials (&gt; 1000 women) ranged from 1009 (<a href="./references#CD004659-bbs2-0013" title="Anonymous . ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnancies. British Journal of Obstetrics and Gynaecology1996;103:39‐47. AtallahAN . ECPPA: randomized trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women [abstract]. Journal of Clinical Epidemiology1997;50 Suppl 1:3S. AtallahAN , TabordaWC . ECPPA: the Brazilian low‐dose aspirin study in high risk pregnant women. Hypertension in Pregnancy1997; Vol. 16, issue 1:139. ">Brazil 1996</a>) to 9364 women (<a href="./references#CD004659-bbs2-0019" title="BarJ , HodM , PardoJ , FischB , RabinersonD , KaplanB , et al. Effect on fetal circulation of low‐dose aspirin for prevention and treatment of pre‐eclampsia and intrauterine growth restriction: Doppler flow study. Ultrasound in Obstetrics &amp; Gynaecology1997;9:262‐5. BarJ , PadoaA , HodM , SullivanMH , KaplanB , KidronD . Decreased pathological placental findings in aspirin‐treated pregnant women at risk of hypertensive complications. Hypertension in Pregnancy1997;16:435‐44. BowerSJ , HarringtonKF , SchuchterK , McGirrC , CampbellS . Prediction of pre‐eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. British Journal of Obstetrics and Gynaecology1996;103:625‐9. CLASP (Collaborative Low‐dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low‐dose aspirin for the prevention and treatment of pre‐eclampsia among 9364 pregnant women. Lancet1994;343:619‐29. CLASP Collaborative Group. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. British Journal of Obstetrics and Gynaecology1994;102:861‐8. KylePM , BuckleyD , KissaneJ , deSwietM , RedmanCW . The angiotensin sensitivity test and low‐dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. American Journal of Obstetrics and Gynecology1995;173:865‐72. MathaiM . Aspirin for pre‐eclampsia. National Medical Journal of India1995;8:23‐4. VikhlyaevaK , AsymbekovaGU , ZerdevVP . Aspirin in profilaxis and treatment of placental insufficiency: lessons from Russian aspirin experience. Hypertension in Pregnancy2000;19(Suppl 1):68. ">CLASP 1994</a>). The total sample size for these nine studies was 32,195 women, hence 79% of the women randomised to the trials included in this review were recruited to these nine studies (<a href="./references#CD004659-bbs2-0002" title="NCT02301780 . Combined multi‐marker screening and treatment with aspirin for pre‐eclampsia prevention. clinicaltrials.gov/ct2/show/record/NCT02301780 (first received 26 November 2014). NicolaidesK , ISRCTN13633058 . Combined multi‐marker screening and randomised patient treatment with ASpirin for evidence‐based PRE‐eclampsia prevention. isrctn.com/ISRCTN13633058 (first received 28 October 2010). O'GormanN , WrightD , RolnikDL , NicolaidesKH , PoonLC . Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence‐based PREeclampsia prevention (ASPRE). BMJ Open2016;6(6):e011801. PoonLC , WrightD , RolnikDL , SyngelakiA , DelgadoJL , TsokakiT , et al. Aspirin for Evidence‐Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal of Obstetrics and Gynecology2017;217(5):585.e1‐585.e5. PoonLC , WrightD , RolnikDL , SyngelakiA , DelgadoJL , TsokakiT , et al. Aspre trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal of Obstetrics and Gynecology2017 [Epub ahead of print]. RolnikDL , WrightD , PoonLC , O'GormanN , SyngelakiA , dePaco MatallanaC , et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine2017; Vol. 377, issue 7:613‐22. RolnikDL , WrightD , PoonLC , O'GormanN , SyngelakiA , dePaco MatallanaC , et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia: a multicentre, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2017;50(Suppl 1):2. RolnikDL , WrightD , PoonLC , SyngelakiA , O'GormanN , dePaco MatallanaC , et al. ASPRE trial: performance of screening for preterm pre‐eclampsia. Ultrasound in Obstetrics &amp; Gynecology2017;50(4):492‐5. SenthilhesL , AzriaE , SchmitzT . Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine2017;377(24):2399‐400. WrightD , PoonLC , RolnikDL , SyngelakiA , DelgadoJL , VojtassakovaD , et al. Aspre trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. American Journal of Obstetrics and Gynecology2017;217(6):685.e1‐5. WrightD , RolnikDL , SyngelakiA , dePaco MatallanaC , MachucaM , deAlvaradoM , et al. Aspirin for evidence‐based preeclampsia prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. American Journal of Obstetrics and Gynecology2018;218(6):612.e1‐612.e6. ">ASPRE 2017</a>; <a href="./references#CD004659-bbs2-0011" title="CruickshankJ , RotchellY . The Barbados low‐dose aspirin study in pregnancy (BLASP). 8th World Congress on Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina. 1992:49. ElderMG , deSwietM , SullivanM . A randomised trial of low dose aspirin for primiparae in pregnancy (golding)/barbados low dose aspirin study in pregnancy (blasp) (rotchell et al.) [Letter; comment]. British Journal of Obstetrics and Gynaecology1999;106(2):180. GriffithsJ , RotchellYE , CruickshankJK , Philips‐GayM , StewartA , FarrellB , et al. The Barbados Low‐dose Aspirin Study in Pregnancy (BLASP): a population‐based trial in a developing country with excess pre‐eclampsia and perinatal mortality [abstract]. West Indian Medical Journal1996;45(2 Suppl):26‐7. RotchellYE , CruickshankJK , GriffithsJ , PhillipsG , StuartA , AyersS , et al. Results of the Barbados low dose aspirin study in pregnancy (BLASP): a population‐based trial in a developing country with excess pre‐eclampsia (PE) and perinatal mortality. 27th British Congress of Obstetrics &amp; Gynaecology; 1995 July 4‐7; Dublin, Ireland. 1995:31. RotchellYE , CruickshankJK , Phillips GayM , GriffithsJ , StuartA , FarrellB , et al. Barbados low dose aspirin study in pregnancy (BLASP): a randomized controlled trial for the prevention of pre‐eclampsia and its complications. British Journal of Obstetrics and Gynaecology1998;105:286‐92. ">Barbados 1998</a>; <a href="./references#CD004659-bbs2-0013" title="Anonymous . ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnancies. British Journal of Obstetrics and Gynaecology1996;103:39‐47. AtallahAN . ECPPA: randomized trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women [abstract]. Journal of Clinical Epidemiology1997;50 Suppl 1:3S. AtallahAN , TabordaWC . ECPPA: the Brazilian low‐dose aspirin study in high risk pregnant women. Hypertension in Pregnancy1997; Vol. 16, issue 1:139. ">Brazil 1996</a>; <a href="./references#CD004659-bbs2-0019" title="BarJ , HodM , PardoJ , FischB , RabinersonD , KaplanB , et al. Effect on fetal circulation of low‐dose aspirin for prevention and treatment of pre‐eclampsia and intrauterine growth restriction: Doppler flow study. Ultrasound in Obstetrics &amp; Gynaecology1997;9:262‐5. BarJ , PadoaA , HodM , SullivanMH , KaplanB , KidronD . Decreased pathological placental findings in aspirin‐treated pregnant women at risk of hypertensive complications. Hypertension in Pregnancy1997;16:435‐44. BowerSJ , HarringtonKF , SchuchterK , McGirrC , CampbellS . Prediction of pre‐eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. British Journal of Obstetrics and Gynaecology1996;103:625‐9. CLASP (Collaborative Low‐dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low‐dose aspirin for the prevention and treatment of pre‐eclampsia among 9364 pregnant women. Lancet1994;343:619‐29. CLASP Collaborative Group. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. British Journal of Obstetrics and Gynaecology1994;102:861‐8. KylePM , BuckleyD , KissaneJ , deSwietM , RedmanCW . The angiotensin sensitivity test and low‐dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. American Journal of Obstetrics and Gynecology1995;173:865‐72. MathaiM . Aspirin for pre‐eclampsia. National Medical Journal of India1995;8:23‐4. VikhlyaevaK , AsymbekovaGU , ZerdevVP . Aspirin in profilaxis and treatment of placental insufficiency: lessons from Russian aspirin experience. Hypertension in Pregnancy2000;19(Suppl 1):68. ">CLASP 1994</a>; <a href="./references#CD004659-bbs2-0023" title='ERASME collaborative group. Failure of systematic low dose aspirin to prevent preeclampsia in primigravidae. Hypertension in Pregnancy2000;19(Suppl 1):34. SubtilD , GoeusseP , PuechF , LequienP , BiausqueS , BreartG , et al. Aspirin (100mg) used for prevention of pre‐eclampsia in nulliparous women: the Essai Regional Aspirine Mere‐Enfant study (Part 1). BJOG: an international journal of obstetrics and gynaecology2003;110:475‐84. SubtilD , QuandalleF , Houfflin‐DebargeV , MalekY , TruffertP , BreartG , et al. Low dose aspirin to prevent preeclampsia: what do we learn from a new "negative" trial? [abstract]. European Journal Obstetrics &amp; Gynecology and Reproductive Biology2002;104:179. '>ERASME 2003</a>; <a href="./references#CD004659-bbs2-0047" title="Italian Study of Aspirin in Pregnancy. Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Lancet1993;341:396‐400. ParazziniDF . Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Geburtshilfe und Frauenheilkunde1993;53:822. ParazziniF . Multicenter randomized Italian study of low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Journal of Nephrology1991;4:127‐9. ParazziniF , BenedettoC , FruscaT , GuaschinoS , RomeroM . The Italian study on low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:32. ParazziniF , BortolusR , ChatenoudL , RestelliS , BenedettoC . Follow‐up of children in the Italian Study of Aspirin in Pregnancy. Lancet1994;343:1235. ParazziniF , BortolusR , ChatenoudL , RestelliS , RicciE , MarozioL , et al. Risk factors for pregnancy‐induced hypertension in women at high risk for the condition. Epidemiology1996;7(3):306‐8. ">Italy 1993</a>; <a href="./references#CD004659-bbs2-0050" title="ElderMG , deSwietM , SullivanM . A randomised trial of low dose aspirin for primiparae in pregnancy (golding)/barbados low dose aspirin study in pregnancy (blasp) (rotchell et al.) [Letter; comment]. British Journal of Obstetrics &amp; Gynaecology1999;106(2):180. ForresterTE , JonesD , McCaw‐BinnsA , Palmer‐LevyM , WilksR , BernardGW , et al. Low‐dose aspirin in pregnancy ‐ are there any benefits? [abstract]. West Indian Medical Journal1996;45(2 Suppl):26. GoldingJ . A randomised trial of low dose aspirin for primiparae in pregnancy. British Journal of Obstetrics and Gynaecology1998;105:293‐9. KahwaEK , SargeantLA , McCaw‐BinnsA , McFarlane‐AndersonN , SmikleM , ForresterT , et al. Anticardiolipin antibodies in jamaican primiparae. Journal of Obstetrics and Gynaecology2006;26(2):122‐6. McCaw‐BinnsA , AshleyD , HawkinsN , MacGillivrayI , GoldingJ . International variation in the incidence of hypertension in pregnancy among primiparae: the jamaican experience. 10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4‐8; Seattle, Washington, USA. 1996:168. McCaw‐BinnsA , Jamaica Low‐Dose Aspirin Group. Low dose aspirin in pregnancy ‐ are there any benefits?. 10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4‐8; Seattle, Washington, USA. 1996:76. ">Jamaica 1998</a>; <a href="./references#CD004659-bbs2-0072" title="AbramoviciA , JaukV , WettaL , EdwardsR , BiggioJ , TitaA . Analysis of low‐dose aspirin by smoking status for select perinatal outcomes. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S261. AndrikopoulouM , PurischSE , Handal‐OreficeR , Gyamfi‐BannermanC . Beyond preeclampsia: low dose aspirin reduces spontaneous preterm birth. American Journal of Obstetrics and Gynecology2018;218(1):S10. CaritisS , SibaiB , ThornE , McLaughlinS , NICHD‐MFM Network. Pregnancy effects of non‐proteinuric gestational hypertension (GH). American Journal of Obstetrics and Gynecology1995;172:376. ConnealyB , CarrenoC , KaseB , HartL , BlackwellS , SibaiB . A history of prior preeclampsia is a major risk factor for preterm birth. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S264. DiSessaTG , MorettiML , KhouryA , PulliamDA , ArheartKL , SibaiBM . Cardiac function in fetuses and newborns exposed to low‐dose aspirin during pregnancy. American Journal of Obstetrics and Gynecology1994;171:892‐900. FrattoVM , AnanthCV , Gyamfi‐BannermanC . Late preterm neonatal morbidity in hypertensive versus normotensive women. Hypertension in Pregnancy2016;35(2):242‐9. OhnoM , GirsenA , O'MalleyK , BlumenfeldY , LyellD , ButwickA , et al. Does low‐dose aspirin for preeclampsia prevention increase the risk of antepartum bleeding or placental abruption?. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S189. SibaiB . Low‐dose aspirin (60 mg/d) in pregnancy for the prevention of preeclampsia. 8th World Congress on Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina 1992. 1992:50. SibaiB , CaritisS , PhillipsE , KlebanoffM , McNellisD , RoccoL . Prevention of preeclampsia: low‐dose aspirin in nulliparous women: a double‐blind, placebo controlled trial. American Journal of Obstetrics and Gynecology1993;168:286. SibaiB , CaritisS , PhillipsE , KlebanoffM , PaulR , WitterF , et al. Safety of low‐dose aspirin in healthy nulliparous women: a double‐blind, placebo‐controlled trial. Proceedings of 40th Annual Meeting Society for Gynecologic Investigation; 1993 March; Toronto, Canada. 1993:S102. SibaiB , CaritisS , ThomE , ShawK , McNellisD , NICHD‐MFM Network. Low‐dose aspirin in nulliparous women: safety of epidural and correlation between bleeding time and maternal‐neonatal bleeding complications. American Journal of Obstetrics and Gynecology1994;170:293. SibaiB , GordonT , PhillipsE , McNellisD , CaritisS , RomeroR , et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. Proceedings of 41st Annual Clinical Meeting of The American College of Obstetricians and Gynecologists; 1993 May 3‐6; Washington DC, USA. 1993:2. SibaiBM , CaritisSN , ThomE , KlebanoffM , McNellisD , RoccoL , et al. Prevention of preeclampsia with low‐dose aspirin in healthy, nulliparous pregnant women. New England Journal of Medicine1993;329:1213‐8. SibaiBM , CaritisSN , ThomE , ShawK , McNellisD , NICHD‐MFM Network. Low dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal‐neonatal bleeding complications. American Journal of Obstetrics and Gynecology1995;172:1533‐7. SibaiBM , GordonT , ThomE , CaritisSN , KlebanoffM , McNellisD , et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. American Journal of Obstetrics and Gynecology1995;172:642‐8. TolcherMC , Sangi‐HaghpeykarH , AagaardKM . Race and ethnicity varies both efficacy and attributable risk of low‐dose aspirin (asa) for preeclampsia prevention among low‐risk women. American Journal of Obstetrics and Gynecology2018;218(1 Suppl):S203. WittenFR . [Personal communication] Double‐blind, placebo‐controlled trial of low‐dose aspirin to prevent pre‐eclampsia. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 6 September 1991. YaffeS . [Personal communication] Clinical trial of low dose aspirin (65mg) as a preventative of pre‐eclampsia. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 3 December 1991. ">USA 1993a</a>; <a href="./references#CD004659-bbs2-0075" title="AbramoviciA , JaukV , WettaL , CantuJ , EdwardsR , BiggioJ , et al. Low‐dose aspirin, smoking status, and the risk of spontaneous preterm birth. American Journal of Perinatology2015;32(5):445‐50. AbramoviciA , JaukV , WettaL , EdwardsR , BiggioJ , TitaA . Low‐dose aspirin is associated with a reduction in spontaneous preterm birth among non‐smokers. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S260‐S261. AdkinsK , AllshouseAA , MetzTD , HeyborneKD . Impact of aspirin on fetal growth in diabetic pregnancies according to white classification. American Journal of Obstetrics and Gynecology2017;217(4):465. AdkinsK , MetzT , HeyborneK , AllshouseA . Impact of low‐dose aspirin on fetal growth in diabetic pregnancies: the importance of white classification. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S292. AllshouseAA , JesselRH , HeyborneKD . The impact of low‐dose aspirin on preterm birth: secondary analysis of a randomized controlled trial. Journal of Perinatology2016;36(6):427‐31. CantuJ , BiggioJ , JaukV , EdwardsR , OwenJ , TitaA . Timing of initiation of low‐dose aspirin therapy and preeclampsia prevention in high‐risk women. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S266. CantuJA , JaukVR , OwenJ , BiggioJR , AbramoviciAR , EdwardsRK , et al. Is low‐dose aspirin therapy to prevent preeclampsia more efficacious in non‐obese women or when initiated early in pregnancy?. Journal of Maternal‐Fetal &amp; Neonatal Medicine2015 Jan;8:1‐5. CantuJA , JaukVR , OwenJ , BiggioJR , AbramoviciAR , EdwardsRK , et al. Is low‐dose aspirin therapy to prevent preeclampsia more efficacious in non‐obese women or when initiated early in pregnancy?. Journal of Maternal‐Fetal &amp; Neonatal Medicine2015;28(10):1128‐32. CaritisNS , NICHD‐MFMU Network. Impact of preeclampsia on a subsequent pregnancy. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S120. CaritisS . Low dose aspirin does not prevent preeclampsia in high risk women. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S3. CaritisS , SibaiB , HauthJ , LindheimerM , KlebanoffM , ThomE , et al. Low‐dose aspirin to prevent preeclampsia in women at high risk. New England Journal of Medicine1998;338:701‐5. CostantineM , WuZ , HanY , SaadeG , BlackwellS . Population norms underestimate rates of small for gestational age neonates in high risk pregnancies compared to customized growth norms. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S303. CostantineM , WuZ , HanY , SaadeG , BlackwellS . Relationship between fetal growth evaluated by a customized versus population approach and adverse pregnancy outcomes. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S303. DixonCL , MarrsC Costantine MM , PachecoLD , SaadeGR , ChiossiG . Effect of low‐dose aspirin on the time of onset of preeclampsia and time of delivery. American Journal of Perinatology2017; Vol. 34, issue 12:1219‐26. EuserAG , MetzTD , AllshouseAA , HeyborneK . Low‐dose aspirin reduces the incidence of preeclampsia in women with multiple gestations and elevated human chorionic gonadotropin. Reproductive Sciences2015;22(Suppl 1):70A‐71A. EuserAG , MetzTD , AllshouseAA , HeyborneKD . Low‐dose aspirin for pre‐eclampsia prevention in twins with elevated human chorionic gonadotropin. Journal of Perinatology2016;36(8):601‐5. FrattoVM , AnanthCV , Gyamfi‐BannermanC . Late preterm neonatal morbidity in hypertensive versus normotensive women. Hypertension in Pregnancy2016;35(2):242‐9. Handal‐OreficeR , PurischS , MillerR , Gyamfi‐BannermanC , AndrikopoulouM . Aspirin: a potential for reducing intrauterine growth restriction in low‐risk women. Reproductive Sciences2018;25(1):100A. HauthJ , SibaiB , CaritisS , VanDorstenP , LindheimerM , KlebanoffM , et al. Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high‐risk pregnancies in a low‐dose aspirin trial. American Journal of Obstetrics and Gynecology1998;179:1193‐9. HauthJC , NICHD MFMU Network. Adverse maternal, fetal and neonatal outcomes in a low dose aspirin trial who developed pre‐eclampsia. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S110. HauthJC , NICHD MFMU Network. Maternal serum thromboxane B2 (TxB2) reduction did not predict improved pregnancy outcome in high risk women in a low dose aspirin trial. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S110. HauthJC , NICHD MFMU Network. Safety of low dose aspirin in high risk patients. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S111. JesselR , AllshouseA , HeyborneK . Does low‐dose aspirin prevent preterm birth?. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S342. LeonMG , MoussaHN , LongoM , PedrozaC , HaidarZA , Mendez‐FigueroaH , et al. Rate of gestational diabetes mellitus and pregnancy outcomes in patients with chronic hypertension. American Journal of Perinatology2016;33(8):745‐50. MooreG , AllshouseA , PostA , GalanH , HeyborneK . Early aspirin decreases late‐onset preeclampsia (&gt;34 weeks), particularly in women with chronic hypertension. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S144‐5. MooreGS , AllshouseAA , PostAL , GalanHL , HeyborneKD . Early initiation of low‐dose aspirin for reduction in preeclampsia risk in high‐risk women: a secondary analysis of the MFMU High Risk Aspirin Study. Journal of Perinatology2015;35:328‐31. MooreGS , AllshouseAA , WinnVD , GalanHL , HeyborneKD . Baseline placental growth factor levels for the prediction of benefit from early aspirin prophylaxis for preeclampsia prevention. Pregnancy Hypertension2015;5(4):280‐6. OhnoM , GirsenA , O'MalleyK , BlumenfeldY , LyellD , ButwickA , et al. Does low‐dose aspirin for preeclampsia prevention increase the risk of antepartum bleeding or placental abruption?. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S189. SibaiB . Low‐dose aspirin (60 mg/d) in pregnancy for the prevention of preeclampsia. 8th World Congress on Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina. 1992:50. TolcherMC , Sangi‐HaghpeykarH , AagaardKM . Low‐dose aspirin (asa) for preeclampsia prevention among high‐risk women by ethnicity and race. American Journal of Obstetrics and Gynecology2018;218(1 Suppl):S564. ">USA 1998</a>). </p> </section> <section id="CD004659-sec-0096"> <h5 class="title">Settings</h5> <p>These trials were largely conducted at maternity hospitals, or maternity units within hospitals. Recruitment was usually at antenatal clinics. Trials were conducted in 27 countries. While the majority (66 trials) were conducted in one country, there were five international trials that recruited in more than one country. Of these, two were large trials including over 1000 women (<a href="./references#CD004659-bbs2-0002" title="NCT02301780 . Combined multi‐marker screening and treatment with aspirin for pre‐eclampsia prevention. clinicaltrials.gov/ct2/show/record/NCT02301780 (first received 26 November 2014). NicolaidesK , ISRCTN13633058 . Combined multi‐marker screening and randomised patient treatment with ASpirin for evidence‐based PRE‐eclampsia prevention. isrctn.com/ISRCTN13633058 (first received 28 October 2010). O'GormanN , WrightD , RolnikDL , NicolaidesKH , PoonLC . Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence‐based PREeclampsia prevention (ASPRE). BMJ Open2016;6(6):e011801. PoonLC , WrightD , RolnikDL , SyngelakiA , DelgadoJL , TsokakiT , et al. Aspirin for Evidence‐Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal of Obstetrics and Gynecology2017;217(5):585.e1‐585.e5. PoonLC , WrightD , RolnikDL , SyngelakiA , DelgadoJL , TsokakiT , et al. Aspre trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal of Obstetrics and Gynecology2017 [Epub ahead of print]. RolnikDL , WrightD , PoonLC , O'GormanN , SyngelakiA , dePaco MatallanaC , et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine2017; Vol. 377, issue 7:613‐22. RolnikDL , WrightD , PoonLC , O'GormanN , SyngelakiA , dePaco MatallanaC , et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia: a multicentre, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2017;50(Suppl 1):2. RolnikDL , WrightD , PoonLC , SyngelakiA , O'GormanN , dePaco MatallanaC , et al. ASPRE trial: performance of screening for preterm pre‐eclampsia. Ultrasound in Obstetrics &amp; Gynecology2017;50(4):492‐5. SenthilhesL , AzriaE , SchmitzT . Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine2017;377(24):2399‐400. WrightD , PoonLC , RolnikDL , SyngelakiA , DelgadoJL , VojtassakovaD , et al. Aspre trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. American Journal of Obstetrics and Gynecology2017;217(6):685.e1‐5. WrightD , RolnikDL , SyngelakiA , dePaco MatallanaC , MachucaM , deAlvaradoM , et al. Aspirin for evidence‐based preeclampsia prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. American Journal of Obstetrics and Gynecology2018;218(6):612.e1‐612.e6. ">ASPRE 2017</a>, <a href="./references#CD004659-bbs2-0019" title="BarJ , HodM , PardoJ , FischB , RabinersonD , KaplanB , et al. Effect on fetal circulation of low‐dose aspirin for prevention and treatment of pre‐eclampsia and intrauterine growth restriction: Doppler flow study. Ultrasound in Obstetrics &amp; Gynaecology1997;9:262‐5. BarJ , PadoaA , HodM , SullivanMH , KaplanB , KidronD . Decreased pathological placental findings in aspirin‐treated pregnant women at risk of hypertensive complications. Hypertension in Pregnancy1997;16:435‐44. BowerSJ , HarringtonKF , SchuchterK , McGirrC , CampbellS . Prediction of pre‐eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. British Journal of Obstetrics and Gynaecology1996;103:625‐9. CLASP (Collaborative Low‐dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low‐dose aspirin for the prevention and treatment of pre‐eclampsia among 9364 pregnant women. Lancet1994;343:619‐29. CLASP Collaborative Group. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. British Journal of Obstetrics and Gynaecology1994;102:861‐8. KylePM , BuckleyD , KissaneJ , deSwietM , RedmanCW . The angiotensin sensitivity test and low‐dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. American Journal of Obstetrics and Gynecology1995;173:865‐72. MathaiM . Aspirin for pre‐eclampsia. National Medical Journal of India1995;8:23‐4. VikhlyaevaK , AsymbekovaGU , ZerdevVP . Aspirin in profilaxis and treatment of placental insufficiency: lessons from Russian aspirin experience. Hypertension in Pregnancy2000;19(Suppl 1):68. ">CLASP 1994</a>). Most trials were conducted in high‐resource settings, but some single‐centre and multicentre trials recruited women in middle‐ and low‐resource settings. There were nine large trials in total: six of these took place in high‐income countries (<a href="./references#CD004659-bbs2-0002" title="NCT02301780 . Combined multi‐marker screening and treatment with aspirin for pre‐eclampsia prevention. clinicaltrials.gov/ct2/show/record/NCT02301780 (first received 26 November 2014). NicolaidesK , ISRCTN13633058 . Combined multi‐marker screening and randomised patient treatment with ASpirin for evidence‐based PRE‐eclampsia prevention. isrctn.com/ISRCTN13633058 (first received 28 October 2010). O'GormanN , WrightD , RolnikDL , NicolaidesKH , PoonLC . Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence‐based PREeclampsia prevention (ASPRE). BMJ Open2016;6(6):e011801. PoonLC , WrightD , RolnikDL , SyngelakiA , DelgadoJL , TsokakiT , et al. Aspirin for Evidence‐Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal of Obstetrics and Gynecology2017;217(5):585.e1‐585.e5. PoonLC , WrightD , RolnikDL , SyngelakiA , DelgadoJL , TsokakiT , et al. Aspre trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal of Obstetrics and Gynecology2017 [Epub ahead of print]. RolnikDL , WrightD , PoonLC , O'GormanN , SyngelakiA , dePaco MatallanaC , et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine2017; Vol. 377, issue 7:613‐22. RolnikDL , WrightD , PoonLC , O'GormanN , SyngelakiA , dePaco MatallanaC , et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia: a multicentre, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2017;50(Suppl 1):2. RolnikDL , WrightD , PoonLC , SyngelakiA , O'GormanN , dePaco MatallanaC , et al. ASPRE trial: performance of screening for preterm pre‐eclampsia. Ultrasound in Obstetrics &amp; Gynecology2017;50(4):492‐5. SenthilhesL , AzriaE , SchmitzT . Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine2017;377(24):2399‐400. WrightD , PoonLC , RolnikDL , SyngelakiA , DelgadoJL , VojtassakovaD , et al. Aspre trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. American Journal of Obstetrics and Gynecology2017;217(6):685.e1‐5. WrightD , RolnikDL , SyngelakiA , dePaco MatallanaC , MachucaM , deAlvaradoM , et al. Aspirin for evidence‐based preeclampsia prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. American Journal of Obstetrics and Gynecology2018;218(6):612.e1‐612.e6. ">ASPRE 2017</a>; <a href="./references#CD004659-bbs2-0011" title="CruickshankJ , RotchellY . The Barbados low‐dose aspirin study in pregnancy (BLASP). 8th World Congress on Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina. 1992:49. ElderMG , deSwietM , SullivanM . A randomised trial of low dose aspirin for primiparae in pregnancy (golding)/barbados low dose aspirin study in pregnancy (blasp) (rotchell et al.) [Letter; comment]. British Journal of Obstetrics and Gynaecology1999;106(2):180. GriffithsJ , RotchellYE , CruickshankJK , Philips‐GayM , StewartA , FarrellB , et al. The Barbados Low‐dose Aspirin Study in Pregnancy (BLASP): a population‐based trial in a developing country with excess pre‐eclampsia and perinatal mortality [abstract]. West Indian Medical Journal1996;45(2 Suppl):26‐7. RotchellYE , CruickshankJK , GriffithsJ , PhillipsG , StuartA , AyersS , et al. Results of the Barbados low dose aspirin study in pregnancy (BLASP): a population‐based trial in a developing country with excess pre‐eclampsia (PE) and perinatal mortality. 27th British Congress of Obstetrics &amp; Gynaecology; 1995 July 4‐7; Dublin, Ireland. 1995:31. RotchellYE , CruickshankJK , Phillips GayM , GriffithsJ , StuartA , FarrellB , et al. Barbados low dose aspirin study in pregnancy (BLASP): a randomized controlled trial for the prevention of pre‐eclampsia and its complications. British Journal of Obstetrics and Gynaecology1998;105:286‐92. ">Barbados 1998</a>; <a href="./references#CD004659-bbs2-0023" title='ERASME collaborative group. Failure of systematic low dose aspirin to prevent preeclampsia in primigravidae. Hypertension in Pregnancy2000;19(Suppl 1):34. SubtilD , GoeusseP , PuechF , LequienP , BiausqueS , BreartG , et al. Aspirin (100mg) used for prevention of pre‐eclampsia in nulliparous women: the Essai Regional Aspirine Mere‐Enfant study (Part 1). BJOG: an international journal of obstetrics and gynaecology2003;110:475‐84. SubtilD , QuandalleF , Houfflin‐DebargeV , MalekY , TruffertP , BreartG , et al. Low dose aspirin to prevent preeclampsia: what do we learn from a new "negative" trial? [abstract]. European Journal Obstetrics &amp; Gynecology and Reproductive Biology2002;104:179. '>ERASME 2003</a>; <a href="./references#CD004659-bbs2-0047" title="Italian Study of Aspirin in Pregnancy. Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Lancet1993;341:396‐400. ParazziniDF . Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Geburtshilfe und Frauenheilkunde1993;53:822. ParazziniF . Multicenter randomized Italian study of low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Journal of Nephrology1991;4:127‐9. ParazziniF , BenedettoC , FruscaT , GuaschinoS , RomeroM . The Italian study on low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:32. ParazziniF , BortolusR , ChatenoudL , RestelliS , BenedettoC . Follow‐up of children in the Italian Study of Aspirin in Pregnancy. Lancet1994;343:1235. ParazziniF , BortolusR , ChatenoudL , RestelliS , RicciE , MarozioL , et al. Risk factors for pregnancy‐induced hypertension in women at high risk for the condition. Epidemiology1996;7(3):306‐8. ">Italy 1993</a>; <a href="./references#CD004659-bbs2-0072" title="AbramoviciA , JaukV , WettaL , EdwardsR , BiggioJ , TitaA . Analysis of low‐dose aspirin by smoking status for select perinatal outcomes. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S261. AndrikopoulouM , PurischSE , Handal‐OreficeR , Gyamfi‐BannermanC . Beyond preeclampsia: low dose aspirin reduces spontaneous preterm birth. American Journal of Obstetrics and Gynecology2018;218(1):S10. CaritisS , SibaiB , ThornE , McLaughlinS , NICHD‐MFM Network. Pregnancy effects of non‐proteinuric gestational hypertension (GH). American Journal of Obstetrics and Gynecology1995;172:376. ConnealyB , CarrenoC , KaseB , HartL , BlackwellS , SibaiB . A history of prior preeclampsia is a major risk factor for preterm birth. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S264. DiSessaTG , MorettiML , KhouryA , PulliamDA , ArheartKL , SibaiBM . Cardiac function in fetuses and newborns exposed to low‐dose aspirin during pregnancy. American Journal of Obstetrics and Gynecology1994;171:892‐900. FrattoVM , AnanthCV , Gyamfi‐BannermanC . Late preterm neonatal morbidity in hypertensive versus normotensive women. Hypertension in Pregnancy2016;35(2):242‐9. OhnoM , GirsenA , O'MalleyK , BlumenfeldY , LyellD , ButwickA , et al. Does low‐dose aspirin for preeclampsia prevention increase the risk of antepartum bleeding or placental abruption?. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S189. SibaiB . Low‐dose aspirin (60 mg/d) in pregnancy for the prevention of preeclampsia. 8th World Congress on Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina 1992. 1992:50. SibaiB , CaritisS , PhillipsE , KlebanoffM , McNellisD , RoccoL . Prevention of preeclampsia: low‐dose aspirin in nulliparous women: a double‐blind, placebo controlled trial. American Journal of Obstetrics and Gynecology1993;168:286. SibaiB , CaritisS , PhillipsE , KlebanoffM , PaulR , WitterF , et al. Safety of low‐dose aspirin in healthy nulliparous women: a double‐blind, placebo‐controlled trial. Proceedings of 40th Annual Meeting Society for Gynecologic Investigation; 1993 March; Toronto, Canada. 1993:S102. SibaiB , CaritisS , ThomE , ShawK , McNellisD , NICHD‐MFM Network. Low‐dose aspirin in nulliparous women: safety of epidural and correlation between bleeding time and maternal‐neonatal bleeding complications. American Journal of Obstetrics and Gynecology1994;170:293. SibaiB , GordonT , PhillipsE , McNellisD , CaritisS , RomeroR , et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. Proceedings of 41st Annual Clinical Meeting of The American College of Obstetricians and Gynecologists; 1993 May 3‐6; Washington DC, USA. 1993:2. SibaiBM , CaritisSN , ThomE , KlebanoffM , McNellisD , RoccoL , et al. Prevention of preeclampsia with low‐dose aspirin in healthy, nulliparous pregnant women. New England Journal of Medicine1993;329:1213‐8. SibaiBM , CaritisSN , ThomE , ShawK , McNellisD , NICHD‐MFM Network. Low dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal‐neonatal bleeding complications. American Journal of Obstetrics and Gynecology1995;172:1533‐7. SibaiBM , GordonT , ThomE , CaritisSN , KlebanoffM , McNellisD , et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. American Journal of Obstetrics and Gynecology1995;172:642‐8. TolcherMC , Sangi‐HaghpeykarH , AagaardKM . Race and ethnicity varies both efficacy and attributable risk of low‐dose aspirin (asa) for preeclampsia prevention among low‐risk women. American Journal of Obstetrics and Gynecology2018;218(1 Suppl):S203. WittenFR . [Personal communication] Double‐blind, placebo‐controlled trial of low‐dose aspirin to prevent pre‐eclampsia. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 6 September 1991. YaffeS . [Personal communication] Clinical trial of low dose aspirin (65mg) as a preventative of pre‐eclampsia. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 3 December 1991. ">USA 1993a</a>; <a href="./references#CD004659-bbs2-0075" title="AbramoviciA , JaukV , WettaL , CantuJ , EdwardsR , BiggioJ , et al. Low‐dose aspirin, smoking status, and the risk of spontaneous preterm birth. American Journal of Perinatology2015;32(5):445‐50. AbramoviciA , JaukV , WettaL , EdwardsR , BiggioJ , TitaA . Low‐dose aspirin is associated with a reduction in spontaneous preterm birth among non‐smokers. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S260‐S261. AdkinsK , AllshouseAA , MetzTD , HeyborneKD . Impact of aspirin on fetal growth in diabetic pregnancies according to white classification. American Journal of Obstetrics and Gynecology2017;217(4):465. AdkinsK , MetzT , HeyborneK , AllshouseA . Impact of low‐dose aspirin on fetal growth in diabetic pregnancies: the importance of white classification. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S292. AllshouseAA , JesselRH , HeyborneKD . The impact of low‐dose aspirin on preterm birth: secondary analysis of a randomized controlled trial. Journal of Perinatology2016;36(6):427‐31. CantuJ , BiggioJ , JaukV , EdwardsR , OwenJ , TitaA . Timing of initiation of low‐dose aspirin therapy and preeclampsia prevention in high‐risk women. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S266. CantuJA , JaukVR , OwenJ , BiggioJR , AbramoviciAR , EdwardsRK , et al. Is low‐dose aspirin therapy to prevent preeclampsia more efficacious in non‐obese women or when initiated early in pregnancy?. Journal of Maternal‐Fetal &amp; Neonatal Medicine2015 Jan;8:1‐5. CantuJA , JaukVR , OwenJ , BiggioJR , AbramoviciAR , EdwardsRK , et al. Is low‐dose aspirin therapy to prevent preeclampsia more efficacious in non‐obese women or when initiated early in pregnancy?. Journal of Maternal‐Fetal &amp; Neonatal Medicine2015;28(10):1128‐32. CaritisNS , NICHD‐MFMU Network. Impact of preeclampsia on a subsequent pregnancy. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S120. CaritisS . Low dose aspirin does not prevent preeclampsia in high risk women. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S3. CaritisS , SibaiB , HauthJ , LindheimerM , KlebanoffM , ThomE , et al. Low‐dose aspirin to prevent preeclampsia in women at high risk. New England Journal of Medicine1998;338:701‐5. CostantineM , WuZ , HanY , SaadeG , BlackwellS . Population norms underestimate rates of small for gestational age neonates in high risk pregnancies compared to customized growth norms. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S303. CostantineM , WuZ , HanY , SaadeG , BlackwellS . Relationship between fetal growth evaluated by a customized versus population approach and adverse pregnancy outcomes. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S303. DixonCL , MarrsC Costantine MM , PachecoLD , SaadeGR , ChiossiG . Effect of low‐dose aspirin on the time of onset of preeclampsia and time of delivery. American Journal of Perinatology2017; Vol. 34, issue 12:1219‐26. EuserAG , MetzTD , AllshouseAA , HeyborneK . Low‐dose aspirin reduces the incidence of preeclampsia in women with multiple gestations and elevated human chorionic gonadotropin. Reproductive Sciences2015;22(Suppl 1):70A‐71A. EuserAG , MetzTD , AllshouseAA , HeyborneKD . Low‐dose aspirin for pre‐eclampsia prevention in twins with elevated human chorionic gonadotropin. Journal of Perinatology2016;36(8):601‐5. FrattoVM , AnanthCV , Gyamfi‐BannermanC . Late preterm neonatal morbidity in hypertensive versus normotensive women. Hypertension in Pregnancy2016;35(2):242‐9. Handal‐OreficeR , PurischS , MillerR , Gyamfi‐BannermanC , AndrikopoulouM . Aspirin: a potential for reducing intrauterine growth restriction in low‐risk women. Reproductive Sciences2018;25(1):100A. HauthJ , SibaiB , CaritisS , VanDorstenP , LindheimerM , KlebanoffM , et al. Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high‐risk pregnancies in a low‐dose aspirin trial. American Journal of Obstetrics and Gynecology1998;179:1193‐9. HauthJC , NICHD MFMU Network. Adverse maternal, fetal and neonatal outcomes in a low dose aspirin trial who developed pre‐eclampsia. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S110. HauthJC , NICHD MFMU Network. Maternal serum thromboxane B2 (TxB2) reduction did not predict improved pregnancy outcome in high risk women in a low dose aspirin trial. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S110. HauthJC , NICHD MFMU Network. Safety of low dose aspirin in high risk patients. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S111. JesselR , AllshouseA , HeyborneK . Does low‐dose aspirin prevent preterm birth?. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S342. LeonMG , MoussaHN , LongoM , PedrozaC , HaidarZA , Mendez‐FigueroaH , et al. Rate of gestational diabetes mellitus and pregnancy outcomes in patients with chronic hypertension. American Journal of Perinatology2016;33(8):745‐50. MooreG , AllshouseA , PostA , GalanH , HeyborneK . Early aspirin decreases late‐onset preeclampsia (&gt;34 weeks), particularly in women with chronic hypertension. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S144‐5. MooreGS , AllshouseAA , PostAL , GalanHL , HeyborneKD . Early initiation of low‐dose aspirin for reduction in preeclampsia risk in high‐risk women: a secondary analysis of the MFMU High Risk Aspirin Study. Journal of Perinatology2015;35:328‐31. MooreGS , AllshouseAA , WinnVD , GalanHL , HeyborneKD . Baseline placental growth factor levels for the prediction of benefit from early aspirin prophylaxis for preeclampsia prevention. Pregnancy Hypertension2015;5(4):280‐6. OhnoM , GirsenA , O'MalleyK , BlumenfeldY , LyellD , ButwickA , et al. Does low‐dose aspirin for preeclampsia prevention increase the risk of antepartum bleeding or placental abruption?. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S189. SibaiB . Low‐dose aspirin (60 mg/d) in pregnancy for the prevention of preeclampsia. 8th World Congress on Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina. 1992:50. TolcherMC , Sangi‐HaghpeykarH , AagaardKM . Low‐dose aspirin (asa) for preeclampsia prevention among high‐risk women by ethnicity and race. American Journal of Obstetrics and Gynecology2018;218(1 Suppl):S564. ">USA 1998</a>); two took place in upper‐middle income countries (<a href="./references#CD004659-bbs2-0013" title="Anonymous . ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnancies. British Journal of Obstetrics and Gynaecology1996;103:39‐47. AtallahAN . ECPPA: randomized trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women [abstract]. Journal of Clinical Epidemiology1997;50 Suppl 1:3S. AtallahAN , TabordaWC . ECPPA: the Brazilian low‐dose aspirin study in high risk pregnant women. Hypertension in Pregnancy1997; Vol. 16, issue 1:139. ">Brazil 1996</a>; <a href="./references#CD004659-bbs2-0050" title="ElderMG , deSwietM , SullivanM . A randomised trial of low dose aspirin for primiparae in pregnancy (golding)/barbados low dose aspirin study in pregnancy (blasp) (rotchell et al.) [Letter; comment]. British Journal of Obstetrics &amp; Gynaecology1999;106(2):180. ForresterTE , JonesD , McCaw‐BinnsA , Palmer‐LevyM , WilksR , BernardGW , et al. Low‐dose aspirin in pregnancy ‐ are there any benefits? [abstract]. West Indian Medical Journal1996;45(2 Suppl):26. GoldingJ . A randomised trial of low dose aspirin for primiparae in pregnancy. British Journal of Obstetrics and Gynaecology1998;105:293‐9. KahwaEK , SargeantLA , McCaw‐BinnsA , McFarlane‐AndersonN , SmikleM , ForresterT , et al. Anticardiolipin antibodies in jamaican primiparae. Journal of Obstetrics and Gynaecology2006;26(2):122‐6. McCaw‐BinnsA , AshleyD , HawkinsN , MacGillivrayI , GoldingJ . International variation in the incidence of hypertension in pregnancy among primiparae: the jamaican experience. 10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4‐8; Seattle, Washington, USA. 1996:168. McCaw‐BinnsA , Jamaica Low‐Dose Aspirin Group. Low dose aspirin in pregnancy ‐ are there any benefits?. 10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4‐8; Seattle, Washington, USA. 1996:76. ">Jamaica 1998</a>), and one took place in centres in both high‐ and upper‐middle income countries (<a href="./references#CD004659-bbs2-0019" title="BarJ , HodM , PardoJ , FischB , RabinersonD , KaplanB , et al. Effect on fetal circulation of low‐dose aspirin for prevention and treatment of pre‐eclampsia and intrauterine growth restriction: Doppler flow study. Ultrasound in Obstetrics &amp; Gynaecology1997;9:262‐5. BarJ , PadoaA , HodM , SullivanMH , KaplanB , KidronD . Decreased pathological placental findings in aspirin‐treated pregnant women at risk of hypertensive complications. Hypertension in Pregnancy1997;16:435‐44. BowerSJ , HarringtonKF , SchuchterK , McGirrC , CampbellS . Prediction of pre‐eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. British Journal of Obstetrics and Gynaecology1996;103:625‐9. CLASP (Collaborative Low‐dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low‐dose aspirin for the prevention and treatment of pre‐eclampsia among 9364 pregnant women. Lancet1994;343:619‐29. CLASP Collaborative Group. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. British Journal of Obstetrics and Gynaecology1994;102:861‐8. KylePM , BuckleyD , KissaneJ , deSwietM , RedmanCW . The angiotensin sensitivity test and low‐dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. American Journal of Obstetrics and Gynecology1995;173:865‐72. MathaiM . Aspirin for pre‐eclampsia. National Medical Journal of India1995;8:23‐4. VikhlyaevaK , AsymbekovaGU , ZerdevVP . Aspirin in profilaxis and treatment of placental insufficiency: lessons from Russian aspirin experience. Hypertension in Pregnancy2000;19(Suppl 1):68. ">CLASP 1994</a>) (economies defined as per <a href="./references#CD004659-bbs2-0274" title="WorldBank . World Bank Country and Lending Groups. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519 (accessed 9th May 2019). ">World Bank 2018</a>). </p> <p>The most common recruitment countries were Australia (eight trials), the USA (seven trials), the UK (seven trials), France (five trials), the Netherlands (five trials), Israel (five trials), Italy (five trials), India (five trials), Finland (five trials), Iran (five trials) and Spain (four trials). </p> <p>Eight trials were published between 1985 and 1989, 48 between 1990 and 1999, 11 between 2000 and 2009, and 10 between 2010 and 2018. </p> </section> <section id="CD004659-sec-0097"> <h5 class="title">Participants</h5> <p>There was a wide range in incidence of pre‐eclampsia between women in different trials (2% to 60% in the placebo arm) and, in many studies, between low‐risk and high‐risk women in the same trial. Most trials were primary prevention studies, and so recruited women without gestational hypertension who were at risk of developing pre‐eclampsia. Early small trials published in the 1980s and early 1990s recruited women at high risk of pre‐eclampsia, The subsequent large trials primarily recruited women across the range of low, moderate or high risk of pre‐eclampsia. IPD data were available for eight of these nine large studies, allowing individual women in each trial to be analysed in the appropriate risk category. In three large trials almost all the women were at low or moderate risk, with just one high‐risk woman in <a href="./references#CD004659-bbs2-0072" title="AbramoviciA , JaukV , WettaL , EdwardsR , BiggioJ , TitaA . Analysis of low‐dose aspirin by smoking status for select perinatal outcomes. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S261. AndrikopoulouM , PurischSE , Handal‐OreficeR , Gyamfi‐BannermanC . Beyond preeclampsia: low dose aspirin reduces spontaneous preterm birth. American Journal of Obstetrics and Gynecology2018;218(1):S10. CaritisS , SibaiB , ThornE , McLaughlinS , NICHD‐MFM Network. Pregnancy effects of non‐proteinuric gestational hypertension (GH). American Journal of Obstetrics and Gynecology1995;172:376. ConnealyB , CarrenoC , KaseB , HartL , BlackwellS , SibaiB . A history of prior preeclampsia is a major risk factor for preterm birth. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S264. DiSessaTG , MorettiML , KhouryA , PulliamDA , ArheartKL , SibaiBM . Cardiac function in fetuses and newborns exposed to low‐dose aspirin during pregnancy. American Journal of Obstetrics and Gynecology1994;171:892‐900. FrattoVM , AnanthCV , Gyamfi‐BannermanC . Late preterm neonatal morbidity in hypertensive versus normotensive women. Hypertension in Pregnancy2016;35(2):242‐9. OhnoM , GirsenA , O'MalleyK , BlumenfeldY , LyellD , ButwickA , et al. Does low‐dose aspirin for preeclampsia prevention increase the risk of antepartum bleeding or placental abruption?. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S189. SibaiB . Low‐dose aspirin (60 mg/d) in pregnancy for the prevention of preeclampsia. 8th World Congress on Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina 1992. 1992:50. SibaiB , CaritisS , PhillipsE , KlebanoffM , McNellisD , RoccoL . Prevention of preeclampsia: low‐dose aspirin in nulliparous women: a double‐blind, placebo controlled trial. American Journal of Obstetrics and Gynecology1993;168:286. SibaiB , CaritisS , PhillipsE , KlebanoffM , PaulR , WitterF , et al. Safety of low‐dose aspirin in healthy nulliparous women: a double‐blind, placebo‐controlled trial. Proceedings of 40th Annual Meeting Society for Gynecologic Investigation; 1993 March; Toronto, Canada. 1993:S102. SibaiB , CaritisS , ThomE , ShawK , McNellisD , NICHD‐MFM Network. Low‐dose aspirin in nulliparous women: safety of epidural and correlation between bleeding time and maternal‐neonatal bleeding complications. American Journal of Obstetrics and Gynecology1994;170:293. SibaiB , GordonT , PhillipsE , McNellisD , CaritisS , RomeroR , et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. Proceedings of 41st Annual Clinical Meeting of The American College of Obstetricians and Gynecologists; 1993 May 3‐6; Washington DC, USA. 1993:2. SibaiBM , CaritisSN , ThomE , KlebanoffM , McNellisD , RoccoL , et al. Prevention of preeclampsia with low‐dose aspirin in healthy, nulliparous pregnant women. New England Journal of Medicine1993;329:1213‐8. SibaiBM , CaritisSN , ThomE , ShawK , McNellisD , NICHD‐MFM Network. Low dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal‐neonatal bleeding complications. American Journal of Obstetrics and Gynecology1995;172:1533‐7. SibaiBM , GordonT , ThomE , CaritisSN , KlebanoffM , McNellisD , et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. American Journal of Obstetrics and Gynecology1995;172:642‐8. TolcherMC , Sangi‐HaghpeykarH , AagaardKM . Race and ethnicity varies both efficacy and attributable risk of low‐dose aspirin (asa) for preeclampsia prevention among low‐risk women. American Journal of Obstetrics and Gynecology2018;218(1 Suppl):S203. WittenFR . [Personal communication] Double‐blind, placebo‐controlled trial of low‐dose aspirin to prevent pre‐eclampsia. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 6 September 1991. YaffeS . [Personal communication] Clinical trial of low dose aspirin (65mg) as a preventative of pre‐eclampsia. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 3 December 1991. ">USA 1993a</a>, 176 (5% of 3,697) in <a href="./references#CD004659-bbs2-0011" title="CruickshankJ , RotchellY . The Barbados low‐dose aspirin study in pregnancy (BLASP). 8th World Congress on Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina. 1992:49. ElderMG , deSwietM , SullivanM . A randomised trial of low dose aspirin for primiparae in pregnancy (golding)/barbados low dose aspirin study in pregnancy (blasp) (rotchell et al.) [Letter; comment]. British Journal of Obstetrics and Gynaecology1999;106(2):180. GriffithsJ , RotchellYE , CruickshankJK , Philips‐GayM , StewartA , FarrellB , et al. The Barbados Low‐dose Aspirin Study in Pregnancy (BLASP): a population‐based trial in a developing country with excess pre‐eclampsia and perinatal mortality [abstract]. West Indian Medical Journal1996;45(2 Suppl):26‐7. RotchellYE , CruickshankJK , GriffithsJ , PhillipsG , StuartA , AyersS , et al. Results of the Barbados low dose aspirin study in pregnancy (BLASP): a population‐based trial in a developing country with excess pre‐eclampsia (PE) and perinatal mortality. 27th British Congress of Obstetrics &amp; Gynaecology; 1995 July 4‐7; Dublin, Ireland. 1995:31. RotchellYE , CruickshankJK , Phillips GayM , GriffithsJ , StuartA , FarrellB , et al. Barbados low dose aspirin study in pregnancy (BLASP): a randomized controlled trial for the prevention of pre‐eclampsia and its complications. British Journal of Obstetrics and Gynaecology1998;105:286‐92. ">Barbados 1998</a>, and 246 (7% of 3294) in <a href="./references#CD004659-bbs2-0023" title='ERASME collaborative group. Failure of systematic low dose aspirin to prevent preeclampsia in primigravidae. Hypertension in Pregnancy2000;19(Suppl 1):34. SubtilD , GoeusseP , PuechF , LequienP , BiausqueS , BreartG , et al. Aspirin (100mg) used for prevention of pre‐eclampsia in nulliparous women: the Essai Regional Aspirine Mere‐Enfant study (Part 1). BJOG: an international journal of obstetrics and gynaecology2003;110:475‐84. SubtilD , QuandalleF , Houfflin‐DebargeV , MalekY , TruffertP , BreartG , et al. Low dose aspirin to prevent preeclampsia: what do we learn from a new "negative" trial? [abstract]. European Journal Obstetrics &amp; Gynecology and Reproductive Biology2002;104:179. '>ERASME 2003</a>. In <a href="./references#CD004659-bbs2-0047" title="Italian Study of Aspirin in Pregnancy. Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Lancet1993;341:396‐400. ParazziniDF . Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Geburtshilfe und Frauenheilkunde1993;53:822. ParazziniF . Multicenter randomized Italian study of low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Journal of Nephrology1991;4:127‐9. ParazziniF , BenedettoC , FruscaT , GuaschinoS , RomeroM . The Italian study on low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:32. ParazziniF , BortolusR , ChatenoudL , RestelliS , BenedettoC . Follow‐up of children in the Italian Study of Aspirin in Pregnancy. Lancet1994;343:1235. ParazziniF , BortolusR , ChatenoudL , RestelliS , RicciE , MarozioL , et al. Risk factors for pregnancy‐induced hypertension in women at high risk for the condition. Epidemiology1996;7(3):306‐8. ">Italy 1993</a> just over one quarter (324/1106, 29%) of women were high risk, and in <a href="./references#CD004659-bbs2-0050" title="ElderMG , deSwietM , SullivanM . A randomised trial of low dose aspirin for primiparae in pregnancy (golding)/barbados low dose aspirin study in pregnancy (blasp) (rotchell et al.) [Letter; comment]. British Journal of Obstetrics &amp; Gynaecology1999;106(2):180. ForresterTE , JonesD , McCaw‐BinnsA , Palmer‐LevyM , WilksR , BernardGW , et al. Low‐dose aspirin in pregnancy ‐ are there any benefits? [abstract]. West Indian Medical Journal1996;45(2 Suppl):26. GoldingJ . A randomised trial of low dose aspirin for primiparae in pregnancy. British Journal of Obstetrics and Gynaecology1998;105:293‐9. KahwaEK , SargeantLA , McCaw‐BinnsA , McFarlane‐AndersonN , SmikleM , ForresterT , et al. Anticardiolipin antibodies in jamaican primiparae. Journal of Obstetrics and Gynaecology2006;26(2):122‐6. McCaw‐BinnsA , AshleyD , HawkinsN , MacGillivrayI , GoldingJ . International variation in the incidence of hypertension in pregnancy among primiparae: the jamaican experience. 10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4‐8; Seattle, Washington, USA. 1996:168. McCaw‐BinnsA , Jamaica Low‐Dose Aspirin Group. Low dose aspirin in pregnancy ‐ are there any benefits?. 10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4‐8; Seattle, Washington, USA. 1996:76. ">Jamaica 1998</a> just under a half. Two thirds of women were high risk in <a href="./references#CD004659-bbs2-0013" title="Anonymous . ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnancies. British Journal of Obstetrics and Gynaecology1996;103:39‐47. AtallahAN . ECPPA: randomized trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women [abstract]. Journal of Clinical Epidemiology1997;50 Suppl 1:3S. AtallahAN , TabordaWC . ECPPA: the Brazilian low‐dose aspirin study in high risk pregnant women. Hypertension in Pregnancy1997; Vol. 16, issue 1:139. ">Brazil 1996</a> (636/1009, 63%) and <a href="./references#CD004659-bbs2-0019" title="BarJ , HodM , PardoJ , FischB , RabinersonD , KaplanB , et al. Effect on fetal circulation of low‐dose aspirin for prevention and treatment of pre‐eclampsia and intrauterine growth restriction: Doppler flow study. Ultrasound in Obstetrics &amp; Gynaecology1997;9:262‐5. BarJ , PadoaA , HodM , SullivanMH , KaplanB , KidronD . Decreased pathological placental findings in aspirin‐treated pregnant women at risk of hypertensive complications. Hypertension in Pregnancy1997;16:435‐44. BowerSJ , HarringtonKF , SchuchterK , McGirrC , CampbellS . Prediction of pre‐eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. British Journal of Obstetrics and Gynaecology1996;103:625‐9. CLASP (Collaborative Low‐dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low‐dose aspirin for the prevention and treatment of pre‐eclampsia among 9364 pregnant women. Lancet1994;343:619‐29. CLASP Collaborative Group. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. British Journal of Obstetrics and Gynaecology1994;102:861‐8. KylePM , BuckleyD , KissaneJ , deSwietM , RedmanCW . The angiotensin sensitivity test and low‐dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. American Journal of Obstetrics and Gynecology1995;173:865‐72. MathaiM . Aspirin for pre‐eclampsia. National Medical Journal of India1995;8:23‐4. VikhlyaevaK , AsymbekovaGU , ZerdevVP . Aspirin in profilaxis and treatment of placental insufficiency: lessons from Russian aspirin experience. Hypertension in Pregnancy2000;19(Suppl 1):68. ">CLASP 1994</a>,(6036/9364, 64%), as were three quarters of those in <a href="./references#CD004659-bbs2-0075" title="AbramoviciA , JaukV , WettaL , CantuJ , EdwardsR , BiggioJ , et al. Low‐dose aspirin, smoking status, and the risk of spontaneous preterm birth. American Journal of Perinatology2015;32(5):445‐50. AbramoviciA , JaukV , WettaL , EdwardsR , BiggioJ , TitaA . Low‐dose aspirin is associated with a reduction in spontaneous preterm birth among non‐smokers. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S260‐S261. AdkinsK , AllshouseAA , MetzTD , HeyborneKD . Impact of aspirin on fetal growth in diabetic pregnancies according to white classification. American Journal of Obstetrics and Gynecology2017;217(4):465. AdkinsK , MetzT , HeyborneK , AllshouseA . Impact of low‐dose aspirin on fetal growth in diabetic pregnancies: the importance of white classification. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S292. AllshouseAA , JesselRH , HeyborneKD . The impact of low‐dose aspirin on preterm birth: secondary analysis of a randomized controlled trial. Journal of Perinatology2016;36(6):427‐31. CantuJ , BiggioJ , JaukV , EdwardsR , OwenJ , TitaA . Timing of initiation of low‐dose aspirin therapy and preeclampsia prevention in high‐risk women. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S266. CantuJA , JaukVR , OwenJ , BiggioJR , AbramoviciAR , EdwardsRK , et al. Is low‐dose aspirin therapy to prevent preeclampsia more efficacious in non‐obese women or when initiated early in pregnancy?. Journal of Maternal‐Fetal &amp; Neonatal Medicine2015 Jan;8:1‐5. CantuJA , JaukVR , OwenJ , BiggioJR , AbramoviciAR , EdwardsRK , et al. Is low‐dose aspirin therapy to prevent preeclampsia more efficacious in non‐obese women or when initiated early in pregnancy?. Journal of Maternal‐Fetal &amp; Neonatal Medicine2015;28(10):1128‐32. CaritisNS , NICHD‐MFMU Network. Impact of preeclampsia on a subsequent pregnancy. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S120. CaritisS . Low dose aspirin does not prevent preeclampsia in high risk women. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S3. CaritisS , SibaiB , HauthJ , LindheimerM , KlebanoffM , ThomE , et al. Low‐dose aspirin to prevent preeclampsia in women at high risk. New England Journal of Medicine1998;338:701‐5. CostantineM , WuZ , HanY , SaadeG , BlackwellS . Population norms underestimate rates of small for gestational age neonates in high risk pregnancies compared to customized growth norms. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S303. CostantineM , WuZ , HanY , SaadeG , BlackwellS . Relationship between fetal growth evaluated by a customized versus population approach and adverse pregnancy outcomes. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S303. DixonCL , MarrsC Costantine MM , PachecoLD , SaadeGR , ChiossiG . Effect of low‐dose aspirin on the time of onset of preeclampsia and time of delivery. American Journal of Perinatology2017; Vol. 34, issue 12:1219‐26. EuserAG , MetzTD , AllshouseAA , HeyborneK . Low‐dose aspirin reduces the incidence of preeclampsia in women with multiple gestations and elevated human chorionic gonadotropin. Reproductive Sciences2015;22(Suppl 1):70A‐71A. EuserAG , MetzTD , AllshouseAA , HeyborneKD . Low‐dose aspirin for pre‐eclampsia prevention in twins with elevated human chorionic gonadotropin. Journal of Perinatology2016;36(8):601‐5. FrattoVM , AnanthCV , Gyamfi‐BannermanC . Late preterm neonatal morbidity in hypertensive versus normotensive women. Hypertension in Pregnancy2016;35(2):242‐9. Handal‐OreficeR , PurischS , MillerR , Gyamfi‐BannermanC , AndrikopoulouM . Aspirin: a potential for reducing intrauterine growth restriction in low‐risk women. Reproductive Sciences2018;25(1):100A. HauthJ , SibaiB , CaritisS , VanDorstenP , LindheimerM , KlebanoffM , et al. Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high‐risk pregnancies in a low‐dose aspirin trial. American Journal of Obstetrics and Gynecology1998;179:1193‐9. HauthJC , NICHD MFMU Network. Adverse maternal, fetal and neonatal outcomes in a low dose aspirin trial who developed pre‐eclampsia. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S110. HauthJC , NICHD MFMU Network. Maternal serum thromboxane B2 (TxB2) reduction did not predict improved pregnancy outcome in high risk women in a low dose aspirin trial. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S110. HauthJC , NICHD MFMU Network. Safety of low dose aspirin in high risk patients. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S111. JesselR , AllshouseA , HeyborneK . Does low‐dose aspirin prevent preterm birth?. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S342. LeonMG , MoussaHN , LongoM , PedrozaC , HaidarZA , Mendez‐FigueroaH , et al. Rate of gestational diabetes mellitus and pregnancy outcomes in patients with chronic hypertension. American Journal of Perinatology2016;33(8):745‐50. MooreG , AllshouseA , PostA , GalanH , HeyborneK . Early aspirin decreases late‐onset preeclampsia (&gt;34 weeks), particularly in women with chronic hypertension. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S144‐5. MooreGS , AllshouseAA , PostAL , GalanHL , HeyborneKD . Early initiation of low‐dose aspirin for reduction in preeclampsia risk in high‐risk women: a secondary analysis of the MFMU High Risk Aspirin Study. Journal of Perinatology2015;35:328‐31. MooreGS , AllshouseAA , WinnVD , GalanHL , HeyborneKD . Baseline placental growth factor levels for the prediction of benefit from early aspirin prophylaxis for preeclampsia prevention. Pregnancy Hypertension2015;5(4):280‐6. OhnoM , GirsenA , O'MalleyK , BlumenfeldY , LyellD , ButwickA , et al. Does low‐dose aspirin for preeclampsia prevention increase the risk of antepartum bleeding or placental abruption?. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S189. SibaiB . Low‐dose aspirin (60 mg/d) in pregnancy for the prevention of preeclampsia. 8th World Congress on Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina. 1992:50. TolcherMC , Sangi‐HaghpeykarH , AagaardKM . Low‐dose aspirin (asa) for preeclampsia prevention among high‐risk women by ethnicity and race. American Journal of Obstetrics and Gynecology2018;218(1 Suppl):S564. ">USA 1998</a> (1882/2539, 74%). For one recently published large trial, IPD data were not available (<a href="./references#CD004659-bbs2-0002" title="NCT02301780 . Combined multi‐marker screening and treatment with aspirin for pre‐eclampsia prevention. clinicaltrials.gov/ct2/show/record/NCT02301780 (first received 26 November 2014). NicolaidesK , ISRCTN13633058 . Combined multi‐marker screening and randomised patient treatment with ASpirin for evidence‐based PRE‐eclampsia prevention. isrctn.com/ISRCTN13633058 (first received 28 October 2010). O'GormanN , WrightD , RolnikDL , NicolaidesKH , PoonLC . Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence‐based PREeclampsia prevention (ASPRE). BMJ Open2016;6(6):e011801. PoonLC , WrightD , RolnikDL , SyngelakiA , DelgadoJL , TsokakiT , et al. Aspirin for Evidence‐Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal of Obstetrics and Gynecology2017;217(5):585.e1‐585.e5. PoonLC , WrightD , RolnikDL , SyngelakiA , DelgadoJL , TsokakiT , et al. Aspre trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal of Obstetrics and Gynecology2017 [Epub ahead of print]. RolnikDL , WrightD , PoonLC , O'GormanN , SyngelakiA , dePaco MatallanaC , et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine2017; Vol. 377, issue 7:613‐22. RolnikDL , WrightD , PoonLC , O'GormanN , SyngelakiA , dePaco MatallanaC , et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia: a multicentre, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2017;50(Suppl 1):2. RolnikDL , WrightD , PoonLC , SyngelakiA , O'GormanN , dePaco MatallanaC , et al. ASPRE trial: performance of screening for preterm pre‐eclampsia. Ultrasound in Obstetrics &amp; Gynecology2017;50(4):492‐5. SenthilhesL , AzriaE , SchmitzT . Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine2017;377(24):2399‐400. WrightD , PoonLC , RolnikDL , SyngelakiA , DelgadoJL , VojtassakovaD , et al. Aspre trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. American Journal of Obstetrics and Gynecology2017;217(6):685.e1‐5. WrightD , RolnikDL , SyngelakiA , dePaco MatallanaC , MachucaM , deAlvaradoM , et al. Aspirin for evidence‐based preeclampsia prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. American Journal of Obstetrics and Gynecology2018;218(6):612.e1‐612.e6. ">ASPRE 2017</a>). This trial aimed to recruit women at high risk for preterm pre‐eclampsia (which they defined as delivery with pre‐eclampsia before 37 weeks' gestation), and risk status for the women at trial entry was assessed using an algorithm that combined maternal factors, mean arterial pressure, uterine artery pulsatility index and maternal serum pregnancy‐associated plasma protein‐A and placental growth factor. </p> <p>A small number of trials were secondary prevention studies, and so recruited women who already had gestational hypertension and/or intrauterine growth restriction at trial entry (<a href="./references#CD004659-bbs2-0003" title="TrudingerBJ , CookCM , ConnellyAJ , GilesWB , ThompsonRS . Aspirin improves fetal weight in placental insufficiency. Proceedings of 8th Annual Meeting of the Society of Perinatal Obstetricians; 1988 February 3‐6; Las Vegas, Nevada, USA. 1988:10. TrudingerBJ , CookCM , ThompsonRS , GilesWB , ConnellyAJ . Low‐dose aspirin improves fetal weight in umbilical placental insufficiency. Lancet1988;2:214‐5. TrudingerBJ , CookCM , ThompsonRS , GilesWB , ConnellyAJ . Low‐dose aspirin therapy improves fetal weight in umbilical placental insufficiency. American Journal of Obstetrics and Gynecology1988;159:681‐5. ">Australia 1988</a>; <a href="./references#CD004659-bbs2-0005" title="NewnhamJP , GodfreyM , WaltersBJ , PhilipsJ , EvansSF . Low dose aspirin for the treatment of fetal growth restriction: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology1995;35:370‐4. ">Australia 1995</a>; <a href="./references#CD004659-bbs2-0032" title="ErdmannM , PaulusWE , FlockF , HergetI , TerindeR , GrabD . Utero and fetoplacental hemodynamic measurements with low dose aspirin [Utero‐und fetoplazentae haemodynamische Messiungen unter low‐dose aspirin]. Zeitschrift fur Gerburtshilfe und Neonatologie1999;203(1):18‐23. GrabD , ErdmannM , PaulusW , OberhofferR , LangD . Effects of low dose aspirin on uterine and fetal blood flow during pregnancy: a randomized placebo controlled double blind trial. Acta Obstetricia et Gynecologica Scandinavica1997;76:38. GrabD , PaulusWE , ErdmannM , TerindeR , OberhofferR , LangD , et al. Effects of low‐dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, placebo‐controlled, double‐blind trial. Ultrasound in Obstetrics &amp; Gynecology2000;15:19‐27. ">Germany 2000</a>; <a href="./references#CD004659-bbs2-0034" title="RaiU , ChakravortyM , JunejaY . Role of low dose aspirin in PIH. Journal of Obstetrics and Gynaecology of India1993:883‐6. ">India 1993</a>; <a href="./references#CD004659-bbs2-0035" title="RoyUK , PanS . A study of low dose aspirin in prevention of pregnancy induced hypertension. Journal of the Indian Medical Association1994;92:188‐91. ">India 1994</a>; <a href="./references#CD004659-bbs2-0036" title="ShenoyS , ChandrikaD , PisharodyR . RCT of low dose aspirin to prevent the progression of pregnancy induced hypertension grade A to B. Journal of Clinical Epidemiology1999;52 Suppl 1:28S. ">India 1999</a>; <a href="./references#CD004659-bbs2-0044" title="SchiffE , BarkaiG , Ben‐BaruchG , MashiachS . Low‐dose aspirin does not influence the clinical course of women with mild pregnancy‐induced hypertension. Obstetrics &amp; Gynecology1990;76:742‐4. ">Israel 1990</a>). Four of the early trials were both primary and secondary prevention studies, and so recruited women with or without gestation hypertension and/or intrauterine growth restriction (<a href="./references#CD004659-bbs2-0013" title="Anonymous . ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnancies. British Journal of Obstetrics and Gynaecology1996;103:39‐47. AtallahAN . ECPPA: randomized trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women [abstract]. Journal of Clinical Epidemiology1997;50 Suppl 1:3S. AtallahAN , TabordaWC . ECPPA: the Brazilian low‐dose aspirin study in high risk pregnant women. Hypertension in Pregnancy1997; Vol. 16, issue 1:139. ">Brazil 1996</a>; <a href="./references#CD004659-bbs2-0019" title="BarJ , HodM , PardoJ , FischB , RabinersonD , KaplanB , et al. Effect on fetal circulation of low‐dose aspirin for prevention and treatment of pre‐eclampsia and intrauterine growth restriction: Doppler flow study. Ultrasound in Obstetrics &amp; Gynaecology1997;9:262‐5. BarJ , PadoaA , HodM , SullivanMH , KaplanB , KidronD . Decreased pathological placental findings in aspirin‐treated pregnant women at risk of hypertensive complications. Hypertension in Pregnancy1997;16:435‐44. BowerSJ , HarringtonKF , SchuchterK , McGirrC , CampbellS . Prediction of pre‐eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. British Journal of Obstetrics and Gynaecology1996;103:625‐9. CLASP (Collaborative Low‐dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low‐dose aspirin for the prevention and treatment of pre‐eclampsia among 9364 pregnant women. Lancet1994;343:619‐29. CLASP Collaborative Group. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. British Journal of Obstetrics and Gynaecology1994;102:861‐8. KylePM , BuckleyD , KissaneJ , deSwietM , RedmanCW . The angiotensin sensitivity test and low‐dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. American Journal of Obstetrics and Gynecology1995;173:865‐72. MathaiM . Aspirin for pre‐eclampsia. National Medical Journal of India1995;8:23‐4. VikhlyaevaK , AsymbekovaGU , ZerdevVP . Aspirin in profilaxis and treatment of placental insufficiency: lessons from Russian aspirin experience. Hypertension in Pregnancy2000;19(Suppl 1):68. ">CLASP 1994</a>; <a href="./references#CD004659-bbs2-0033" title="GroverV , SachdevaS , KumariS . Evaluation of dipyridamole and aspirin in prevention and management of intrauterine growth retardation. Journal of Perinatal Medicine1991;19(2):104. ">India 1991</a>; <a href="./references#CD004659-bbs2-0047" title="Italian Study of Aspirin in Pregnancy. Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Lancet1993;341:396‐400. ParazziniDF . Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Geburtshilfe und Frauenheilkunde1993;53:822. ParazziniF . Multicenter randomized Italian study of low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Journal of Nephrology1991;4:127‐9. ParazziniF , BenedettoC , FruscaT , GuaschinoS , RomeroM . The Italian study on low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:32. ParazziniF , BortolusR , ChatenoudL , RestelliS , BenedettoC . Follow‐up of children in the Italian Study of Aspirin in Pregnancy. Lancet1994;343:1235. ParazziniF , BortolusR , ChatenoudL , RestelliS , RicciE , MarozioL , et al. Risk factors for pregnancy‐induced hypertension in women at high risk for the condition. Epidemiology1996;7(3):306‐8. ">Italy 1993</a>). </p> </section> <section id="CD004659-sec-0098"> <h5 class="title">Interventions and comparisons</h5> <p>Interventions varied as to dose of aspirin, gestation at commencement, and use of other treatments. In most trials, aspirin alone was compared with placebo or no treatment. Aspirin alone was the intervention for all nine large trials. The dose was 50 mg in one trial (<a href="./references#CD004659-bbs2-0047" title="Italian Study of Aspirin in Pregnancy. Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Lancet1993;341:396‐400. ParazziniDF . Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Geburtshilfe und Frauenheilkunde1993;53:822. ParazziniF . Multicenter randomized Italian study of low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Journal of Nephrology1991;4:127‐9. ParazziniF , BenedettoC , FruscaT , GuaschinoS , RomeroM . The Italian study on low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:32. ParazziniF , BortolusR , ChatenoudL , RestelliS , BenedettoC . Follow‐up of children in the Italian Study of Aspirin in Pregnancy. Lancet1994;343:1235. ParazziniF , BortolusR , ChatenoudL , RestelliS , RicciE , MarozioL , et al. Risk factors for pregnancy‐induced hypertension in women at high risk for the condition. Epidemiology1996;7(3):306‐8. ">Italy 1993</a>), 60 mg in five (<a href="./references#CD004659-bbs2-0013" title="Anonymous . ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnancies. British Journal of Obstetrics and Gynaecology1996;103:39‐47. AtallahAN . ECPPA: randomized trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women [abstract]. Journal of Clinical Epidemiology1997;50 Suppl 1:3S. AtallahAN , TabordaWC . ECPPA: the Brazilian low‐dose aspirin study in high risk pregnant women. Hypertension in Pregnancy1997; Vol. 16, issue 1:139. ">Brazil 1996</a>; <a href="./references#CD004659-bbs2-0019" title="BarJ , HodM , PardoJ , FischB , RabinersonD , KaplanB , et al. Effect on fetal circulation of low‐dose aspirin for prevention and treatment of pre‐eclampsia and intrauterine growth restriction: Doppler flow study. Ultrasound in Obstetrics &amp; Gynaecology1997;9:262‐5. BarJ , PadoaA , HodM , SullivanMH , KaplanB , KidronD . Decreased pathological placental findings in aspirin‐treated pregnant women at risk of hypertensive complications. Hypertension in Pregnancy1997;16:435‐44. BowerSJ , HarringtonKF , SchuchterK , McGirrC , CampbellS . Prediction of pre‐eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. British Journal of Obstetrics and Gynaecology1996;103:625‐9. CLASP (Collaborative Low‐dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low‐dose aspirin for the prevention and treatment of pre‐eclampsia among 9364 pregnant women. Lancet1994;343:619‐29. CLASP Collaborative Group. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. British Journal of Obstetrics and Gynaecology1994;102:861‐8. KylePM , BuckleyD , KissaneJ , deSwietM , RedmanCW . The angiotensin sensitivity test and low‐dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. American Journal of Obstetrics and Gynecology1995;173:865‐72. MathaiM . Aspirin for pre‐eclampsia. National Medical Journal of India1995;8:23‐4. VikhlyaevaK , AsymbekovaGU , ZerdevVP . Aspirin in profilaxis and treatment of placental insufficiency: lessons from Russian aspirin experience. Hypertension in Pregnancy2000;19(Suppl 1):68. ">CLASP 1994</a>; <a href="./references#CD004659-bbs2-0050" title="ElderMG , deSwietM , SullivanM . A randomised trial of low dose aspirin for primiparae in pregnancy (golding)/barbados low dose aspirin study in pregnancy (blasp) (rotchell et al.) [Letter; comment]. British Journal of Obstetrics &amp; Gynaecology1999;106(2):180. ForresterTE , JonesD , McCaw‐BinnsA , Palmer‐LevyM , WilksR , BernardGW , et al. Low‐dose aspirin in pregnancy ‐ are there any benefits? [abstract]. West Indian Medical Journal1996;45(2 Suppl):26. GoldingJ . A randomised trial of low dose aspirin for primiparae in pregnancy. British Journal of Obstetrics and Gynaecology1998;105:293‐9. KahwaEK , SargeantLA , McCaw‐BinnsA , McFarlane‐AndersonN , SmikleM , ForresterT , et al. Anticardiolipin antibodies in jamaican primiparae. Journal of Obstetrics and Gynaecology2006;26(2):122‐6. McCaw‐BinnsA , AshleyD , HawkinsN , MacGillivrayI , GoldingJ . International variation in the incidence of hypertension in pregnancy among primiparae: the jamaican experience. 10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4‐8; Seattle, Washington, USA. 1996:168. McCaw‐BinnsA , Jamaica Low‐Dose Aspirin Group. Low dose aspirin in pregnancy ‐ are there any benefits?. 10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4‐8; Seattle, Washington, USA. 1996:76. ">Jamaica 1998</a>; <a href="./references#CD004659-bbs2-0072" title="AbramoviciA , JaukV , WettaL , EdwardsR , BiggioJ , TitaA . Analysis of low‐dose aspirin by smoking status for select perinatal outcomes. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S261. AndrikopoulouM , PurischSE , Handal‐OreficeR , Gyamfi‐BannermanC . Beyond preeclampsia: low dose aspirin reduces spontaneous preterm birth. American Journal of Obstetrics and Gynecology2018;218(1):S10. CaritisS , SibaiB , ThornE , McLaughlinS , NICHD‐MFM Network. Pregnancy effects of non‐proteinuric gestational hypertension (GH). American Journal of Obstetrics and Gynecology1995;172:376. ConnealyB , CarrenoC , KaseB , HartL , BlackwellS , SibaiB . A history of prior preeclampsia is a major risk factor for preterm birth. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S264. DiSessaTG , MorettiML , KhouryA , PulliamDA , ArheartKL , SibaiBM . Cardiac function in fetuses and newborns exposed to low‐dose aspirin during pregnancy. American Journal of Obstetrics and Gynecology1994;171:892‐900. FrattoVM , AnanthCV , Gyamfi‐BannermanC . Late preterm neonatal morbidity in hypertensive versus normotensive women. Hypertension in Pregnancy2016;35(2):242‐9. OhnoM , GirsenA , O'MalleyK , BlumenfeldY , LyellD , ButwickA , et al. Does low‐dose aspirin for preeclampsia prevention increase the risk of antepartum bleeding or placental abruption?. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S189. SibaiB . Low‐dose aspirin (60 mg/d) in pregnancy for the prevention of preeclampsia. 8th World Congress on Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina 1992. 1992:50. SibaiB , CaritisS , PhillipsE , KlebanoffM , McNellisD , RoccoL . Prevention of preeclampsia: low‐dose aspirin in nulliparous women: a double‐blind, placebo controlled trial. American Journal of Obstetrics and Gynecology1993;168:286. SibaiB , CaritisS , PhillipsE , KlebanoffM , PaulR , WitterF , et al. Safety of low‐dose aspirin in healthy nulliparous women: a double‐blind, placebo‐controlled trial. Proceedings of 40th Annual Meeting Society for Gynecologic Investigation; 1993 March; Toronto, Canada. 1993:S102. SibaiB , CaritisS , ThomE , ShawK , McNellisD , NICHD‐MFM Network. Low‐dose aspirin in nulliparous women: safety of epidural and correlation between bleeding time and maternal‐neonatal bleeding complications. American Journal of Obstetrics and Gynecology1994;170:293. SibaiB , GordonT , PhillipsE , McNellisD , CaritisS , RomeroR , et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. Proceedings of 41st Annual Clinical Meeting of The American College of Obstetricians and Gynecologists; 1993 May 3‐6; Washington DC, USA. 1993:2. SibaiBM , CaritisSN , ThomE , KlebanoffM , McNellisD , RoccoL , et al. Prevention of preeclampsia with low‐dose aspirin in healthy, nulliparous pregnant women. New England Journal of Medicine1993;329:1213‐8. SibaiBM , CaritisSN , ThomE , ShawK , McNellisD , NICHD‐MFM Network. Low dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal‐neonatal bleeding complications. American Journal of Obstetrics and Gynecology1995;172:1533‐7. SibaiBM , GordonT , ThomE , CaritisSN , KlebanoffM , McNellisD , et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. American Journal of Obstetrics and Gynecology1995;172:642‐8. TolcherMC , Sangi‐HaghpeykarH , AagaardKM . Race and ethnicity varies both efficacy and attributable risk of low‐dose aspirin (asa) for preeclampsia prevention among low‐risk women. American Journal of Obstetrics and Gynecology2018;218(1 Suppl):S203. WittenFR . [Personal communication] Double‐blind, placebo‐controlled trial of low‐dose aspirin to prevent pre‐eclampsia. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 6 September 1991. YaffeS . [Personal communication] Clinical trial of low dose aspirin (65mg) as a preventative of pre‐eclampsia. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 3 December 1991. ">USA 1993a</a>; <a href="./references#CD004659-bbs2-0075" title="AbramoviciA , JaukV , WettaL , CantuJ , EdwardsR , BiggioJ , et al. Low‐dose aspirin, smoking status, and the risk of spontaneous preterm birth. American Journal of Perinatology2015;32(5):445‐50. AbramoviciA , JaukV , WettaL , EdwardsR , BiggioJ , TitaA . Low‐dose aspirin is associated with a reduction in spontaneous preterm birth among non‐smokers. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S260‐S261. AdkinsK , AllshouseAA , MetzTD , HeyborneKD . Impact of aspirin on fetal growth in diabetic pregnancies according to white classification. American Journal of Obstetrics and Gynecology2017;217(4):465. AdkinsK , MetzT , HeyborneK , AllshouseA . Impact of low‐dose aspirin on fetal growth in diabetic pregnancies: the importance of white classification. American Journal of Obstetrics and Gynecology2017;216(1 Suppl 1):S292. AllshouseAA , JesselRH , HeyborneKD . The impact of low‐dose aspirin on preterm birth: secondary analysis of a randomized controlled trial. Journal of Perinatology2016;36(6):427‐31. CantuJ , BiggioJ , JaukV , EdwardsR , OwenJ , TitaA . Timing of initiation of low‐dose aspirin therapy and preeclampsia prevention in high‐risk women. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S266. CantuJA , JaukVR , OwenJ , BiggioJR , AbramoviciAR , EdwardsRK , et al. Is low‐dose aspirin therapy to prevent preeclampsia more efficacious in non‐obese women or when initiated early in pregnancy?. Journal of Maternal‐Fetal &amp; Neonatal Medicine2015 Jan;8:1‐5. CantuJA , JaukVR , OwenJ , BiggioJR , AbramoviciAR , EdwardsRK , et al. Is low‐dose aspirin therapy to prevent preeclampsia more efficacious in non‐obese women or when initiated early in pregnancy?. Journal of Maternal‐Fetal &amp; Neonatal Medicine2015;28(10):1128‐32. CaritisNS , NICHD‐MFMU Network. Impact of preeclampsia on a subsequent pregnancy. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S120. CaritisS . Low dose aspirin does not prevent preeclampsia in high risk women. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S3. CaritisS , SibaiB , HauthJ , LindheimerM , KlebanoffM , ThomE , et al. Low‐dose aspirin to prevent preeclampsia in women at high risk. New England Journal of Medicine1998;338:701‐5. CostantineM , WuZ , HanY , SaadeG , BlackwellS . Population norms underestimate rates of small for gestational age neonates in high risk pregnancies compared to customized growth norms. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S303. CostantineM , WuZ , HanY , SaadeG , BlackwellS . Relationship between fetal growth evaluated by a customized versus population approach and adverse pregnancy outcomes. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S303. DixonCL , MarrsC Costantine MM , PachecoLD , SaadeGR , ChiossiG . Effect of low‐dose aspirin on the time of onset of preeclampsia and time of delivery. American Journal of Perinatology2017; Vol. 34, issue 12:1219‐26. EuserAG , MetzTD , AllshouseAA , HeyborneK . Low‐dose aspirin reduces the incidence of preeclampsia in women with multiple gestations and elevated human chorionic gonadotropin. Reproductive Sciences2015;22(Suppl 1):70A‐71A. EuserAG , MetzTD , AllshouseAA , HeyborneKD . Low‐dose aspirin for pre‐eclampsia prevention in twins with elevated human chorionic gonadotropin. Journal of Perinatology2016;36(8):601‐5. FrattoVM , AnanthCV , Gyamfi‐BannermanC . Late preterm neonatal morbidity in hypertensive versus normotensive women. Hypertension in Pregnancy2016;35(2):242‐9. Handal‐OreficeR , PurischS , MillerR , Gyamfi‐BannermanC , AndrikopoulouM . Aspirin: a potential for reducing intrauterine growth restriction in low‐risk women. Reproductive Sciences2018;25(1):100A. HauthJ , SibaiB , CaritisS , VanDorstenP , LindheimerM , KlebanoffM , et al. Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high‐risk pregnancies in a low‐dose aspirin trial. American Journal of Obstetrics and Gynecology1998;179:1193‐9. HauthJC , NICHD MFMU Network. Adverse maternal, fetal and neonatal outcomes in a low dose aspirin trial who developed pre‐eclampsia. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S110. HauthJC , NICHD MFMU Network. Maternal serum thromboxane B2 (TxB2) reduction did not predict improved pregnancy outcome in high risk women in a low dose aspirin trial. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S110. HauthJC , NICHD MFMU Network. Safety of low dose aspirin in high risk patients. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S111. JesselR , AllshouseA , HeyborneK . Does low‐dose aspirin prevent preterm birth?. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S342. LeonMG , MoussaHN , LongoM , PedrozaC , HaidarZA , Mendez‐FigueroaH , et al. Rate of gestational diabetes mellitus and pregnancy outcomes in patients with chronic hypertension. American Journal of Perinatology2016;33(8):745‐50. MooreG , AllshouseA , PostA , GalanH , HeyborneK . Early aspirin decreases late‐onset preeclampsia (&gt;34 weeks), particularly in women with chronic hypertension. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S144‐5. MooreGS , AllshouseAA , PostAL , GalanHL , HeyborneKD . Early initiation of low‐dose aspirin for reduction in preeclampsia risk in high‐risk women: a secondary analysis of the MFMU High Risk Aspirin Study. Journal of Perinatology2015;35:328‐31. MooreGS , AllshouseAA , WinnVD , GalanHL , HeyborneKD . Baseline placental growth factor levels for the prediction of benefit from early aspirin prophylaxis for preeclampsia prevention. Pregnancy Hypertension2015;5(4):280‐6. OhnoM , GirsenA , O'MalleyK , BlumenfeldY , LyellD , ButwickA , et al. Does low‐dose aspirin for preeclampsia prevention increase the risk of antepartum bleeding or placental abruption?. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S189. SibaiB . Low‐dose aspirin (60 mg/d) in pregnancy for the prevention of preeclampsia. 8th World Congress on Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina. 1992:50. TolcherMC , Sangi‐HaghpeykarH , AagaardKM . Low‐dose aspirin (asa) for preeclampsia prevention among high‐risk women by ethnicity and race. American Journal of Obstetrics and Gynecology2018;218(1 Suppl):S564. ">USA 1998</a>), 100 mg in one (<a href="./references#CD004659-bbs2-0023" title='ERASME collaborative group. Failure of systematic low dose aspirin to prevent preeclampsia in primigravidae. Hypertension in Pregnancy2000;19(Suppl 1):34. SubtilD , GoeusseP , PuechF , LequienP , BiausqueS , BreartG , et al. Aspirin (100mg) used for prevention of pre‐eclampsia in nulliparous women: the Essai Regional Aspirine Mere‐Enfant study (Part 1). BJOG: an international journal of obstetrics and gynaecology2003;110:475‐84. SubtilD , QuandalleF , Houfflin‐DebargeV , MalekY , TruffertP , BreartG , et al. Low dose aspirin to prevent preeclampsia: what do we learn from a new "negative" trial? [abstract]. European Journal Obstetrics &amp; Gynecology and Reproductive Biology2002;104:179. '>ERASME 2003</a>) and 150 mg in one (<a href="./references#CD004659-bbs2-0002" title="NCT02301780 . Combined multi‐marker screening and treatment with aspirin for pre‐eclampsia prevention. clinicaltrials.gov/ct2/show/record/NCT02301780 (first received 26 November 2014). NicolaidesK , ISRCTN13633058 . Combined multi‐marker screening and randomised patient treatment with ASpirin for evidence‐based PRE‐eclampsia prevention. isrctn.com/ISRCTN13633058 (first received 28 October 2010). O'GormanN , WrightD , RolnikDL , NicolaidesKH , PoonLC . Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence‐based PREeclampsia prevention (ASPRE). BMJ Open2016;6(6):e011801. PoonLC , WrightD , RolnikDL , SyngelakiA , DelgadoJL , TsokakiT , et al. Aspirin for Evidence‐Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal of Obstetrics and Gynecology2017;217(5):585.e1‐585.e5. PoonLC , WrightD , RolnikDL , SyngelakiA , DelgadoJL , TsokakiT , et al. Aspre trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal of Obstetrics and Gynecology2017 [Epub ahead of print]. RolnikDL , WrightD , PoonLC , O'GormanN , SyngelakiA , dePaco MatallanaC , et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine2017; Vol. 377, issue 7:613‐22. RolnikDL , WrightD , PoonLC , O'GormanN , SyngelakiA , dePaco MatallanaC , et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia: a multicentre, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2017;50(Suppl 1):2. RolnikDL , WrightD , PoonLC , SyngelakiA , O'GormanN , dePaco MatallanaC , et al. ASPRE trial: performance of screening for preterm pre‐eclampsia. Ultrasound in Obstetrics &amp; Gynecology2017;50(4):492‐5. SenthilhesL , AzriaE , SchmitzT . Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine2017;377(24):2399‐400. WrightD , PoonLC , RolnikDL , SyngelakiA , DelgadoJL , VojtassakovaD , et al. Aspre trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. American Journal of Obstetrics and Gynecology2017;217(6):685.e1‐5. WrightD , RolnikDL , SyngelakiA , dePaco MatallanaC , MachucaM , deAlvaradoM , et al. Aspirin for evidence‐based preeclampsia prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. American Journal of Obstetrics and Gynecology2018;218(6):612.e1‐612.e6. ">ASPRE 2017</a>) Eight of these large trials used placebo for the control group, and for one (<a href="./references#CD004659-bbs2-0047" title="Italian Study of Aspirin in Pregnancy. Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Lancet1993;341:396‐400. ParazziniDF . Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Geburtshilfe und Frauenheilkunde1993;53:822. ParazziniF . Multicenter randomized Italian study of low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Journal of Nephrology1991;4:127‐9. ParazziniF , BenedettoC , FruscaT , GuaschinoS , RomeroM . The Italian study on low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:32. ParazziniF , BortolusR , ChatenoudL , RestelliS , BenedettoC . Follow‐up of children in the Italian Study of Aspirin in Pregnancy. Lancet1994;343:1235. ParazziniF , BortolusR , ChatenoudL , RestelliS , RicciE , MarozioL , et al. Risk factors for pregnancy‐induced hypertension in women at high risk for the condition. Epidemiology1996;7(3):306‐8. ">Italy 1993</a>) no treatment was the control intervention. Of the smaller trials using an intervention that was not aspirin alone, five used a combination of aspirin and dipyridamole or dipyridamole alone versus control (<a href="./references#CD004659-bbs2-0022" title="BeaufilsM , UzanS , BreartG , BazinB , ParisJ . Prevention of preeclampsia with low‐dose aspirin: results of the epreda trial. XIth International Congress of Nephrology; 1990 July 15‐20; Tokyo, Japan. 1990:319A. SureauC . Prevention of perinatal consequences of pre‐eclampsia with low‐dose aspirin: results of the EPREDA trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1991;41:71‐3. UzanM , BeaufilsM , BreartG , BazinB , CapitantC , ParisJ , et al. Prevention of pre‐eclampsia with low‐dose aspirin: results of the EPREDA trial. Journal of Perinatal Medicine1990;18 Suppl:116. UzanS , BeaufilsM , BreartG , BazinB , CapitantC , ParisJ . Prevention of fetal growth retardation with low‐dose aspirin: findings of the EPREDA trial. Lancet1991;337:1427‐31. UzanS , BeaufilsM , BreartG , BazinB , CapitantC , ParisJ . Prevention of pre‐eclampsia with low‐dose aspirin: results of the EPREDA trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;44:12. UzanS , BeaufilsM , BreartG , BazinB , ParisJ . Prevention of pre‐eclampsia with low‐dose aspirin: results of the EPREDA trial. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:34. UzanS , BeaufilsM , BreartG , UzanM , ParisJ . Prevention of intrauterine growth retardation and pre‐eclampsia by small doses of aspirin. Results of the French multicenter trial EPREDA and comparison with data in the literature; value of uterine Doppler [Prevention du retard de croissance intra‐uterin et de la preeclampsie par des petites doses d'Aspirine: resultats de l'essai multicentrique francais EPREDA et comparison avec les donnees de la litterature; interet du Doppler uterin]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1992;21(3):315‐8. ">EPREDA 1991</a>; <a href="./references#CD004659-bbs2-0029" title="BeaufilsM , UzanS , DonsimoniR , ColauJC . A controlled trial of prophylactic treatment of preeclampsia: preliminary results. Archives des Maladies du Coeur1984;77:1226‐8. BeaufilsM , UzanS , DonsimoniR , ColauJC . Prevention of pre‐eclampsia by early antiplatelet therapy. Lancet1985;1:840‐2. ">France 1985</a>; <a href="./references#CD004659-bbs2-0030" title="AzarR , TurpinD . Effect of antiplatelet therapy in women at high risk for pregnancy‐induced hypertension. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:257. ">France 1990</a>; <a href="./references#CD004659-bbs2-0059" title="RogovV , TareevaI , SidorovaS , AndrosovaS . Prevention of pregnancy complications with acetylsalicylic acid (ASA) and dipyridamol (DP) in women with chronic glomerulonephritis (CGN) and essential hypertension (EH). Proceedings of 9th International Congress of the International Society for the Study of Hypertension in Pregnancy; 1994 March 15‐18; Sydney, Australia. 1994:280. RogovVA , TareevaI , SidorovaS , AndrosovaSO , KatamadzeKT , NikiforovaOV . Prevention of pregnancy complications in glomerulonephritis and hypertension with acetylsalicylic acid and curantyl. Terapevticheskii Arkhiv1993;65:65‐8. ">Russia 1993</a>; <a href="./references#CD004659-bbs2-0060" title="RailtonA , DaveyA . Aspirin and dipyridamole in the prevention of pre‐eclampsia: effect on plasma prostanoids 6 keto PG1a and TXB2 and clinical outcome of pregnancy. Proceedings of the 6th International Congress of the International Society for the Study of Hypertension in Pregnancy; 1988 May 22‐26; Montreal, Quebec, Canada. 1988:60. RailtonA , DaveyDA . Aspirin and dipyridamole in the prevention of pre‐eclampsia: effect on plasma 6 keto PGF1alpha and TxB2 and clinical outcome of pregnancy. Proceedings of 1st European Congress on Prostaglandins in Reproduction; 1988 July 6‐9; Vienna, Austria. 1988:48. ">S Africa 1988</a>), one small trial used heparin and dipyridamole versus control (<a href="./references#CD004659-bbs2-0006" title="Kincaid SmithP , NorthRA , FairleyKF , KlossM , IhleBU . Prevention of pre‐eclampsia in high risk women with renal disease: a prospective randomized trial of heparin and dipyridamole. Nephrology1995;1:297‐300. NorthRA , FairleyKF , KlossM , IhleB , Kincaid‐SmithP . Prevention of pre‐eclampsia in women with renal disease. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:75. NorthRA , FairleyKF , KlossM , IhleB , Kincaid‐SmithP . Prevention of preeclampsia in women with renal disease [abstract]. 26th Annual Meeting of the Australasian Society of Nephrology; 1990 March 14‐16; Brisbane, Australia. 1990:9. NorthRA , FairleyKF , KlossM , IhleB , OatsJ , Kincaid‐SmithP . Prevention of pre‐eclampsia in women with renal disease. Proceedings of 6th International Congress of the International Society for the study of Hypertension in Pregnancy; 1988 May 22‐26; Montreal, Quebec, Canada. 1988:193. ">Australia 1995a</a>), another combined aspirin with vitamins C and E and fish oil (<a href="./references#CD004659-bbs2-0076" title="Rivas‐EcheverriaCA , EcheverriaY , MolinaL , NovoaD . Synergic use of aspirin, fish oil and vitamins C and E for the prevention of preeclampsia. Hypertension in Pregnancy2000;19:30. ">Venezuela 2000</a>), another compared ozagrel hydrochloride with placebo (<a href="./references#CD004659-bbs2-0051" title="SekiH , KuromakiK , TakedaS , KinoshitaK , SatohK . Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia. Hypertension in Pregnancy1999;18:157‐64. ">Japan 1999</a>) ,and one compared trapidil with placebo (<a href="./references#CD004659-bbs2-0031" title="NiederJ , ClausP , AugustinW . Prevention of pre‐eclampsia and fetal growth retardation by trapidil. Zentralblatt fur Gynakologie1995;117:23‐8. ">Germany 1995</a>). Most trials used some form of placebo. One small trial compared different duration of aspirin treatment (to 32 weeks or 36 weeks) with placebo (<a href="./references#CD004659-bbs2-0058" title="StanescuAD , BanicaR , SimaRM , PlesL . Low dose aspirin for preventing fetal growth restriction: a randomised trial. Journal of Perinatal Medicine2015;43(Suppl 1):Abstract no: O‐0040. StanescuAD , BanicaR , SimaRM , PlesL . Low dose aspirin for preventing fetal growth restriction: a randomised trial. Journal of Perinatal Medicine2018 [epub ahead of print]. ">Romania 2018</a>); the two intervention groups are combined in this review. </p> </section> <section id="CD004659-sec-0099"> <h5 class="title">Outcomes</h5> <p>Most trials reported data for the main outcomes pre‐eclampsia, preterm delivery, perinatal death and the infant being small‐for‐gestational age. Our secondary outcomes were often not reported by the included studies. </p> </section> </section> <section id="CD004659-sec-0100"> <h4 class="title">Excluded studies</h4> <p>Overall, 77 studies were excluded from the review. The reasons for exclusion for each trial are listed in the <a href="./references#CD004659-sec-0180" title="">Characteristics of excluded studies</a> table. </p> <p>Reasons for exclusion were: 31 studies were excluded because they were not randomised trials, or because allocation was quasi‐random or unclear (<a href="./references#CD004659-bbs2-0078" title="FraireJC , LopezJ . Cyclooxygenase and lipoxygenase inhibition in gestational hypertension. Journal of the American Society of Nephrology1994;5(3):561. ">Argentina 1994</a>; <a href="./references#CD004659-bbs2-0081" title="MontenegroCA . The effect of aspirin therapy on the uterine circulation in preeclampsia. Proceedings of the 8th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina. 1992:66. ">Brazil 1992</a>; <a href="./references#CD004659-bbs2-0082" title="daCamara FrancaBE , DaSilvaLG , NettoHC , deRezende FilhoJ , DeMelloLI , MontenegroCA . The role of acetylsalicylic acid in prostaglandins syntesis in mild preeclampsia. Jornal Brasileiro de Ginecologia1995;105(6):249‐68. ">Brazil 1995</a>; <a href="./references#CD004659-bbs2-0086" title="LiuFM , ZhaoM , WangM , YangHL , LiL . Effect of regular oral intake of aspirin during pregnancy on pregnancy outcome of high‐risk pregnancy‐induced hypertension syndrome patients. European Review for Medical and Pharmacological Sciences2016;20(23):5013‐6. ">China 2016</a>; <a href="./references#CD004659-bbs2-0087" title="LiuF , YangH , ZouK , ChenY , LiG . Effect of a small dose of aspirin on quantitative test of 24‐h urinary protein in patients with hypertension in pregnancy. Experimental and Therapeutic Medicine2017;13(1):37‐40. ">China 2017</a>; <a href="./references#CD004659-bbs2-0090" title="HeinrichJ . Prophylactic management of pregnancy induced hypertension (PIH). Proceedings of 11th European Congress of Perinatal Medicine; 1988; Rome, Italy. 1988:274. ">East Germany 1988</a>; <a href="./references#CD004659-bbs2-0092" title="ShalanH , KurjakA , LakkanyN . The effect of low dose aspirin versus allylestrinol on uterine artery blood flow. Prenatal and Neonatal Medicine1998;3 Suppl 1:141. ">Egypt 1998</a>; <a href="./references#CD004659-bbs2-0100" title="BhattacharyaN , ChaudhuriN , GhoshS , PradhanP , GhoshCR . Effect of platelet aggregation inhibitor on fetal outcome in EPH gestosis with IUGR. Proceedings of the 5th Congress of the International Society for the Study of Hypertension in Pregnancy; 1986 July 7‐10; Nottingham, UK. 1986:82. ">India 1986</a>; <a href="./references#CD004659-bbs2-0101" title="TewariS , KaushishR , SharmaS , GulatiN . Role of low dose aspirin in prevention of pregnancy induced hypertension. Journal of the Indian Medical Association1997;95:43‐5, 47. ">India 1997</a>; <a href="./references#CD004659-bbs2-0102" title="DasariR , NarangA , VasishtaK , GarewalG . Effect of maternal low dose aspirin on neonatal platelet function. Indian Pediatrics1998;35:507‐11. ">India 1998</a>; <a href="./references#CD004659-bbs2-0104" title="DesaiP , RaoS . Role of low dose aspirin in mothers registering high serum HCG levels at mid trimester. Journal of Obstetrics and Gynecology of India2002;52(5):30‐2. ">India 2002</a>; <a href="./references#CD004659-bbs2-0105" title="KhannaA , PrabhakarS . Maternal and foetal outcome with low dose aspirin in pregnancy induced hypertension. Journal of Obstetrics and Gynecology of India2002;52(3):62‐4. ">India 2002a</a>; <a href="./references#CD004659-bbs2-0109" title="MesdaghiniaE , TalariH , Abedzadeh‐KalahroudiM . Effect of aspirin for prevention of preeclampsia in women with abnormal ultrasonic findings in uterine artery. Journal of Kashan University of Medical Sciences2011;15(2):98‐104. TalariH , MesdaghiniaE , Abedzadeh KalahroudiM . Aspirin and preeclampsia prevention in patients with abnormal uterine artery blood flow. Iranian Red Crescent Medical Journal2014;16(8):e17175. ">Iran 2014</a>; <a href="./references#CD004659-bbs2-0116" title="DiIorioR , HorvathS , MarinoniE , ManzariG , MartinicoE , BresadolaM . Use of a thromboxane receptor inhibitor in pregnancy‐induced hypertension. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:75. ">Italy 1990</a>; <a href="./references#CD004659-bbs2-0117" title="AiroldiML , BertulessiC , BoscoP , OssolaMW , BarbieriM , PolvaniF . Effectiveness of Heparin Calcium and Dipyridamole in preventing pregnancy hypertension. Proceedings of the 22nd International Congress on Pathophysiology of Pregnancy, June 21‐23, Budapest, Hungary. Department of Obstetrics and Gynecology Albert Szent‐Györgyi Medical University, 1990:17. CapettaP , AiroldiL , IurlaroF , RossiE , PolvaniF . Prevention of pre‐eclampsia. New Trends in Gestational and Perinatal Hypertension1990;1(3/4):265‐70. ">Italy 1990a</a>; <a href="./references#CD004659-bbs2-0118" title="AiroldiML , BertulessiC , BoscoP , CapettaP , OssolaMW , BarbieriM , et al. Prevention of pregnancy hypertension and fetal damage in patients with LLAC and ANA. Clinical and Experimental Hypertension1991;B10(1 &amp; 2):180. ">Italy 1991</a>; <a href="./references#CD004659-bbs2-0119" title="ValensiseH , RomaniniC . Uterine Doppler in the identification of patients at risk for hypertension and IUGR. Journal of Perinatal Medicine1994;22 Suppl 1:69‐72. ">Italy 1994</a>; <a href="./references#CD004659-bbs2-0120" title="FruscaT , LojaconoA , FratelliN , PlattoC , ValcamonicoA , BianchiUA . Can low dose aspirin improve perinatal outcome in chronic hypertensive patients [abstract]. Hypertension in Pregnancy2002;21(Suppl 1):44. ">Italy 2002</a>; <a href="./references#CD004659-bbs2-0124" title="TeraoT , KobayashiT , ImaiN , OdaH , KarasawaT . Pathological state of the coagulatory and fibrinolytic system in preeclampsia and the the possibility of its treatment with AT III concentrate. Asia‐Oceania Journal of Obstetrics and Gynaecology1989;15:25‐32. ">Japan 1989</a>; <a href="./references#CD004659-bbs2-0125" title="Elmahaishi . The uses of low dose aspirin (150mg/day) in primigravida reduces the severity and complications of pregnancy induced hypertension. XVI FIGO World Congress of Obstetrics and Gynaecology; 2000 Sept 3‐8; Washington DC, USA (Book 1). 2000:98. ">Libya 2000</a>; <a href="./references#CD004659-bbs2-0129" title="GilaniA , KhanZ . Role of aspirin in management of pregnancy induced hypertension. A study in Pakistani population. Specialist1994;10:323‐5. ">Pakistan 1994</a>; <a href="./references#CD004659-bbs2-0131" title="CiszekV , KokotF , WiecekA . Influence of acetylsalicylic acid on the hormonal profile of pregnant women with EPH gestosis [abstract]. Nephrology, Dialysis, Transplantation1996;11:1419. ">Poland 1996</a>; <a href="./references#CD004659-bbs2-0132" title="KalinkaJ , SieroszewskiP , HankeW , LaudanskiT , SuzinJ . Evaluation of the effectiveness of a low dose aspirin in the treatment of intrauterine growth retardation (IUGR). Ginekologia Polska1999;70:126‐34. ">Poland 1999</a>; <a href="./references#CD004659-bbs2-0134" title="Sajina‐StritarB . The effect of acetylsalicylic acid and n‐3 fatty acids in prevention of complications of hypertension diseases in pregnancy. Zdravstveni Vestnik1998;67:489‐93. ">Slovenia 1998</a>; <a href="./references#CD004659-bbs2-0137" title="HerabutyaY , JetsawangsriT , SaropalaN . The use of low‐dose aspirin to prevent preeclampsia. International Journal of Gynecology &amp; Obstetrics1996;54:177‐8. JetsawangsriT , HerabutyaY , SaropalaN . The use of low‐dose aspirin to prevent pre‐eclampsia. Abstracts of 9th Congress of the Federation of the Asia and Oceania Perinatal Societies; 1996 November 10‐14; Singapore. 1996:129. ">Thailand 1996</a>; <a href="./references#CD004659-bbs2-0138" title="BassawB , RoopnarinesinghS , RoopnarinesinghA , HomerH . Prevention of hypertensive disorders of pregnancy. Journal of Obstetrics and Gynaecology1998;18(2):123‐6. ">Trinidad 1998</a>; <a href="./references#CD004659-bbs2-0139" title="HachichaJ , AmmousA , DamakJ , HammamiM , GhorbelA , RekikS , et al. Prevention of complications of hypertension in pregnancy with antiplatelets. Presse Medicale1989;18:767‐9. HachichaJ , AmmousA , MidassiH , DammakJ , GhorbelA , ChaabouniMN , et al. Place of antiplatelet therapy (APT) in vasculo‐renal accidents's (VRA) preventive treatment during pregnancy. 6th International Congress, International Society for the Study of Hypertension in Pregnancy; 1988 May 22‐26; Montreal, Quebec, Canada. 1988:185. RekikS , MidassiH , BayoudhH , MezghaniM , AbidR , GhorbelA . Place of antiplatelet therapy (APT) in vasculorenal accidents (VRA) preventive treatment in pregnancy. World Congress of Gynecology and Obstetrics; 1988 October 23‐28; Brazil. 1988:185. ">Tunisia 1989</a>; <a href="./references#CD004659-bbs2-0141" title="OktenS , PolatG , AyataD , AlbayrakU . Low‐dose aspirin prophylaxis in high‐risk pregnancies [Riskli gebeliklerde proflaktik dusuk doz aspirin]. Jinekoloji Ve Obstetrik Dergisi1994;8(4):150‐6. ">Turkey 1994</a>; <a href="./references#CD004659-bbs2-0147" title="RobertsCS , BeesonJH . Low dose aspirin in the prevention of preeclampsia in nulliparas. Preliminary results of a prospective, placebo‐controlled, double blind study. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 January 23‐27; Houston, Texas, USA. 1990:89. ">USA 1990</a>; <a href="./references#CD004659-bbs2-0153" title="CaoNT , VuQH , TruongQV , VoVD , TranML . Effectiveness of low‐dose aspirin for the prevention of pre‐eclampsia. Journal of Obstetrics and Gynaecology Research2017;43:69. ">Vietnam 2017</a>; <a href="./references#CD004659-bbs2-0154" title="WolfrumR , BordaschC , HolwegJ , SchulzG . The therapy of chronic nutritional placenta disorders ‐ preliminary results of a double blind study. Archives of Gynecology1977;224:114. ">West Germany 1977</a>). One study was a cross‐over design (<a href="./references#CD004659-bbs2-0091" title="ToppozadaM , DarwishEA , OsmanYF , Abd‐RabboMS . Low dose acetyl salicylic acid in severe pre‐eclampsia. International Journal of Gynecology &amp; Obstetrics1991;35:311‐7. ">Egypt 1991</a>). For 10 studies, the trial was not addressing the question of prevention of pre‐eclampsia (for example studies were of prevention of miscarriage, women were recruited before pregnancy, or women were not at risk of pre‐eclampsia at recruitment) (<a href="./references#CD004659-bbs2-0093" title="AliMK , AbbasAM , YosefAH , BahloulM . The effect of low‐dose aspirin on fetal weight of idiopathic asymmetrically intrauterine growth restricted fetuses with abnormal umbilical artery doppler indices: a randomized clinical trial. Journal of Maternal‐Fetal &amp; Neonatal Medicine2017 [Epub ahead of print]. AliMK , NCT03038607 . Effect of low‐dose aspirin on fetal weight of idiopathic asymmetrically intrauterine growth restricted fetuses with abnormal umbilical doppler indices. clinicaltrials.gov/ct2/show/record/NCT03038607 (first received 31 January 2017). ">Egypt 2017</a>; <a href="./references#CD004659-bbs2-0095" title="SubtilD , GoeusseP , Houfflin‐DebargeV , PuechF , LequienP , BreartG , et al. Aspirin (100mg) used for prevention of pre‐eclampsia in nulliparous women: the Essai Regional Aspirine Mere‐Enfant study (Part 2). BJOG: an international journal of obstetrics and gynaecology2003;110:485‐91. ">ERASME 2003a</a>; <a href="./references#CD004659-bbs2-0097" title="HaapsamoM , MartikainenH , TinkanenH , HeinonenS , Nuojua‐HuttunenS , RasanenJ . Low‐dose aspirin therapy and hypertensive pregnancy complications in unselected IVF and ICSI patients: a randomized, placebo‐controlled, double‐blind study. Human Reproduction2010;25(12):2972‐7. HaapsamoM , RasanenJ . Low‐dose aspirin reduces uteroplacental vascular impedance during the first half of pregnancy in IVF/ICSI patients: a randomized placebo‐controlled study. American Journal of Obstetrics and Gynecology2007;197(6 Suppl 1):S31, Abstract no: 70. HaapsamoM , RasanenJ , GravettM , NagallaS . Low‐dose aspirin influences early pregnancy placentation in IVF/ICSI patients: evidenced by a distinct maternal serum proteome profile. American Journal of Obstetrics and Gynecology2007;197(6 Suppl 1):S83, Abstract no: 256. ">Finland 2007</a>; <a href="./references#CD004659-bbs2-0098" title="Goffinet F. AboulkerD , Paris‐LladoJ , BucourtM , UzanM , PapiernikE , et al. Screening with a uterine Doppler in low risk pregnant women followed by low dose aspirin in women with abnormal results: a multicenter randomised controlled trial. BJOG: an international journal of obstetrics and gynaecology2001;108:510‐8. SubtilD , TruffertP , GoeusseP , DufourP , UzanS , BreartG , et al. Value of systematic doppler +/‐ low dose aspirin to prevent vascular complications in primigravidae. Hypertension in Pregnancy2000;19(Suppl 1):9. ">France 2001</a>; <a href="./references#CD004659-bbs2-0110" title="HashemiM , Heshmat‐GhahdarijaniK , BahraniS , BaktashF , ZareanE . Evaluation the effect of low‐dose aspirin on endothelial dysfunction in preeclamptic patients. Journal of Research in Medical Sciences2016;21:128. HeshmatK , IRCT2016040527135N2 . Evaluation of the effect of low dose aspirin on endothelial dysfunction in preeclamptic patients. http://en.irct.ir/trial/22305 (first received 4 June 2016). ">Iran 2016</a>; <a href="./references#CD004659-bbs2-0111" title="EbrahimiBM , IRCT2016022020035N2 . Study of effect of vitamin E and low‐dose aspirin on uterine artery blood flow velocity in women with recurrent pregnancy loss due to impaired uterine perfusion: clinical trial. http://en.irct.ir/trial/17776 (first received 10 May 2016). MesdaghiniaE , Mohammad‐EbrahimiB , ForoozanfardF , BanafsheHR . The effect of vitamin e and aspirin on the uterine artery blood flow in women with recurrent abortion: a single‐blind randomized controlled trial. International Journal of Reproductive Biomedicine (Yazd, Iran)2017;15(10):635‐40. ">Iran 2017</a>; <a href="./references#CD004659-bbs2-0123" title="LazzarinN , VaqueroE , ExacoustosC , BertonottiE , RomaniniME , ArduiniD . Low‐dose aspirin and omega‐3 fatty acids improve uterine artery blood flow velocity in women with recurrent miscarriage due to impaired uterine perfusion. Fertility and Sterility2009;92(1):296‐300. ">Italy 2009</a>; <a href="./references#CD004659-bbs2-0136" title="BlomqvistL , HellgrenM , StrandellA . Acetylsalicylic acid for prevention of pregnancy loss: a randomized trial. Human Reproduction2017;32:i11‐i12. ">Sweden 2017</a>; <a href="./references#CD004659-bbs2-0146" title="MirroR , SibaiBM , LefflerCW , ChesneyCM . Low dose aspirin during pregnancy. Pediatric Research1988;23:419A. SibaiBM , MirroR , ChesneyCM , LefflerC . Low‐dose aspirin in pregnancy. Obstetrics &amp; Gynecology1989;74:551‐7. ">USA 1989</a>; <a href="./references#CD004659-bbs2-0152" title="AhrensKA , SilverRM , MumfordSL , SjaardaLA , PerkinsNJ , Wactawski‐WendeJ , et al. Complications and safety of preconception low‐dose aspirin among women with prior pregnancy losses. Obstetrics &amp; Gynecology2016;127(4):689‐98. ConnellMT , SjaardaLA , RadinRG , KuhrD , MumfordSL , PlowdenTC , et al. The effects of aspirin in gestation and reproduction (eager) trial: a story of discovery. Seminars in Reproductive Medicine2017;35(4):344‐52. GibbinsKJ , BranchDW , SilverRM , SjaardaLA , MumfordSL , PerkinsNJ , et al. Recurrent pregnancy loss in women with and without antiphospholipid antibodies. American Journal of Obstetrics &amp; Gynecology2016;214(1 Suppl):S199. LesherLL , MatyasRA , SjaardaLA , NewmanSL , SilverRM , GalaiN , et al. Recruitment for longitudinal, randomised pregnancy trials initiated preconception: lessons from the Effects of Aspirin in Gestation and Reproduction trial. Paediatric and Perinatal Epidemiology2015;29(2):162‐7. MoneF , McAuliffeFM . Preconception low‐dose aspirin and pregnancy outcomes: results from the EAGeR randomized trial. Irish Medical Journal2015;108(1):5. MumfordSL , SilverRM , SjaardaLA , Wactawski‐WendeJ , TownsendJM , LynchAM , et al. Expanded findings from a randomized controlled trial of preconception low‐dose aspirin and pregnancy loss. Human Reproduction2016;31(3):657‐65. PughSJ , SchistermanEF , BrowneRW , LynchAM , MumfordSL , PerkinsNJ , et al. Preconception maternal lipoprotein levels in relation to fecundability. Human Reproduction2017;32(5):1055‐63. RadinRG , MumfordSL , SilverRM , LesherLL , GalaiN , FaraggiD , et al. Sex ratio following preconception low‐dose aspirin in women with prior pregnancy loss. Journal of Clinical Investigation2015;125(9):3619‐26. RadinRG , SjaardaLA , PerkinsNJ , SilverRM , ChenZ , LesherLL , et al. Low‐dose aspirin and sporadic anovulation in the EAGeR randomized trial. Journal of Clinical Endocrinology and Metabolism2017;102(1):86‐92. SchistermanE , SilverR , LesherL , FaraggiD , Wactawski‐WendeJ , TownsendJ , et al. Randomized clinical trial of preconception low dose aspirin use to improve pregnancy outcomes: EAGeR (Effects of Aspirin in Gestation and Reproduction) trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S352. SchistermanEF . Erratum. Paediatric and Perinatal Epidemiology2014;28(3):27. SchistermanEF , MumfordSL , SchliepKC , SjaardaLA , StanfordJB , LesherLL , et al. Preconception low dose aspirin and time to pregnancy: findings from the EAGER (Effects of Aspirin in Gestation And Reproduction) randomized trial. Journal of Clinical Endocrinology and Metabolism2015;100(5):1785‐91. SchistermanEF , NCT00467363 . The effects of aspirin in gestation and reproduction: a multi‐center, controlled, double‐blind randomized trial. clinicaltrials.gov/ct2/show/record/NCT00467363 (first received 30 April 2007). SchistermanEF , SilverRM , LesherLL , FaraggiD , Wactawski‐WendeJ , TownsendJM , et al. Preconception low‐dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. Lancet2014;384(9937):29‐36. SchistermanEF , SilverRM , MumfordSL , GalaiN , Wactawski‐WendeJ , StanfordJB . Randomized clinical trial of preconception low dose aspirin use and time‐to‐pregnancy: The EAGeR trial. Fertility and Sterility2013;100(3 Suppl 1):S100. SchistermanEF , SilverRM , PerkinsNJ , MumfordSL , WhitcombBW , StanfordJB , et al. A randomised trial to evaluate the effects of low‐dose aspirin in gestation and reproduction: design and baseline characteristics.[Erratum appears in Paediatr Perinat Epidemiol. 2014 May;28(3):275]. Paediatric and Perinatal Epidemiology2013;27(6):598‐609. SilverRM , AhrensK , WongLF , PerkinsNJ , GalaiN , LesherLL , et al. Low‐dose aspirin and preterm birth: a randomized controlled trial. Obstetrics and Gynecology2015;125(4):876‐84. SjaardaL , MitchellE , MumfordSL , RadinR , PerkinsNJ , GalaiN , et al. Preconception low dose aspirin treatment improves clinical pregnancy and live birth in women with higher systemic inflammation. Fertility and Sterility2015;104(3 Suppl 1):e349. SjaardaLA , RadinRG , SilverRM , MitchellE , MumfordSL , WilcoxB , et al. Preconception low‐dose aspirin restores diminished pregnancy and live birth rates in women with low grade inflammation: a secondary analysis of a randomized trial. Journal of Clinical Endocrinology and Metabolism2017;102(5):1495‐504. ">USA 2013</a>). Ten studies were not trials evaluating antiplatelet drugs versus placebo or no treatment (<a href="./references#CD004659-bbs2-0084" title="BujoldE , NCT01352234 . Evaluation of dose‐response effect of acetylsalicylic acid on placental development, preterm birth, fetal growth and hypertension in pregnancy in women with previous history of preeclampsia. clinicaltrials.gov/ct2/show/NCT01352234 (first received 11 May 2011). TappS , DemersS , GiguereY , LeclairG , NicolaidesK , CoteS , et al. Comparison of 80 versus 160 mg of aspirin in pregnant women with previous history of pre‐eclampsia: a randomised controlled trial. Ultrasound in Obstetrics &amp; Gynecology2015;46(Suppl 1):S4. ">Canada 2015</a>; <a href="./references#CD004659-bbs2-0106" title="PapalkarJ , RaniD , Shrivastava . Comparison of lycopene and low dose aspirin with only low dose aspirin pre‐eclampsia. 54th All India Congress of Obstetrics and Gynaecology; 2011 January 5‐9; Hyderabad, Andhra Pradesh, India. 2011:310. ">India 2011</a>; <a href="./references#CD004659-bbs2-0112" title="ReganCL , McAdamBF , McParlandP , BoylanPC , FitzGeraldGA , FitzgeraldDJ . Reduced fetal exposure to aspirin using a novel controlled release preparation in normotensive and hypertensive pregnancies. British Journal of Obstetrics and Gynaecology1998;105:732‐8. ReganCL , McAdamBV , McParlandP , BoylanP , FitzGeraldGA , FitzgeraldDJ . Pharmacology of low dose aspirin in normotensive and hypertensive pregnancies. 27th British Congress of Obstetrics and Gynaecology; 1995 July 4‐7; Dublin, Ireland. 1995:301. ">Ireland 1995</a>; <a href="./references#CD004659-bbs2-0114" title="DolitzkyM , InbalA , SegalY , WeissA , BrennerB , CarpH . A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertility and Sterility2006;86(2):362‐6. ">Israel 2006</a>; <a href="./references#CD004659-bbs2-0121" title="MelloG , ParrettiE , FatiniC , RivielloC , GensiniF , MarchionniM , et al. Efficacy of LMWH in lowering the recurrence rate of preeclampsia and in restoring the physiological vascular changes in ACE DD genotype women [abstract]. Hypertension in Pregnancy2004;23(Suppl 1):162. MelloG , ParrettiE , FatiniC , RivielloC , GensiniF , MarchionniM , et al. Low‐molecular‐weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin‐converting enzyme DD women. Hypertension2005;45(1):86‐91. ">Italy 2005</a>; <a href="./references#CD004659-bbs2-0122" title="ChistoliniA , TorelliF , GiancottiA , PignoloniP , MutoB , CosimoC , et al. Recurrent fetal loss: prospective evaluation of the efficacy of three different thromboprophylaxis regimens: aspirin versus low molecular weight heparin versus low molecular weight heparin plus aspirin [abstract]. Hematology Journal2006;91(Suppl 1):146. GiancottiA , TorreRL , SpagnuoloA , D'AmbrosioV , CerekjaA , PiazzeJ , et al. Efficacy of three different antithrombotic regimens on pregnancy outcome in pregnant women affected by recurrent pregnancy loss. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(7):1191‐4. ">Italy 2006</a>; <a href="./references#CD004659-bbs2-0130" title="Vigil‐De GraciaP , DominguezL , SolisA . Management of chronic hypertension during pregnancy with furosemide, amlodipine or aspirin: a pilot clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(13):1291‐4. ">Panama 2014</a>; <a href="./references#CD004659-bbs2-0133" title="ZozuliaOV , RogovVA , PiatakovaNV , TareevaIE . Nitric oxide: its role in the development of pregnancy complications and in their prevention in women with hypertension and chronic glomerulonephritis. Terapevticheskii Arkhiv1997;69(6):17‐20. ">Russia 1997</a>; <a href="./references#CD004659-bbs2-0140" title="HachichaJ , BellajA , GhorbelL , AbidR , RekikS , JarrayaA . Aspirin or aspirin and dipyridamole to prevent vasculo‐renal accidents in pregnancy. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:256. HachichaJ , Ben HmidaM , KharratM , JarrayaF , RekikS , JarrayaA . Aspirin or aspirin and dipyridamole to prevent pregnancy‐induced hypertension [abstract]. Nephrology, Dialysis, Transplantation1994;9:926. ">Tunisia 1990</a>; <a href="./references#CD004659-bbs2-0148" title="SilverRK , MacGregorSN , ShollJS , HobartJM , NeerhofMG , RaginA . Comparative trial of prednisone plus aspirin vs aspirin alone in the treatment of anticardiolipin antibody‐positive obstetric patients. American Journal of Obstetrics and Gynecology1993;169:1411‐7. SilverRK , ShollJS , MacGregorSN , HobartJH , NeerhofMG , HickmanAH . Prospective evaluation of single (low‐dose aspirin) vs combined (aspirin plus prednisone) therapy in the treatment of the antiphospholipid syndrome. Proceedings of 39th Annual Meeting of the Society for Gynecologic Investigation; 1992 March 18‐21; San Antonio, Texas, USA. 1992:125. ">USA 1993b</a>). Twelve studies did not report any relevant clinical outcomes (<a href="./references#CD004659-bbs2-0080" title="TrudingerBJ , CookCM , GilesWB , ConnellyAJ , ThompsonRS . Low‐dose aspirin and twin pregnancy. Lancet1989;334(8673):1214. ">Australia 1989a</a>; <a href="./references#CD004659-bbs2-0085" title="ChengWW , ZhangZJ . Low‐dose aspirin preventing pregnancy induced hypertension. Chung Hua Fu Chan Ko Tsa Chih1991;26(6):342‐5. ">China 1991</a>; <a href="./references#CD004659-bbs2-0089" title="PeterseimH , HofmannKD , WagnerF , PeterseimS , MeierP . Inhibition of prostaglandin synthetase by low‐dose acetylsalicylic acid ‐ effects on severity of pregnancy induced hypertension and fetal outcome. Proceedings of 10th European Congress of Perinatal Medicine; 1986 August 12‐16; Leipzig, Germany. 1986:290. ">East Germany 1986</a>; <a href="./references#CD004659-bbs2-0094" title="ArmandoCA , MarthaCC , GaloEV . Prevention of the development of preeclampsia by means of the administration of low doses of aspirin. Quito1998:80. ">Equador 1998</a>; <a href="./references#CD004659-bbs2-0096" title="KaajaR , JulkunenH , ViinikkaL , YlikorkalaO . Production of prostacyclin and thromboxane in lupus pregnancies: effect of small dose of aspirin. Obstetrics &amp; Gynecology1993;81:327‐31. ">Finland 1993a</a>; <a href="./references#CD004659-bbs2-0099" title="NiednerW , BellerFK . The influence of ASA on pre‐eclampsia. Proceedings of the 5th International Congress of the Society for the Study of Hypertension in Pregnancy; 1986 July 7‐10; Nottingham, UK. 1986:101. ">Germany 1986</a>; <a href="./references#CD004659-bbs2-0113" title="BreathnachF , ISRCTN13355246 . Early aspirin to improve pregnancy outcome in diabetes. isrctn.com/ISRCTN13355246 (first received 12 February 2014). SubiehHA , McHughA , CorcoranS , BackleyS , TullyE , McDermottR , et al. Aspirin for optimising pregnancy outcome in pregestational diabetes: the value of objective testing of study participant compliance. Pilot for the IRELAND study (investigating the role of early low‐dose aspirin in pre‐existing diabetes). BJOG: an international journal of obstetrics and gynaecology2017; Vol. 124:142‐3. ">Ireland 2014</a>; <a href="./references#CD004659-bbs2-0126" title="HuttonJD , WilkinsonAM . Poor participation of nulliparous women in a low dose aspirin study to prevent preeclampsia. New Zealand Medical Journal1990;103:511‐2. ">New Zealand 1990</a>; <a href="./references#CD004659-bbs2-0142" title="McParlandP , PearceJM . Effect of low dose aspirin on maternal and fetal flow velocity waveforms. American Journal of Obstetrics and Gynecology1992;166:438. ">UK 1992a</a>; <a href="./references#CD004659-bbs2-0143" title="WilliamsHD , HowardR , O'DonnellN , FindleyI . The effect of low dose aspirin on bleeding times. Anaesthesia1993;48:331‐3. ">UK 1993</a>; <a href="./references#CD004659-bbs2-0149" title="O'BrienWF , KrammerJ , O'LearyTD , MastrogiannisDS . The effect of acetaminophen on prostacyclin production in pregnant women. American Journal of Obstetrics and Gynecology1993;168:1164‐9. ">USA 1993c</a>; <a href="./references#CD004659-bbs2-0150" title="MartinC , VarnerMW , BranchDW , RodgersG , MitchellMD . Dose‐related effects of low dose aspirin on hemostasis parameters and prostacyclin/thromboxane ratios in late pregnancy. Prostaglandins1996;51:321‐30. ">USA 1996</a>). For another 13 studies, there were other concerns about risk of bias (<a href="./references#CD004659-bbs2-0079" title="RobinsonJS . [Personal communication] Can the genetic risk of pre‐eclampsia be reduced by low dose aspirin?. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 25 March 1993. ">Australia 1989</a>; <a href="./references#CD004659-bbs2-0083" title="SassN , RochaNS , CallegariAH , LimaPC , CamanoL . The low dose aspirin study in pregnancy with chronic hypertension (AASHAC). Proceedings of the 10th World Congress on Hypertension in Pregnancy; 1996 August 4‐8; Seattle, USA. 1996:152. ">Brazil 1996a</a>; <a href="./references#CD004659-bbs2-0088" title="HernandezF , MartinezMF , CameroA , PinzonJA . Low dose aspirin as prophylactic therapy of pregnancy induced hypertension. Revista Colombiana de Obstetricia y Ginecologia1996;47:197‐201. ">Colombia 1996</a>; <a href="./references#CD004659-bbs2-0103" title="SehgalR , SoodM . Role of low dose aspirin for prevention of pregnancy induced hypertension. Journal of Obstetrics and Gynecology of India2001;51(5):81‐4. ">India 2001</a>; <a href="./references#CD004659-bbs2-0107" title="TaherianA , TaherianA , ShirvaniA . Prevention of preeclampsia with low‐dose aspirin or calcium supplementation. Archives of Iranian Medicine2002;5:151‐6. ">Iran 2002</a>; <a href="./references#CD004659-bbs2-0108" title="AbdaliK , IRCT138803211548N5 . The effect of taking aspirin in two different diurnal times (morning and night) on mean of 24 hours blood pressure in women who are at preeclampsia risk. http://en.irct.ir/trial/5621 (first received 20 February 2010). AbdaliK , TaghizadehR , AmoeiS , TabatabaiSH . Comparison between aspirin and placebo on the mean of 24 hour blood pressure in pregnant women at preeclampsia risk, a double blind randomized controlled clinical trial. International Journal of Community Based Nursing and Midwifery2013;1:283‐9. ">Iran 2013</a>; <a href="./references#CD004659-bbs2-0115" title="AiroldiML , CapettaP , TascaA , BertulessiC , RossiE , PolvaniF . Role of early prevention with heparin and dipyridamole in the prevention of pre‐eclampsia and placental insufficiency. Proceedings of the 6th International Congress of the International Society for the study of Hypertension in Pregnancy; 1988 May 22‐26; Montreal, Quebec, Canada. 1988:233. CapettaP , AiroldiML , TascaA , BertulessiC , RossiE , PolvaniF . Prevention of pre‐eclampsia and placental insufficiency. Lancet1986;1:919. ">Italy 1988</a>; <a href="./references#CD004659-bbs2-0127" title="McCowanL , HardingJ , FordC , BarkerS , RobertsA , TownendK . Prenatal treatment with low dose aspirin in small for gestational age fetuses with abnormal umbilical doppler: a randomised controlled trial. 2nd Annual Congress of the Perinatal Society of Australia and New Zealand; 1998 March 30‐April 4; Alice Springs, Australia. 1998:135. McCowanLM , HardingJ , RobertsA , BarkerS , FordC , StewartA . Administration of low dose aspirin to mothers with small for gestational age fetuses and abnormal umbilical Doppler studies to increase birthweight: a randomised double‐blind controlled trial. British Journal of Obstetrics and Gynaecology1999;106:647‐51. ">New Zealand 1998</a>; <a href="./references#CD004659-bbs2-0128" title="PattisonN , ChamleyL , BirdsallM , ZanderigoA , LiddellH , McDougallJ . Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. American Journal of Obstetrics and Gynecology2000;183:1008‐12. ">New Zealand 2000</a>; <a href="./references#CD004659-bbs2-0135" title="CaberoL , BellartJ , BertiniA , AlthabeO , BichouC , BucheliR . Aspirin in early pregnancy to reduce the incidence and/or severity of pregnancy induced hypertension and intrauterine growth retardation in healthy pregnant women. Hypertension in Pregnancy2000;19(1):98. ">Spain + others 2000</a>; <a href="./references#CD004659-bbs2-0144" title="HamidR , RobsonM , PearceJM . Low dose aspirin in women with raised maternal serum alpha‐fetoprotein and abnormal Doppler waveform patterns from the uteroplacental bed. British Journal of Obstetrics and Gynaecology1994;101:481‐4. HamidR , RobsonM , PearceJM . Low dose aspirin in women with raised maternal serum alpha‐fetoprotein and abnormal Doppler waveform patterns from the uteroplacental circulation. International Journal of Gynecology &amp; Obstetrics1995;48:348‐9. ">UK 1994</a>; <a href="./references#CD004659-bbs2-0145" title="HarringtonK , KurdiW , AquilinaJ , EnglandP , CampbellS . A prospective management study of slow‐release aspirin in the palliation of uteroplacental insufficiency predicted by uterine artery Doppler at 20 weeks. Ultrasound in Obstetrics &amp; Gynecology2000;15:13‐8. KurdiW , FayyadA , ThakurV , HarringtonK . Delayed normalisation of the uterine artery Doppler waveforms is not a benign phenomenon. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2004;117(1):20‐3. ">UK 2000</a>; <a href="./references#CD004659-bbs2-0151" title="OdiboA , NCT01547390 . Early prediction and aspirin for prevention of preeclampsia. clinicaltrials.gov/ct2/show/record/NCT01547390 (first received 7 March 2012). OdiboAO , GoetzingerKR , OdiboL , TuuliMG . Early Prediction and Aspirin for Prevention of Pre‐eclampsia study (EPAPP study): a randomized controlled trial. Ultrasound in Obstetrics &amp; Gynecology2015;46:414‐8. PapatheodorouSI . Re: early prediction and aspirin for prevention of pre‐eclampsia (epapp) study: a randomized controlled trial. A. O. Odibo, K. R. Goetzinger, l. Odibo and M. G. Tuuli. Ultrasound Obstet Gynecol 2015; 46: 414‐8. Ultrasound in Obstetrics &amp; Gynecology2015;46(4):389. ">USA 2012</a>). </p> </section> </section> <section id="CD004659-sec-0101"> <h3 class="title">Risk of bias in included studies</h3> <p>Details for each trial are in the <a href="./references#CD004659-sec-0179" title="">Characteristics of included studies</a> table. There is variation in study quality, although overall most studies were either low risk of bias or unclear risk of bias (<a href="#CD004659-fig-0002">Figure 2</a>; <a href="#CD004659-fig-0004">Figure 4</a>). The studies with unclear risk of bias are mostly the smaller trials, with the nine large studies (more than 1000 women) having low risk of bias (<a href="#CD004659-fig-0003">Figure 3</a>; <a href="#CD004659-fig-0005">Figure 5</a>). Of the nine large trials, six were low risk of bias for all domains (<a href="#CD004659-fig-0005">Figure 5</a>). One study (<a href="./references#CD004659-bbs2-0072" title="AbramoviciA , JaukV , WettaL , EdwardsR , BiggioJ , TitaA . Analysis of low‐dose aspirin by smoking status for select perinatal outcomes. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S261. AndrikopoulouM , PurischSE , Handal‐OreficeR , Gyamfi‐BannermanC . Beyond preeclampsia: low dose aspirin reduces spontaneous preterm birth. American Journal of Obstetrics and Gynecology2018;218(1):S10. CaritisS , SibaiB , ThornE , McLaughlinS , NICHD‐MFM Network. Pregnancy effects of non‐proteinuric gestational hypertension (GH). American Journal of Obstetrics and Gynecology1995;172:376. ConnealyB , CarrenoC , KaseB , HartL , BlackwellS , SibaiB . A history of prior preeclampsia is a major risk factor for preterm birth. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S264. DiSessaTG , MorettiML , KhouryA , PulliamDA , ArheartKL , SibaiBM . Cardiac function in fetuses and newborns exposed to low‐dose aspirin during pregnancy. American Journal of Obstetrics and Gynecology1994;171:892‐900. FrattoVM , AnanthCV , Gyamfi‐BannermanC . Late preterm neonatal morbidity in hypertensive versus normotensive women. Hypertension in Pregnancy2016;35(2):242‐9. OhnoM , GirsenA , O'MalleyK , BlumenfeldY , LyellD , ButwickA , et al. Does low‐dose aspirin for preeclampsia prevention increase the risk of antepartum bleeding or placental abruption?. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S189. SibaiB . Low‐dose aspirin (60 mg/d) in pregnancy for the prevention of preeclampsia. 8th World Congress on Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina 1992. 1992:50. SibaiB , CaritisS , PhillipsE , KlebanoffM , McNellisD , RoccoL . Prevention of preeclampsia: low‐dose aspirin in nulliparous women: a double‐blind, placebo controlled trial. American Journal of Obstetrics and Gynecology1993;168:286. SibaiB , CaritisS , PhillipsE , KlebanoffM , PaulR , WitterF , et al. Safety of low‐dose aspirin in healthy nulliparous women: a double‐blind, placebo‐controlled trial. Proceedings of 40th Annual Meeting Society for Gynecologic Investigation; 1993 March; Toronto, Canada. 1993:S102. SibaiB , CaritisS , ThomE , ShawK , McNellisD , NICHD‐MFM Network. Low‐dose aspirin in nulliparous women: safety of epidural and correlation between bleeding time and maternal‐neonatal bleeding complications. American Journal of Obstetrics and Gynecology1994;170:293. SibaiB , GordonT , PhillipsE , McNellisD , CaritisS , RomeroR , et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. Proceedings of 41st Annual Clinical Meeting of The American College of Obstetricians and Gynecologists; 1993 May 3‐6; Washington DC, USA. 1993:2. SibaiBM , CaritisSN , ThomE , KlebanoffM , McNellisD , RoccoL , et al. Prevention of preeclampsia with low‐dose aspirin in healthy, nulliparous pregnant women. New England Journal of Medicine1993;329:1213‐8. SibaiBM , CaritisSN , ThomE , ShawK , McNellisD , NICHD‐MFM Network. Low dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal‐neonatal bleeding complications. American Journal of Obstetrics and Gynecology1995;172:1533‐7. SibaiBM , GordonT , ThomE , CaritisSN , KlebanoffM , McNellisD , et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. American Journal of Obstetrics and Gynecology1995;172:642‐8. TolcherMC , Sangi‐HaghpeykarH , AagaardKM . Race and ethnicity varies both efficacy and attributable risk of low‐dose aspirin (asa) for preeclampsia prevention among low‐risk women. American Journal of Obstetrics and Gynecology2018;218(1 Suppl):S203. WittenFR . [Personal communication] Double‐blind, placebo‐controlled trial of low‐dose aspirin to prevent pre‐eclampsia. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 6 September 1991. YaffeS . [Personal communication] Clinical trial of low dose aspirin (65mg) as a preventative of pre‐eclampsia. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 3 December 1991. ">USA 1993a</a>), was deemed at unclear risk of selection bias because there was no information about the method of randomisation, and also at unclear risk of 'other bias' due to concerns that the baseline characteristics of the enrolled population may have been unrepresentative of the general population; another (<a href="./references#CD004659-bbs2-0047" title="Italian Study of Aspirin in Pregnancy. Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Lancet1993;341:396‐400. ParazziniDF . Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Geburtshilfe und Frauenheilkunde1993;53:822. ParazziniF . Multicenter randomized Italian study of low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Journal of Nephrology1991;4:127‐9. ParazziniF , BenedettoC , FruscaT , GuaschinoS , RomeroM . The Italian study on low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:32. ParazziniF , BortolusR , ChatenoudL , RestelliS , BenedettoC . Follow‐up of children in the Italian Study of Aspirin in Pregnancy. Lancet1994;343:1235. ParazziniF , BortolusR , ChatenoudL , RestelliS , RicciE , MarozioL , et al. Risk factors for pregnancy‐induced hypertension in women at high risk for the condition. Epidemiology1996;7(3):306‐8. ">Italy 1993</a>) did not use a placebo, and was also assessed as high risk of bias for blinding of the assessment of outcome and for attrition bias (there was higher loss to follow‐up in the no treatment arm); the third (<a href="./references#CD004659-bbs2-0050" title="ElderMG , deSwietM , SullivanM . A randomised trial of low dose aspirin for primiparae in pregnancy (golding)/barbados low dose aspirin study in pregnancy (blasp) (rotchell et al.) [Letter; comment]. British Journal of Obstetrics &amp; Gynaecology1999;106(2):180. ForresterTE , JonesD , McCaw‐BinnsA , Palmer‐LevyM , WilksR , BernardGW , et al. Low‐dose aspirin in pregnancy ‐ are there any benefits? [abstract]. West Indian Medical Journal1996;45(2 Suppl):26. GoldingJ . A randomised trial of low dose aspirin for primiparae in pregnancy. British Journal of Obstetrics and Gynaecology1998;105:293‐9. KahwaEK , SargeantLA , McCaw‐BinnsA , McFarlane‐AndersonN , SmikleM , ForresterT , et al. Anticardiolipin antibodies in jamaican primiparae. Journal of Obstetrics and Gynaecology2006;26(2):122‐6. McCaw‐BinnsA , AshleyD , HawkinsN , MacGillivrayI , GoldingJ . International variation in the incidence of hypertension in pregnancy among primiparae: the jamaican experience. 10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4‐8; Seattle, Washington, USA. 1996:168. McCaw‐BinnsA , Jamaica Low‐Dose Aspirin Group. Low dose aspirin in pregnancy ‐ are there any benefits?. 10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4‐8; Seattle, Washington, USA. 1996:76. ">Jamaica 1998</a>) was unclear risk of 'other' bias, as significantly fewer women taking aspirin complied with their treatment than those taking placebo (63% versus 68%). </p> <div class="figure" id="CD004659-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="'Risk of bias' summary for the nine large trials: review authors' judgements about each risk of bias item for each study" data-id="CD004659-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary for the nine large trials: review authors' judgements about each risk of bias item for each study </p> </div> </div> </div> <p>Overall, the nine large (more than 1000 women) trials were low risk of bias and together recruited 32,195 women (80% of women in the review). Most women in the review were therefore recruited to studies with low risk of bias. The AD studies had smaller samples sizes, and many had unclear risk of bias. </p> <section id="CD004659-sec-0102"> <h4 class="title">Allocation</h4> <p>Seven of the nine large studies (&gt; 1000 women) were low risk for both selection bias domains (<a href="#CD004659-fig-0005">Figure 5</a>). For two of the large studies, risk of bias for sequence generation was unclear; in one (<a href="./references#CD004659-bbs2-0047" title="Italian Study of Aspirin in Pregnancy. Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Lancet1993;341:396‐400. ParazziniDF . Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Geburtshilfe und Frauenheilkunde1993;53:822. ParazziniF . Multicenter randomized Italian study of low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Journal of Nephrology1991;4:127‐9. ParazziniF , BenedettoC , FruscaT , GuaschinoS , RomeroM . The Italian study on low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:32. ParazziniF , BortolusR , ChatenoudL , RestelliS , BenedettoC . Follow‐up of children in the Italian Study of Aspirin in Pregnancy. Lancet1994;343:1235. ParazziniF , BortolusR , ChatenoudL , RestelliS , RicciE , MarozioL , et al. Risk factors for pregnancy‐induced hypertension in women at high risk for the condition. Epidemiology1996;7(3):306‐8. ">Italy 1993</a>), the same randomisation sheets were used in error for several centres in the early stages of the trial, and for the other (<a href="./references#CD004659-bbs2-0072" title="AbramoviciA , JaukV , WettaL , EdwardsR , BiggioJ , TitaA . Analysis of low‐dose aspirin by smoking status for select perinatal outcomes. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S261. AndrikopoulouM , PurischSE , Handal‐OreficeR , Gyamfi‐BannermanC . Beyond preeclampsia: low dose aspirin reduces spontaneous preterm birth. American Journal of Obstetrics and Gynecology2018;218(1):S10. CaritisS , SibaiB , ThornE , McLaughlinS , NICHD‐MFM Network. Pregnancy effects of non‐proteinuric gestational hypertension (GH). American Journal of Obstetrics and Gynecology1995;172:376. ConnealyB , CarrenoC , KaseB , HartL , BlackwellS , SibaiB . A history of prior preeclampsia is a major risk factor for preterm birth. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S264. DiSessaTG , MorettiML , KhouryA , PulliamDA , ArheartKL , SibaiBM . Cardiac function in fetuses and newborns exposed to low‐dose aspirin during pregnancy. American Journal of Obstetrics and Gynecology1994;171:892‐900. FrattoVM , AnanthCV , Gyamfi‐BannermanC . Late preterm neonatal morbidity in hypertensive versus normotensive women. Hypertension in Pregnancy2016;35(2):242‐9. OhnoM , GirsenA , O'MalleyK , BlumenfeldY , LyellD , ButwickA , et al. Does low‐dose aspirin for preeclampsia prevention increase the risk of antepartum bleeding or placental abruption?. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S189. SibaiB . Low‐dose aspirin (60 mg/d) in pregnancy for the prevention of preeclampsia. 8th World Congress on Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina 1992. 1992:50. SibaiB , CaritisS , PhillipsE , KlebanoffM , McNellisD , RoccoL . Prevention of preeclampsia: low‐dose aspirin in nulliparous women: a double‐blind, placebo controlled trial. American Journal of Obstetrics and Gynecology1993;168:286. SibaiB , CaritisS , PhillipsE , KlebanoffM , PaulR , WitterF , et al. Safety of low‐dose aspirin in healthy nulliparous women: a double‐blind, placebo‐controlled trial. Proceedings of 40th Annual Meeting Society for Gynecologic Investigation; 1993 March; Toronto, Canada. 1993:S102. SibaiB , CaritisS , ThomE , ShawK , McNellisD , NICHD‐MFM Network. Low‐dose aspirin in nulliparous women: safety of epidural and correlation between bleeding time and maternal‐neonatal bleeding complications. American Journal of Obstetrics and Gynecology1994;170:293. SibaiB , GordonT , PhillipsE , McNellisD , CaritisS , RomeroR , et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. Proceedings of 41st Annual Clinical Meeting of The American College of Obstetricians and Gynecologists; 1993 May 3‐6; Washington DC, USA. 1993:2. SibaiBM , CaritisSN , ThomE , KlebanoffM , McNellisD , RoccoL , et al. Prevention of preeclampsia with low‐dose aspirin in healthy, nulliparous pregnant women. New England Journal of Medicine1993;329:1213‐8. SibaiBM , CaritisSN , ThomE , ShawK , McNellisD , NICHD‐MFM Network. Low dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal‐neonatal bleeding complications. American Journal of Obstetrics and Gynecology1995;172:1533‐7. SibaiBM , GordonT , ThomE , CaritisSN , KlebanoffM , McNellisD , et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. American Journal of Obstetrics and Gynecology1995;172:642‐8. TolcherMC , Sangi‐HaghpeykarH , AagaardKM . Race and ethnicity varies both efficacy and attributable risk of low‐dose aspirin (asa) for preeclampsia prevention among low‐risk women. American Journal of Obstetrics and Gynecology2018;218(1 Suppl):S203. WittenFR . [Personal communication] Double‐blind, placebo‐controlled trial of low‐dose aspirin to prevent pre‐eclampsia. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 6 September 1991. YaffeS . [Personal communication] Clinical trial of low dose aspirin (65mg) as a preventative of pre‐eclampsia. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 3 December 1991. ">USA 1993a</a>), the method for sequence generation is not stated. No included studies were high risk of bias for sequence generation. All nine large trials were low risk of bias for concealment of allocation. Only two studies were high risk for concealment of allocation (<a href="./references#CD004659-bbs2-0037" title="SharmaN , SrinivasanKJ , NadhamuniK , SrinivasanS . Role of aspirin in high pulsatility index of uterine artery: a consort study. Journal of Obstetrics and Gynecology of India2017 [Epub ahead of print]. ">India 2017</a>; <a href="./references#CD004659-bbs2-0065" title="RamaiyaC , MgayaH . Low dose aspirin in prevention of pregnancy‐induced hypertension in primigravidae at the Muhimbili Medical Centre, Dar Es Salaam. Acta Obstetricia et Gynecologica Scandinavica1997;76(167):1. RamaiyaC , MgayaHN . Low dose aspirin in prevention of pregnancy‐induced hypertension in primigravidae at the Muhimbili Medical Centre, Dar es Salaam. East African Medical Journal1995;72:690‐3. RamaiyaCP . Low dosage of aspirin in prevention of pregnancy induced hypertension (PIH) in primigravidae at Muhimbili Medical Centre, Dar es Salaam [MD thesis]. Ethiopia: University of Dar es Salaam, 1992. ">Tanzania 1995</a>). For the smaller studies, it was unclear whether sequence generation was adequate for 33 of them, and whether concealment of the allocation at trial entry was adequate for 33 of them. </p> </section> <section id="CD004659-sec-0103"> <h4 class="title">Blinding</h4> <p>In the majority of trials,including eight of the nine large trials, participants, clinicians and research personnel were blinded to the treatment, and the risk of bias in this domain was low. Only one of the larger trials (<a href="./references#CD004659-bbs2-0047" title="Italian Study of Aspirin in Pregnancy. Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Lancet1993;341:396‐400. ParazziniDF . Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Geburtshilfe und Frauenheilkunde1993;53:822. ParazziniF . Multicenter randomized Italian study of low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Journal of Nephrology1991;4:127‐9. ParazziniF , BenedettoC , FruscaT , GuaschinoS , RomeroM . The Italian study on low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:32. ParazziniF , BortolusR , ChatenoudL , RestelliS , BenedettoC . Follow‐up of children in the Italian Study of Aspirin in Pregnancy. Lancet1994;343:1235. ParazziniF , BortolusR , ChatenoudL , RestelliS , RicciE , MarozioL , et al. Risk factors for pregnancy‐induced hypertension in women at high risk for the condition. Epidemiology1996;7(3):306‐8. ">Italy 1993</a>) and 18 of the smaller trials did not blind adequately. In most cases this was because they did not use a placebo, and none of the trials without a placebo attempted to blind assessment of the outcome; these trials were high risk for both performance bias and detection bias. </p> </section> <section id="CD004659-sec-0104"> <h4 class="title">Incomplete outcome data</h4> <p>Overall, 40 trials were low risk of attrition bias, whilst for 32 trials risk of this bias was unclear, and five were at high risk of attrition bias. Of the nine large trials, eight were low risk (<a href="#CD004659-fig-0005">Figure 5</a>). For one large trial risk of attrition bias was high (<a href="./references#CD004659-bbs2-0047" title="Italian Study of Aspirin in Pregnancy. Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Lancet1993;341:396‐400. ParazziniDF . Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Geburtshilfe und Frauenheilkunde1993;53:822. ParazziniF . Multicenter randomized Italian study of low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Journal of Nephrology1991;4:127‐9. ParazziniF , BenedettoC , FruscaT , GuaschinoS , RomeroM . The Italian study on low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:32. ParazziniF , BortolusR , ChatenoudL , RestelliS , BenedettoC . Follow‐up of children in the Italian Study of Aspirin in Pregnancy. Lancet1994;343:1235. ParazziniF , BortolusR , ChatenoudL , RestelliS , RicciE , MarozioL , et al. Risk factors for pregnancy‐induced hypertension in women at high risk for the condition. Epidemiology1996;7(3):306‐8. ">Italy 1993</a>), as there was a higher loss to follow‐up in the no treatment arm in this study (which did not use a placebo). For four small trials risk of bias for incomplete outcome data was also high (<a href="./references#CD004659-bbs2-0037" title="SharmaN , SrinivasanKJ , NadhamuniK , SrinivasanS . Role of aspirin in high pulsatility index of uterine artery: a consort study. Journal of Obstetrics and Gynecology of India2017 [Epub ahead of print]. ">India 2017</a>; <a href="./references#CD004659-bbs2-0042" title="KhazardoostS , IRCT201203018954N1 . Aspirin for prevention of adverse pregnancy outcome in women with elevated alfa‐feto protein in second trimester screening,a randomised clinical trial. http://en.irct.ir/trial/9411 (first received 5 June 2012). KhazardoostS , MousaviS , BornaS , HantoushzadehS , AlaviA , KhezerlouN . Effect of aspirin in prevention of adverse pregnancy outcome in women with elevated alpha‐fetoprotein. Journal of Maternal‐Fetal and Neonatal Medicine2014; Vol. 27, issue 6:561‐5. MousaviS . Effect of aspirin in prevention of adverse pregnancy outcome in women with elevated alpha‐fetoprotein. Journal of Perinatal Medicine2015;43(Suppl 1):Abstract no: P‐0743. ">Iran 2014a</a>; <a href="./references#CD004659-bbs2-0056" title="LambersMJ , GroeneveldE , HoozemansDA , SchatsR , HomburgR , LambalkCB , et al. Lower incidence of hypertensive complications during pregnancy in patients treated with low‐dose aspirin during in vitro fertilization and early pregnancy. Human Reproduction2009;24(10):2447‐50. LambersMJ , HoozemansDA , SchatsR , HomburgR , Lambalk CornelisB , HompesPG . Low‐dose aspirin in non‐tubal IVF patients with previous failed conception: a prospective randomized double‐blind placebo‐controlled trial. Fertility and Sterility2009;92(3):923‐9. ">Netherlands 2009</a>; <a href="./references#CD004659-bbs2-0064" title="EudraCT Number:2012‐000622‐22 . Aspirin for the enhancement of trophoblastic invasion in women with abnormal uterine artery Doppler at 11‐14 weeks of gestation. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2012‐000622‐22 (first received 10 May 2012). ScazzocchioE , OrosD , DiazD , RamirezJC , RicartM , MelerE , et al. Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery doppler at 11 ‐ 14 weeks: a randomized controlled study (asap). Ultrasound in Obstetrics &amp; Gynecology2017;49:435‐41. ">Spain 2017</a>), largely due to imbalanced losses to follow‐up between groups. </p> </section> <section id="CD004659-sec-0105"> <h4 class="title">Selective reporting</h4> <p>Overall, 40 trials were low risk of bias for selective reporting, and for 35 this risk was unclear. Risk of reporting bias was low for all nine large trials (<a href="#CD004659-fig-0005">Figure 5</a>). Risk of reporting bias was high for two trials; <a href="./references#CD004659-bbs2-0028" title="KajantieE , TaipaleP , MurtoniemiK , PesonenA‐K , RaikkonenK , LaivuoriH , et al. The effect of low‐dose aspirin on placental growth factor concentration in a high‐risk predo cohort. Reproductive Sciences2018;25(1 Suppl):100A. TaipaleP , ISRCTN14030412 . Prediction and prevention of preeclampsia, intrauterine growth restriction, prenatal stress and fetal programming of child's psychological development (ongoing trial). isrctn.com/ISRCTN14030412 (first received 28 February 2007). VillaP , KajantieE , RaikkonenK , PesonenAK , HamalainenE , VainioM , et al. Aspirin in the prevention of pre‐eclampsia in high‐risk women: a randomised placebo‐controlled PREDO Trial and a meta‐analysis of randomised trials. BJOG: an International Journal of Obstetrics and Gynaecology2013;120(1):64‐74. VillaP , TaipaleP , RaikkonenK , HamalainenE , PesonenA , Kajantie , E , et al. PREDO trial ‐ acetylsalicylic acid in preventing pre‐eclampsia in high‐risk women. Pregnancy Hypertension2010;1 Suppl 1:S20. ">Finland 2013</a> as reported different outcomes in the registration document than in the paper, and <a href="./references#CD004659-bbs2-0007" title="FerrierC , NorthR , Kincaid‐SmithP . Low dose aspirin delays the onset of pre‐eclampsia in pregnancies with abnormal uteroplacental circulation. Proceedings of the 10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4‐8; Seattle, Washington, USA. 1996:151. Kincaid‐SmithP . [personal communication] Trial to evaluate the role of aspirin (60mg) in the prevention of idiopathic intrauterine growth retardation and pregnancy induced hypertension in primigravid women with abnormal uterine artery waveforms on Doppler examination at 22‐24 weeks gestation. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford UK 30 October 1991. ">Australia 1996</a> did not report data on the primary outcome of perinatal death. Risk of reporting bias was unclear for 35 small trials where the expected outcomes were not reported, outcomes additional to those pre‐specified were reported, or there was insufficient information to judge in the absence of a protocol. </p> </section> <section id="CD004659-sec-0106"> <h4 class="title">Other potential sources of bias</h4> <p>In total, 30 trials were low risk of other potential sources of bias, and for 40 this risk was unclear. Of the large trials, seven were at low risk of other potential biases, and two were at unclear risk: for one (<a href="./references#CD004659-bbs2-0050" title="ElderMG , deSwietM , SullivanM . A randomised trial of low dose aspirin for primiparae in pregnancy (golding)/barbados low dose aspirin study in pregnancy (blasp) (rotchell et al.) [Letter; comment]. British Journal of Obstetrics &amp; Gynaecology1999;106(2):180. ForresterTE , JonesD , McCaw‐BinnsA , Palmer‐LevyM , WilksR , BernardGW , et al. Low‐dose aspirin in pregnancy ‐ are there any benefits? [abstract]. West Indian Medical Journal1996;45(2 Suppl):26. GoldingJ . A randomised trial of low dose aspirin for primiparae in pregnancy. British Journal of Obstetrics and Gynaecology1998;105:293‐9. KahwaEK , SargeantLA , McCaw‐BinnsA , McFarlane‐AndersonN , SmikleM , ForresterT , et al. Anticardiolipin antibodies in jamaican primiparae. Journal of Obstetrics and Gynaecology2006;26(2):122‐6. McCaw‐BinnsA , AshleyD , HawkinsN , MacGillivrayI , GoldingJ . International variation in the incidence of hypertension in pregnancy among primiparae: the jamaican experience. 10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4‐8; Seattle, Washington, USA. 1996:168. McCaw‐BinnsA , Jamaica Low‐Dose Aspirin Group. Low dose aspirin in pregnancy ‐ are there any benefits?. 10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4‐8; Seattle, Washington, USA. 1996:76. ">Jamaica 1998</a>), this was due to slight imbalances in two baseline characteristics and the fact that fewer women taking aspirin complied with their treatment than those taking placebo; for the other (<a href="./references#CD004659-bbs2-0072" title="AbramoviciA , JaukV , WettaL , EdwardsR , BiggioJ , TitaA . Analysis of low‐dose aspirin by smoking status for select perinatal outcomes. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S261. AndrikopoulouM , PurischSE , Handal‐OreficeR , Gyamfi‐BannermanC . Beyond preeclampsia: low dose aspirin reduces spontaneous preterm birth. American Journal of Obstetrics and Gynecology2018;218(1):S10. CaritisS , SibaiB , ThornE , McLaughlinS , NICHD‐MFM Network. Pregnancy effects of non‐proteinuric gestational hypertension (GH). American Journal of Obstetrics and Gynecology1995;172:376. ConnealyB , CarrenoC , KaseB , HartL , BlackwellS , SibaiB . A history of prior preeclampsia is a major risk factor for preterm birth. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S264. DiSessaTG , MorettiML , KhouryA , PulliamDA , ArheartKL , SibaiBM . Cardiac function in fetuses and newborns exposed to low‐dose aspirin during pregnancy. American Journal of Obstetrics and Gynecology1994;171:892‐900. FrattoVM , AnanthCV , Gyamfi‐BannermanC . Late preterm neonatal morbidity in hypertensive versus normotensive women. Hypertension in Pregnancy2016;35(2):242‐9. OhnoM , GirsenA , O'MalleyK , BlumenfeldY , LyellD , ButwickA , et al. Does low‐dose aspirin for preeclampsia prevention increase the risk of antepartum bleeding or placental abruption?. American Journal of Obstetrics and Gynecology2014;210(1 Suppl):S189. SibaiB . Low‐dose aspirin (60 mg/d) in pregnancy for the prevention of preeclampsia. 8th World Congress on Hypertension in Pregnancy; 1992 November 8‐12; Buenos Aires, Argentina 1992. 1992:50. SibaiB , CaritisS , PhillipsE , KlebanoffM , McNellisD , RoccoL . Prevention of preeclampsia: low‐dose aspirin in nulliparous women: a double‐blind, placebo controlled trial. American Journal of Obstetrics and Gynecology1993;168:286. SibaiB , CaritisS , PhillipsE , KlebanoffM , PaulR , WitterF , et al. Safety of low‐dose aspirin in healthy nulliparous women: a double‐blind, placebo‐controlled trial. Proceedings of 40th Annual Meeting Society for Gynecologic Investigation; 1993 March; Toronto, Canada. 1993:S102. SibaiB , CaritisS , ThomE , ShawK , McNellisD , NICHD‐MFM Network. Low‐dose aspirin in nulliparous women: safety of epidural and correlation between bleeding time and maternal‐neonatal bleeding complications. American Journal of Obstetrics and Gynecology1994;170:293. SibaiB , GordonT , PhillipsE , McNellisD , CaritisS , RomeroR , et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. Proceedings of 41st Annual Clinical Meeting of The American College of Obstetricians and Gynecologists; 1993 May 3‐6; Washington DC, USA. 1993:2. SibaiBM , CaritisSN , ThomE , KlebanoffM , McNellisD , RoccoL , et al. Prevention of preeclampsia with low‐dose aspirin in healthy, nulliparous pregnant women. New England Journal of Medicine1993;329:1213‐8. SibaiBM , CaritisSN , ThomE , ShawK , McNellisD , NICHD‐MFM Network. Low dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal‐neonatal bleeding complications. American Journal of Obstetrics and Gynecology1995;172:1533‐7. SibaiBM , GordonT , ThomE , CaritisSN , KlebanoffM , McNellisD , et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. American Journal of Obstetrics and Gynecology1995;172:642‐8. TolcherMC , Sangi‐HaghpeykarH , AagaardKM . Race and ethnicity varies both efficacy and attributable risk of low‐dose aspirin (asa) for preeclampsia prevention among low‐risk women. American Journal of Obstetrics and Gynecology2018;218(1 Suppl):S203. WittenFR . [Personal communication] Double‐blind, placebo‐controlled trial of low‐dose aspirin to prevent pre‐eclampsia. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 6 September 1991. YaffeS . [Personal communication] Clinical trial of low dose aspirin (65mg) as a preventative of pre‐eclampsia. Letter to: Cochrane Pregnancy and Childbirth Group, Oxford, UK 3 December 1991. ">USA 1993a</a>), there was an imbalance in systolic blood pressure at trial entry, and concern that the trial population was not representative of the general population of women (<a href="#CD004659-fig-0005">Figure 5</a>). There were seven small trials that had high risk of other potential sources of bias. Five trials stopped early, three due to results from interim analyses (<a href="./references#CD004659-bbs2-0005" title="NewnhamJP , GodfreyM , WaltersBJ , PhilipsJ , EvansSF . Low dose aspirin for the treatment of fetal growth restriction: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology1995;35:370‐4. ">Australia 1995</a>; <a href="./references#CD004659-bbs2-0006" title="Kincaid SmithP , NorthRA , FairleyKF , KlossM , IhleBU . Prevention of pre‐eclampsia in high risk women with renal disease: a prospective randomized trial of heparin and dipyridamole. Nephrology1995;1:297‐300. NorthRA , FairleyKF , KlossM , IhleB , Kincaid‐SmithP . Prevention of pre‐eclampsia in women with renal disease. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:75. NorthRA , FairleyKF , KlossM , IhleB , Kincaid‐SmithP . Prevention of preeclampsia in women with renal disease [abstract]. 26th Annual Meeting of the Australasian Society of Nephrology; 1990 March 14‐16; Brisbane, Australia. 1990:9. NorthRA , FairleyKF , KlossM , IhleB , OatsJ , Kincaid‐SmithP . Prevention of pre‐eclampsia in women with renal disease. Proceedings of 6th International Congress of the International Society for the study of Hypertension in Pregnancy; 1988 May 22‐26; Montreal, Quebec, Canada. 1988:193. ">Australia 1995a</a>; <a href="./references#CD004659-bbs2-0043" title="SchiffE , PelegE , GoldenbergM , RosenthalT , RuppinE , TamarkinM , et al. The use of aspirin to prevent pregnancy‐induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. New England Journal of Medicine1989;321:351‐6. ">Israel 1989</a>), and two because of slow recruitment (<a href="./references#CD004659-bbs2-0020" title="PorrecoRP , HickokDE , WilliamsMA , KrenningC . Low‐dose aspirin and hypertension in pregnancy. Lancet1993;341:312. ">Colorado 1993</a>; <a href="./references#CD004659-bbs2-0049" title="ChiaffarinoF , ParazziniF , PaladiniD , AcaiaB , OssolaW , MarozioL , et al. A small randomised trial of low‐dose aspirin in women at high risk of pre‐eclampsia. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2004;112:142‐4. ">Italy 2004</a>). Two trials were high risk of bias because of differences in baseline characteristics (<a href="./references#CD004659-bbs2-0045" title="CaspiE , RazielA , ShermanD , ArieliS , BukovskiI , WeintraubZ . Prevention of pregnancy induced hypertension in twins by early administration of low‐dose aspirin: a preliminary report. American Journal of Reproductive Immunology1994;31:19‐24. ">Israel 1994</a>; <a href="./references#CD004659-bbs2-0058" title="StanescuAD , BanicaR , SimaRM , PlesL . Low dose aspirin for preventing fetal growth restriction: a randomised trial. Journal of Perinatal Medicine2015;43(Suppl 1):Abstract no: O‐0040. StanescuAD , BanicaR , SimaRM , PlesL . Low dose aspirin for preventing fetal growth restriction: a randomised trial. Journal of Perinatal Medicine2018 [epub ahead of print]. ">Romania 2018</a>). </p> </section> </section> <section id="CD004659-sec-0107"> <h3 class="title" id="CD004659-sec-0107">Effects of interventions</h3> <p>See: <a href="./full#CD004659-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <p>Overall, 77 trials involving 40,249 women and their babies are included in this review. Of these trials, 31 individual patient data (IPD) trials plus 38 aggregate data (AD trials) included primary prevention (prevention of pre‐eclampsia for women without gestational hypertension or intrauterine growth restriction at trial entry) only; and five IPD trials plus three AD trials included secondary prevention (prevention of pre‐eclampsia treatment for women who already have gestational hypertension, and/or intrauterine growth restriction at trial entry) only; and four trials, all IPD (<a href="./references#CD004659-bbs2-0013" title="Anonymous . ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnancies. British Journal of Obstetrics and Gynaecology1996;103:39‐47. AtallahAN . ECPPA: randomized trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women [abstract]. Journal of Clinical Epidemiology1997;50 Suppl 1:3S. AtallahAN , TabordaWC . ECPPA: the Brazilian low‐dose aspirin study in high risk pregnant women. Hypertension in Pregnancy1997; Vol. 16, issue 1:139. ">Brazil 1996</a>; <a href="./references#CD004659-bbs2-0019" title="BarJ , HodM , PardoJ , FischB , RabinersonD , KaplanB , et al. Effect on fetal circulation of low‐dose aspirin for prevention and treatment of pre‐eclampsia and intrauterine growth restriction: Doppler flow study. Ultrasound in Obstetrics &amp; Gynaecology1997;9:262‐5. BarJ , PadoaA , HodM , SullivanMH , KaplanB , KidronD . Decreased pathological placental findings in aspirin‐treated pregnant women at risk of hypertensive complications. Hypertension in Pregnancy1997;16:435‐44. BowerSJ , HarringtonKF , SchuchterK , McGirrC , CampbellS . Prediction of pre‐eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. British Journal of Obstetrics and Gynaecology1996;103:625‐9. CLASP (Collaborative Low‐dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low‐dose aspirin for the prevention and treatment of pre‐eclampsia among 9364 pregnant women. Lancet1994;343:619‐29. CLASP Collaborative Group. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. British Journal of Obstetrics and Gynaecology1994;102:861‐8. KylePM , BuckleyD , KissaneJ , deSwietM , RedmanCW . The angiotensin sensitivity test and low‐dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. American Journal of Obstetrics and Gynecology1995;173:865‐72. MathaiM . Aspirin for pre‐eclampsia. National Medical Journal of India1995;8:23‐4. VikhlyaevaK , AsymbekovaGU , ZerdevVP . Aspirin in profilaxis and treatment of placental insufficiency: lessons from Russian aspirin experience. Hypertension in Pregnancy2000;19(Suppl 1):68. ">CLASP 1994</a>; <a href="./references#CD004659-bbs2-0033" title="GroverV , SachdevaS , KumariS . Evaluation of dipyridamole and aspirin in prevention and management of intrauterine growth retardation. Journal of Perinatal Medicine1991;19(2):104. ">India 1991</a>; <a href="./references#CD004659-bbs2-0047" title="Italian Study of Aspirin in Pregnancy. Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Lancet1993;341:396‐400. ParazziniDF . Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Geburtshilfe und Frauenheilkunde1993;53:822. ParazziniF . Multicenter randomized Italian study of low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Journal of Nephrology1991;4:127‐9. ParazziniF , BenedettoC , FruscaT , GuaschinoS , RomeroM . The Italian study on low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:32. ParazziniF , BortolusR , ChatenoudL , RestelliS , BenedettoC . Follow‐up of children in the Italian Study of Aspirin in Pregnancy. Lancet1994;343:1235. ParazziniF , BortolusR , ChatenoudL , RestelliS , RicciE , MarozioL , et al. Risk factors for pregnancy‐induced hypertension in women at high risk for the condition. Epidemiology1996;7(3):306‐8. ">Italy 1993</a>), included both primary prevention and secondary prevention arms. Where possible, data have been presented in the appropriate comparison. AD trials were largely for primary prevention; a small proportion included secondary prevention women who could not be separated out, therefore data for all women have been included under primary prevention. </p> <section id="CD004659-sec-0108"> <h4 class="title">Antiplatelet agents versus placebo or no treatment for the primary prevention of pre‐eclampsia and its complications </h4> <section id="CD004659-sec-0109"> <h5 class="title">Primary outcomes</h5> <section id="CD004659-sec-0110"> <h6 class="title">Proteinuric pre‐eclampsia</h6> <p>Overall there was an 18% reduction in the risk of pre‐eclampsia associated with the use of antiplatelet agents (36,716 women, 60 trials; risk ratio (RR) 0.82, 95% confidence interval (CI) 0.77 to 0.88; assumed risk with placebo/no treatment 92 per 1000 women; corresponding risk with antiplatelet agents 16 fewer per 1000, 95% CI 22 fewer to 11 fewer; high‐quality evidence) (<a href="./full#CD004659-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./references#CD004659-fig-0036" title="">Analysis 1.1</a>; <a href="#CD004659-fig-0006">Figure 6</a>). The risk difference (RD) was ‐1.66% (95% CI ‐2.23% to ‐1.09%), with the number needed to treat for one woman to benefit by avoiding pre‐eclampsia (NNTB) being 61 women (95% CI 45 to 92). </p> <div class="figure" id="CD004659-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), outcome: 1.1 Pre‐eclampsia (IPD vs AD)." data-id="CD004659-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), outcome: 1.1 Pre‐eclampsia (IPD vs AD). </p> </div> </div> </div> <section id="CD004659-sec-0111"> <p><b>Subgroups by maternal risk</b></p> <p>There appear to be no significant differences between the subgroups when participants were subgrouped by maternal risk of pre‐eclampsia at trial entry (Chi² = 8.13, df = 3 (P = 0.04), I² = 63.1%; <a href="./references#CD004659-fig-0040" title="">Analysis 1.5</a>). However, the subgroups were very imbalanced in size making possible subgroup differences hard to assess. For women at low risk, in the 25 trials reporting IPD there was a 12% reduction in pre‐eclampsia (20,583 women, 25 trials; RR 0.88, 95% CI 0.77 to 1.00), and in the six trials with AD, although the point estimate suggests a larger reduction, the CI is wide (543 women, 6 trials; RR 0.49, 95% CI 0.27 to 0.89; <a href="./references#CD004659-fig-0036" title="">Analysis 1.1</a>.2). For the small number of moderate‐risk women in trials with IPD, the overall CI was wide and includes 1.00 (708 women, 13 trials; RR 0.71, 95% CI 0.47 to 1.06), whilst in the seven trials with only AD available the reduction in RR appears to more clearly indicate a reduction (708 women, 7 trials; RR 0.59, 95% CI 0.42 to 0.84). For high‐risk women, in studies with IPD available there was a reduction in RR (11,076 women, 26 trials; RR 0.90, 95% CI 0.82 to 0.98) that was consistent with the overall effect, whilst for the small studies with only AD available there appears to be a larger risk reduction (3006 women, 13 trials; RR 0.59, 95% CI 0.49 to 0.72). </p> </section> <section id="CD004659-sec-0112"> <p><b>Subgroups by gestation at randomisation</b></p> <p>For women randomised before 20 weeks' gestation, there was a reduction in risk of pre‐eclampsia associated with the use of antiplatelet agents in studies with IPD available (18,950 women, 27 trials; RR 0.86, 95% CI 0.78 to 0.95; <a href="./references#CD004659-fig-0044" title="">Analysis 2.1</a>.1). For women randomised at or after 20 weeks' gestation with IPD available, the results did not clearly indicate a risk reduction (13,173 women, 26 trials; RR 0.93, 95% CI 0.84 to 1.04). However, the CIs overlap, so we are uncertain whether this is suggestive of real differences between the two subgroups. In trials with only AD available, the risk reduction appears to be larger both for women randomised before 20 weeks' gestation (3560 women, 19 trials; RR 0.61, 95% CI 0.51 to 0.73) and for those randomised at or after 20 weeks (7 trials, 515 women; RR 0.26, 95% CI 0.14 to 0.49), when compared with the IPD subgroups. For the AD trials, the CIs do not overlap, suggesting a possible subgroup difference by gestation at randomisation, with the effect being greater for women randomised at or after 20 weeks', However, the AD should be interpreted with particular caution, as the numbers in each subgroup are relatively small and individual women are not necessarily in the correct subgroup. </p> <p>The PARIS review protocol included a planned subgroup analysis based on gestation at trial entry: less than 16 weeks, 16 to 19 completed weeks, 20 to 23 completed weeks, 24 to 27 completed weeks, and 28 weeks or more (<a href="./references#CD004659-bbs2-0244" title="Perinatal Antiplatelet Review of International Studies (PARIS) Collaboration Steering Group on behalf of the PARIS collaboration. Antiplatelet agents for prevention of pre‐eclampsia and its consequences: a systematic review and individual patient data meta‐analysis. BMC Pregnancy and Childbirth2005;5:7. ">PARIS 2005</a>). Data for this subgroup analysis are presented here (<a href="#CD004659-fig-0007">Figure 7</a>). There are no clear differences between the subgroups. Due to recent interest in whether earlier administration of antiplatelets before 16 weeks' gestation might be beneficial, the IPD for trial entry before 16 weeks and at or after 16 weeks are presented in <a href="#CD004659-fig-0008">Figure 8</a>; there is no clear difference between the subgroups (RR 0.90, 95% CI 0.78 to 1.03 and RR 0.90, 95% CI 0.83 to 0.99, respectively). </p> <div class="figure" id="CD004659-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Pre‐specified subgroup analysis using PARIS IPD" data-id="CD004659-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Pre‐specified subgroup analysis using PARIS IPD</p> </div> </div> </div> <div class="figure" id="CD004659-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Condensed version of (2 subgroups only) using PARIS IPD" data-id="CD004659-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Condensed version of <a href="#CD004659-fig-0004">Figure 4</a> (2 subgroups only) using PARIS IPD </p> </div> </div> </div> </section> <section id="CD004659-sec-0113"> <p><b>Subgroups by use of placebo</b></p> <p>We did not detect likely differences between the subgroups by use of placebo. When assessing subgroup differences by use of placebo, the subgroups were very imbalanced in size for both IPD and AD trials, because in both cases many more women were given a placebo than not. The reduction in risk of pre‐eclampsia was similar regardless of whether women were recruited to placebo‐controlled trials or not, both in studies with IPD (albeit there was no significant reduction in the fewer and smaller IPD trials that were not placebo controlled) and those with AD (<a href="./references#CD004659-fig-0048" title="">Analysis 3.1</a>). </p> </section> <section id="CD004659-sec-0114"> <p><b>Subgroups by dose of aspirin</b></p> <p>There was a reduction in the risk of pre‐eclampsia for women allocated 75 mg aspirin or more in the IPD trials (9107 women, 16 trials; RR 0.78, 95% CI 0.66 to 0.92), and the point estimate suggested a larger reduction in AD trials (3505 women, 19 trials; RR 0.58, 95% CI 0.49 to 0.70; <a href="./references#CD004659-fig-0052" title="">Analysis 4.1</a>). For women allocated aspirin &lt; 75 mg, there was a slight reduction in studies with IPD, however the 95% CI includes the possibility of no effect (11 trials, 22,618 women; RR 0.92, 95% CI 0.85 to 1.00), whilst there appeared to be a more marked reduction in studies with only AD (586 women, 6 trials; RR 0.59, 95% CI 0.39 to 0.89). </p> <p>A few small trials combined aspirin with dipyridamole. In view of the small numbers, we are uncertain about the effect of aspirin with dipyridamole on pre‐eclampsia for both IPD studies (218 women, 3 trials; RR 0.55, 95% CI 0.26 to 1.16), and AD studies (248 women, 3 trials; RR 0.18, 95% CI 0.05 to 0.69; <a href="./references#CD004659-fig-0052" title="">Analysis 4.1</a>). </p> </section> </section> <section id="CD004659-sec-0115"> <h6 class="title">Any reported death: fetal, neonatal or before hospital discharge</h6> <p>Fifty‐two trials (35,391 babies) reported fetal deaths, neonatal deaths or infant deaths. When any reported deaths were analysed together, regardless of when the death occurred, there was a 15% reduction in the risk of a baby death before hospital discharge associated with the use of antiplatelet agents (35,391 women, 52 trials; RR 0.85, 95% CI 0.76 to 0.95; assumed risk with placebo/no treatment 33 per 1000 babies; corresponding risk with antiplatelet agents 5 fewer per 1000, 95% CI 9 fewer to 1 fewer; high‐quality evidence) (<a href="./full#CD004659-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./references#CD004659-fig-0037" title="">Analysis 1.2</a>; <a href="#CD004659-fig-0009">Figure 9</a>). The risk difference is ‐0.51% (95% CI ‐0.87% to ‐0.15%), and NNTB 197 (115 to 681). </p> <div class="figure" id="CD004659-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (subgrouped by maternal risk), outcome: 1.4 Fetal and neonatal deaths." data-id="CD004659-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (subgrouped by maternal risk), outcome: 1.4 Fetal and neonatal deaths. </p> </div> </div> </div> <section id="CD004659-sec-0116"> <p><b>Subgroups by maternal risk</b></p> <p>This reduction in the RR for baby death was consistent across the subgroups by maternal risk at trial entry (Chi² = 2.02, df = 3 (P = 0.57), I² = 0%; <a href="./references#CD004659-fig-0041" title="">Analysis 1.6</a>). </p> </section> <section id="CD004659-sec-0117"> <p><b>Subgroups by gestation at randomisation, use of placebo, and dose of aspirin</b></p> <p>For women randomised before 20 weeks' gestation, aspirin resulted in a reduction in fetal, neonatal, or infant death in both the IPD trials (18,950 babies, 27 trials; RR 0.87, 95% CI 0.75 to 1.02), and the AD trials (2657 babies, 11 trials; RR 0.62, 95% CI 0.44 to 0.88). For those randomised at or after 20 weeks, there was little or no difference between antiplatelet agents and placebo/no treatment for IPD trials (13,173 babies, 26 trials; RR 0.93, 95% CI 0.76 to 1.15), and the findings were unclear for AD trials, probably due to small sample size and few events; (350 babies; 6 trials; RR 0.46, 95% CI 0.11 to 1.98; <a href="./references#CD004659-fig-0045" title="">Analysis 2.2</a>). </p> <p>When subgrouped by use of placebo, similar effects were seen in trials with and without placebo control for both IPD and AD. However, the 95% CIs for most subgroups included no effect, probably due to smaller sample sizes and thus wider CIs (<a href="./references#CD004659-fig-0049" title="">Analysis 3.2</a>). </p> <p>The results for &lt; 75 mg aspirin alone were consistent across analyses using IPD and AD. For studies using less than 75 mg of aspirin there is probably a small reduction associated with antiplatelet agents, in the IPD trials (27,025 babies, 16 trials; RR 0.89, 0.78, 1.01), and in the AD trials a similar point estimate but wider CI due to the smaller number of babies (720 babies, 10 trials; RR 0.81, 95% CI 0.45 to 1.45). The effect of antiplatelet agents compared with placebo/no treatment where women were given 75 mg or more of aspirin was somewhat unclear for IPD trials (4733 babies, 12 trials; RR 0.94, 95% CI 0.61 to 1.45), while evidence from trials with AD giving women more than 75 mg aspirin suggested a large reduction in fetal or neonatal death for this subgroup (2165 babies, 6 trials; RR 0.51, 95% CI 0.34 to 0.78). In the small studies using 75 mg or more aspirin plus dipyridamole, we are uncertain about the effect on fetal or neonatal death, because of the small sample sizes and low event rates for both IPD (218 babies, 3 trials; RR 0.66, 95% CI 0.21 to 1.80), and AD (256 babies 4 trials; RR 0.90, 95% CI 0.23 to 3.51; <a href="./references#CD004659-fig-0053" title="">Analysis 4.2</a>). </p> <p>Classifying deaths by the time of death (fetal, neonatal, infant or childhood death), there appear to be no differences in the risk of death in any of the categories (<a href="./references#CD004659-fig-0067" title="">Analysis 5.12</a>; <a href="#CD004659-fig-0010">Figure 10</a>). </p> <div class="figure" id="CD004659-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.12 Fetal, neonatal, infant and childhood deaths (subgroups by time of death)." data-id="CD004659-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.12 Fetal, neonatal, infant and childhood deaths (subgroups by time of death). </p> </div> </div> </div> </section> </section> <section id="CD004659-sec-0118"> <h6 class="title">Preterm birth</h6> <p>Overall, in the 47 trials reporting this outcome (35,212 women), there was a small (9%) reduction in the RR for birth before 37 completed weeks (35,212 women, 47 trials; RR 0.91, 95% CI 0.87 to 0.95; assumed risk with placebo/no treatment 175 per 1000 women; corresponding risk with antiplatelet agents 16 fewer per 1000, 95% CI 23 fewer to 9 fewer; high‐quality evidence) (<a href="./full#CD004659-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./references#CD004659-fig-0038" title="">Analysis 1.3</a>; <a href="#CD004659-fig-0011">Figure 11</a>), with a risk difference of ‐1.64% (95% CI ‐2.38% to ‐0.88%); NNTB 61 (42 to 114). </p> <div class="figure" id="CD004659-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), outcome: 1.3 Preterm birth (IPD vs AD)." data-id="CD004659-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), outcome: 1.3 Preterm birth (IPD vs AD). </p> </div> </div> </div> <p>There was evidence to suggest a slight reduction in preterm birth before 34 weeks' gestation amongst women given antiplatelet agents compared with those given placebo/no treatment (32,253 women, 31 trials; RR 0.90, 95% CI 0.83 to 0.97; <a href="./references#CD004659-fig-0070" title="">Analysis 5.15</a>; <a href="#CD004659-fig-0012">Figure 12</a>). The effects were less clear for preterm births before 32 weeks (32,319 women, 31 trials; RR 0.92, 95% CI 0.83 to 1.02; <a href="./references#CD004659-fig-0071" title="">Analysis 5.16</a>; <a href="#CD004659-fig-0013">Figure 13</a>), and before 28 weeks' gestation (32,135 women, 30 trials; RR 0.87, 95% CI 0.74 to 1.01; <a href="./references#CD004659-fig-0072" title="">Analysis 5.17</a>; <a href="#CD004659-fig-0014">Figure 14</a>), both of which included a slight reduction but the CI crossed the line of no effect. We conducted further analysis of evidence on the effects of antiplatelet agents on preterm birth provided by IPD trials only, analysed in terms of mutually exclusive subgroups by time of preterm birth. However, looking at preterm birth before 28 weeks (32,155 women, 30 trials; RR 0.87, 95% CI 0.74 to 1.01), from 28 to 31 weeks (32,155 women, 30 trials; RR 0.98, 95% CI 0.85 to 1.13), from 32 to 33 weeks (32,155 women, 30 trials; RR 0.84, 95% CI 0.73 to 0.97), and from 34 to 36 weeks' gestation (32,155 women, 30 trials; RR 0.93, 95% CI 0.87 to 1.00), there were no clear differences between these subgroups (<a href="./references#CD004659-fig-0073" title="">Analysis 5.18</a>; <a href="#CD004659-fig-0015">Figure 15</a>). </p> <div class="figure" id="CD004659-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.15 Preterm birth (&lt; 34 weeks)." data-id="CD004659-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.15 Preterm birth (&lt; 34 weeks). </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.16 Preterm birth (&lt; 32 weeks)." data-id="CD004659-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.16 Preterm birth (&lt; 32 weeks). </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.17 Preterm birth (&lt; 28 weeks)." data-id="CD004659-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG14.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.17 Preterm birth (&lt; 28 weeks). </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.18 Preterm birth (mutually exclusive subgroups) ‐ IPD only." data-id="CD004659-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG15.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.18 Preterm birth (mutually exclusive subgroups) ‐ IPD only. </p> </div> </div> </div> <section id="CD004659-sec-0119"> <p><b>Subgroups by maternal risk</b></p> <p>There appeared to be no significant heterogeneity between the subgroups by maternal risk, but again the subgroups are imbalanced in size (Chi² = 6.39, df = 3 (P = 0.09), I² = 53.0%; <a href="./references#CD004659-fig-0042" title="">Analysis 1.7</a>). While the CIs largely overlap, there was no clear reduction in preterm birth in the low‐risk group for trials where IPD were available (20,563 women, 25 trials; RR 0.95, 95% CI 0.89 to 1.01), but a 10% reduction in the high‐risk group for IPD (11,076 women, 26 trials; RR 0.90 95%, CI 0.84 to 0.97). In the small subgroup of women at moderate risk of pre‐eclampsia in IPD trials, the evidence suggested there was probably little or no difference in preterm birth between women receiving antiplatelet agents and those receiving placebo/no treatment (558 women, 12 trials; RR 1.09, 95% CI 0.94 to 1.27), but we note that this subgroup is substantially smaller than the others for IPD, so this result probably reflects the play of chance in a small subgroup. The results from the small trials with AD suggested a larger reduction in preterm birth for women at low risk of pre‐eclampsia (453 women, 5 trials; RR 0.54, 95% CI 0.42 to 0.68) and also for those at high‐risk (2013 women, 5 trials; RR 0.62, 95% CI 0.47 to 0.82). For AD trials, the effects for women at moderate‐risk of pre‐eclampsia were unclear (503 women, 5 trials; RR 0.84, 95% CI 0.60 to 1.18; <a href="./references#CD004659-fig-0038" title="">Analysis 1.3</a>.4). </p> </section> <section id="CD004659-sec-0120"> <p><b>Subgroups by gestation at randomisation</b></p> <p>Most subgroups suggested a consistent small reduction in preterm birth, regardless of whether recruitment was before or after 20 weeks' gestation, although again the subgroups varied considerably in size (<a href="./references#CD004659-fig-0046" title="">Analysis 2.3</a>). For women randomised before 20 weeks' gestation, IPD trials suggested a slight reduction in preterm birth amongst women receiving antiplatelet agents beginning before 20 weeks' gestation, although the CI touched on no effect (18,930 women, 27 trials; RR 0.94, 95% CI 0.88 to 1.00); whereas AD trials suggested a more substantial benefit (2610 women, 11 trials; RR 0.63, 95% CI 0.53 to 0.74). For women randomised at or after 20 weeks' gestation, trials with IPD suggested a similar effect to women beginning the drugs earlier (13,173 women, 26 trials; RR 0.91, 95% CI 0.85 to 0.98), whereas the effects were unclear in the AD trials (287 women, 4 trials; RR 0.56, 95% CI 0.28 to 1.12). </p> </section> <section id="CD004659-sec-0121"> <p><b>Subgroups by use of placebo</b></p> <p>There was no indication of clear subgroup differences by use of placebo for this outcome, however there were some differences between the IPD and the AD effect estimates. The findings from IPD trials where women received placebo (31,070 women, 24 trials; RR 0.93, 95% CI 0.89 to 0.98) were not substantially different from those without placebo, although the 95% CI without placebo crossed the line of no effect (1127 women, 7 trials; RR 0.90, 95% CI 0.72 to 1.14) . In AD trials the pattern was similar ‐ with the results for no placebo being unclear ‐ although the point estimates were greater both with placebo (2423 women, 11 trials; RR 0.57, 95% CI 0.47 to 0.69) and without (592 women, 5 trials; RR 0.79; 95% CI 0.58, 1.08; <a href="./references#CD004659-fig-0050" title="">Analysis 3.3</a>). </p> </section> <section id="CD004659-sec-0122"> <p><b>Subgroups by dose of aspirin</b></p> <p>The evidence did not suggest different rates of preterm birth by aspirin dosing. In IPD trials, the findings when women received less than 75 mg (22,618 women, 11 trials; RR 0.93, 95% CI 0.89 to 0.98) overlapped substantially with the findings from women who received 75 mg or more (9087 women, 16 trials; RR 0.86, 95% CI 0.73 to 1.01). For AD trials, the findings were unclear when women received less than 75 mg aspirin (79 women, 2 trials; RR 0.29, 95% CI 0.08 to 1.09), while the effect seemed to indicate a more marked reduction than the IPD data when women received 75 mg or more (2712 women, 12 trials; RR 0.65, 95% CI 0.50 to 0.84). Again, in view of the small number of women involved in trials combining aspirin with dipyridamole, we are uncertain about the effect of aspirin with dipyridamole on preterm birth for both IPD (218 women, 3 trials; RR 1.37, 95% CI 0.34 to 5.51) and AD studies (64 women, 1 trial; RR 0.89, 95% CI 0.30 to 2.61; <a href="./references#CD004659-fig-0054" title="">Analysis 4.3</a>). </p> </section> </section> <section id="CD004659-sec-0123"> <h6 class="title">Small‐for‐gestational‐age baby</h6> <p>There was a 16% reduction in the risk of the baby being born small‐for‐gestational‐age when women were given antiplatelet agents compared with placebo/no treatment (35,761 babies, 50 trials; RR 0.84, 95% CI 0.76 to 0.92; assumed risk with placebo 47 per 1000 women; corresponding risk with antiplatelet agents 7 fewer per 1000, 95% CI 11 fewer to 3 fewer; high‐quality evidence) (<a href="./full#CD004659-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./references#CD004659-fig-0039" title="">Analysis 1.4</a>; <a href="#CD004659-fig-0016">Figure 16</a>). The risk difference was ‐0.69%, 95% CI ‐1.11% to ‐0.26%; NNTB 146, 95% CI 90 to 386. Results for this outcome are also analysed by severerity for AD (<a href="./references#CD004659-fig-0074" title="">Analysis 5.19</a>; <a href="#CD004659-fig-0017">Figure 17</a>) and IPD (<a href="./references#CD004659-fig-0075" title="">Analysis 5.20</a>; <a href="#CD004659-fig-0018">Figure 18</a>). </p> <div class="figure" id="CD004659-fig-0016"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 16</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), outcome: 1.4 Small‐for‐gestational age (IPD vs AD)." data-id="CD004659-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG16.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), outcome: 1.4 Small‐for‐gestational age (IPD vs AD). </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0017"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 17</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.19 Small‐for‐gestational age (subgrouped by severity) ‐ AD only, trial definition." data-id="CD004659-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG17.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.19 Small‐for‐gestational age (subgrouped by severity) ‐ AD only, trial definition. </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0018"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 18</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.20 Any baby SGA &lt; 3rd centile or as reported ‐ IPD only." data-id="CD004659-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG18.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.20 Any baby SGA &lt; 3rd centile or as reported ‐ IPD only. </p> </div> </div> </div> <section id="CD004659-sec-0124"> <p><b>Subgroups by maternal risk</b></p> <p>This result was consistent across the subgroups by risk status at trial entry (Chi² = 1.76, df = 3 (P = 0.62), I² = 0%; <a href="./references#CD004659-fig-0043" title="">Analysis 1.8</a>). </p> </section> <section id="CD004659-sec-0125"> <p><b>Subgroups by gestation at randomisation</b></p> <p>There was a reduction the risk of the baby being born small‐for‐gestational‐age if the mother was randomised before 20 weeks' gestation (IPD trials: 18,950 babies, 27 trials: RR 0.82, 95% CI 0.70 to 0.95; AD trials: 3211 babies, 13 trials: RR 0.67, 95% CI 0.55 to 0.82), but antiplatelet agents made little or no difference in IPD trials for women randomised at 20 weeks or after (IPD 13,173 women, 26 trials: RR 0.99 95% CI 0.85 to 1.16), and for AD trials the effect was unclear (AD trials 315 women, 5 trials: RR 0.69, 95% CI 0.35 to 1.37; <a href="./references#CD004659-fig-0047" title="">Analysis 2.4</a>). Again, although the effects appeared to differ slightly across these subgroups, all the subgroups are imbalanced in size, so it is not clear whether there are likely to be any real differences by gestation at randomisation for this outcome. </p> </section> <section id="CD004659-sec-0126"> <p><b>Subgroups by use of placebo</b></p> <p>Subgroup analyses do not suggest differences by use of placebo, however the results from IPD trials do not completely align with those from AD. In trials with both IPD and AD that were controlled by placebo, antiplatelet agents appeared to reduce the risk of the baby being small‐for‐gestational‐age, although the CI touched on no effect in IPD trials (31,090 women, 24 trials; RR 0.90 95% CI 0.81 to 1.00) while the reduction appeared clearer in AD trials (2885 women, 13 trials; RR 0.72, 95% CI 0.58 to 0.90). When no placebo was given to women in the control group, the effect was unclear in the IPD trials (1127 women, 7 trials; RR 0.91, 95% CI 0.52 to 1.58), whereas AD suggested a clear reduction (504 women, 5 trials; RR 0.52, 95% CI 0.33 to 0.82). For AD trials both with and without placebo, the reduction in risk appeared greater than in IPD trials (<a href="./references#CD004659-fig-0051" title="">Analysis 3.4</a>). </p> </section> <section id="CD004659-sec-0127"> <p><b>Subgroups by dose of aspirin</b></p> <p>There was no clear indication of subgroup differences by dose of aspirin for this outcome. For IPD trials, the effects appeared to be similar whether women were given less than 75 mg aspirin (22,618 women, 11 trials; RR 0.92, 95% CI 0.79 to 1.07), or greater than or equal to 75 mg (9107 women, 16 trials; RR 0.76, 95% CI 0.53 to 1.08). For trials with AD giving women less than 75 mg aspirin, the effect was unclear (299 women, 4 trials; RR 0.49, 95% CI 0.22 to 1.13), whereas there seemed to be a marked reduction for women given 75 mg or more (3092 women, 13 trials; RR 0.72, 95% CI 0.58 to 0.88). Where trials gave aspirin with dipyridamole, the sample sizes were too small to yield precise effect estimates so the effects are unclear (<a href="./references#CD004659-fig-0055" title="">Analysis 4.4</a>). </p> </section> </section> </section> <section id="CD004659-sec-0128"> <h5 class="title">Secondary outcomes</h5> <section id="CD004659-sec-0129"> <h6 class="title">Gestational hypertension</h6> <p>There was only evidence available from IPD trials for this outcome. Findings using the best available definition of gestational hypertension suggested that compared with placebo or no treatment, antiplatelet agents make little or no difference to whether women developed gestational hypertension after trial entry (27,834 women; 25 studies; RR 0.95, 95% CI 0.90 to 1.01; <a href="./references#CD004659-fig-0063" title="">Analysis 5.8</a>; <a href="#CD004659-fig-0019">Figure 19</a>). The findings using triallists' own definition of gestational hypertension (27,834 women, 25 studies; RR 0.95, 95% CI 0.89 to 1.01; <a href="./references#CD004659-fig-0064" title="">Analysis 5.9</a>; <a href="#CD004659-fig-0020">Figure 20</a>) and using the PARIS definition (27,519 women, 24 studies; RR 0.95, 95% CI 0.90 to 1.02; <a href="./references#CD004659-fig-0065" title="">Analysis 5.10</a>; <a href="#CD004659-fig-0021">Figure 21</a>) were very similar. </p> <div class="figure" id="CD004659-fig-0019"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 19</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.8 Gestational hypertension using best available definition ‐ IPD only." data-id="CD004659-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG19.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.8 Gestational hypertension using best available definition ‐ IPD only. </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0020"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 20</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.9 Gestational hypertension using trialists own definition ‐ IPD only." data-id="CD004659-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG20.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.9 Gestational hypertension using trialists own definition ‐ IPD only. </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0021"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 21</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.10 Gestational hypertension PARIS definition ‐ IPD only." data-id="CD004659-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG21.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.10 Gestational hypertension PARIS definition ‐ IPD only. </p> </div> </div> </div> </section> <section id="CD004659-sec-0130"> <h6 class="title">Postpartum haemorrhage &gt; 500 mL</h6> <p>Data on postpartum haemorrhage were not included in previous versions of this Cochrane Review, but are included in this update as this outcome was part of the dataset collected for the PARIS IPD review. We used the trialist‐defined outcome of 'postpartum haemorrhage', which was usually defined as more than 500 mL. Evidence from 19 trials with reliable available data (16 IPD trials, three AD trials) suggested that antiplatelet agents probably slightly increase the risk of postpartum haemorrhage, although the 95% CI touches on the line of no effect (23,769 women, 19 trials; RR 1.06, 95% CI 1.00 to 1.12; assumed risk with placebo/no treatment 143 per 1000; corresponding risk with antiplatelet agents 9 more per 1000, 95% CI 0 more to 19 more; moderate‐quality evidence; <a href="./references#CD004659-fig-0082" title="">Analysis 5.27</a>; <a href="#CD004659-fig-0022">Figure 22</a>). </p> <div class="figure" id="CD004659-fig-0022"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 22</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.27 Postpartum haemorrhage &gt; 500 mL." data-id="CD004659-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG22.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.27 Postpartum haemorrhage &gt; 500 mL. </p> </div> </div> </div> </section> <section id="CD004659-sec-0131"> <h6 class="title">Pregnancy with serious adverse outcome</h6> <p>The availability of IPD from the PARIS Collaboration enabled the analysis of a composite outcome of 'pregnancy with serious adverse outcome'. This was defined as a pregnancy where the mother dies or develops pre‐eclampsia, or where any baby is preterm, small‐for‐gestational age, or does not survive to discharge from hospital. Analysis of these data suggest that antiplatelets reduce the incidence of this composite of adverse outcomes (17,382 women, 13 trials; average RR 0.90, 95% CI 0.85 to 0.96; assumed risk with placebo/no treatment 197 per 1000 women; corresponding risk with antiplatelet agents 20 fewer per 1000, 95% CI 30 fewer to 8 fewer; high‐quality evidence; <a href="./references#CD004659-fig-0077" title="">Analysis 5.22</a>; <a href="#CD004659-fig-0023">Figure 23</a>). </p> <div class="figure" id="CD004659-fig-0023"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 23</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.22 Pregnancy with SAO (including maternal death, baby death, PE, SGA, preterm) ‐ IPD only." data-id="CD004659-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG23.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.22 Pregnancy with SAO (including maternal death, baby death, PE, SGA, preterm) ‐ IPD only. </p> </div> </div> </div> </section> <section id="CD004659-sec-0132"> <h6 class="title">Placental abruption</h6> <p>Antiplatelet agents probably marginally increase the risk of placental abruption, however the 95% CI included both the line of no effect and a substantial increase in this outcome. This imprecision in the effect estimate is likely to be due to the rarity of this outcome 30,775 women, 29 trials; RR 1.21, 95% CI 0.95 to 1.54; assumed risk with placebo/no treatment 7 per 1000 women; corresponding risk with antiplatelet agents 2 more per 1000, 95% CI 0 more to 4 more; moderate‐quality evidence; <a href="./references#CD004659-fig-0081" title="">Analysis 5.26</a>; <a href="#CD004659-fig-0024">Figure 24</a>). </p> <div class="figure" id="CD004659-fig-0024"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 24</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.26 Placental abruption." data-id="CD004659-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG24.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.26 Placental abruption. </p> </div> </div> </div> </section> <section id="CD004659-sec-0133"> <h6 class="title">Long‐term follow‐up for the children</h6> <p>Two trials assessed the children in early childhood (<a href="./references#CD004659-bbs2-0019" title="BarJ , HodM , PardoJ , FischB , RabinersonD , KaplanB , et al. Effect on fetal circulation of low‐dose aspirin for prevention and treatment of pre‐eclampsia and intrauterine growth restriction: Doppler flow study. Ultrasound in Obstetrics &amp; Gynaecology1997;9:262‐5. BarJ , PadoaA , HodM , SullivanMH , KaplanB , KidronD . Decreased pathological placental findings in aspirin‐treated pregnant women at risk of hypertensive complications. Hypertension in Pregnancy1997;16:435‐44. BowerSJ , HarringtonKF , SchuchterK , McGirrC , CampbellS . Prediction of pre‐eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. British Journal of Obstetrics and Gynaecology1996;103:625‐9. CLASP (Collaborative Low‐dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low‐dose aspirin for the prevention and treatment of pre‐eclampsia among 9364 pregnant women. Lancet1994;343:619‐29. CLASP Collaborative Group. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. British Journal of Obstetrics and Gynaecology1994;102:861‐8. KylePM , BuckleyD , KissaneJ , deSwietM , RedmanCW . The angiotensin sensitivity test and low‐dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. American Journal of Obstetrics and Gynecology1995;173:865‐72. MathaiM . Aspirin for pre‐eclampsia. National Medical Journal of India1995;8:23‐4. VikhlyaevaK , AsymbekovaGU , ZerdevVP . Aspirin in profilaxis and treatment of placental insufficiency: lessons from Russian aspirin experience. Hypertension in Pregnancy2000;19(Suppl 1):68. ">CLASP 1994</a>; <a href="./references#CD004659-bbs2-0047" title="Italian Study of Aspirin in Pregnancy. Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Lancet1993;341:396‐400. ParazziniDF . Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Geburtshilfe und Frauenheilkunde1993;53:822. ParazziniF . Multicenter randomized Italian study of low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Journal of Nephrology1991;4:127‐9. ParazziniF , BenedettoC , FruscaT , GuaschinoS , RomeroM . The Italian study on low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:32. ParazziniF , BortolusR , ChatenoudL , RestelliS , BenedettoC . Follow‐up of children in the Italian Study of Aspirin in Pregnancy. Lancet1994;343:1235. ParazziniF , BortolusR , ChatenoudL , RestelliS , RicciE , MarozioL , et al. Risk factors for pregnancy‐induced hypertension in women at high risk for the condition. Epidemiology1996;7(3):306‐8. ">Italy 1993</a>) . <a href="./references#CD004659-bbs2-0019" title="BarJ , HodM , PardoJ , FischB , RabinersonD , KaplanB , et al. Effect on fetal circulation of low‐dose aspirin for prevention and treatment of pre‐eclampsia and intrauterine growth restriction: Doppler flow study. Ultrasound in Obstetrics &amp; Gynaecology1997;9:262‐5. BarJ , PadoaA , HodM , SullivanMH , KaplanB , KidronD . Decreased pathological placental findings in aspirin‐treated pregnant women at risk of hypertensive complications. Hypertension in Pregnancy1997;16:435‐44. BowerSJ , HarringtonKF , SchuchterK , McGirrC , CampbellS . Prediction of pre‐eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. British Journal of Obstetrics and Gynaecology1996;103:625‐9. CLASP (Collaborative Low‐dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low‐dose aspirin for the prevention and treatment of pre‐eclampsia among 9364 pregnant women. Lancet1994;343:619‐29. CLASP Collaborative Group. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. British Journal of Obstetrics and Gynaecology1994;102:861‐8. KylePM , BuckleyD , KissaneJ , deSwietM , RedmanCW . The angiotensin sensitivity test and low‐dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. American Journal of Obstetrics and Gynecology1995;173:865‐72. MathaiM . Aspirin for pre‐eclampsia. National Medical Journal of India1995;8:23‐4. VikhlyaevaK , AsymbekovaGU , ZerdevVP . Aspirin in profilaxis and treatment of placental insufficiency: lessons from Russian aspirin experience. Hypertension in Pregnancy2000;19(Suppl 1):68. ">CLASP 1994</a> suggested no difference between treatment and control groups in any of the measures of health and development at 12 to 18 months (<a href="./references#CD004659-fig-0086" title="">Analysis 5.31</a>; <a href="./references#CD004659-fig-0087" title="">Analysis 5.32</a>; <a href="./references#CD004659-fig-0089" title="">Analysis 5.34</a>). (<a href="./references#CD004659-bbs2-0047" title="Italian Study of Aspirin in Pregnancy. Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Lancet1993;341:396‐400. ParazziniDF . Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension. Geburtshilfe und Frauenheilkunde1993;53:822. ParazziniF . Multicenter randomized Italian study of low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Journal of Nephrology1991;4:127‐9. ParazziniF , BenedettoC , FruscaT , GuaschinoS , RomeroM . The Italian study on low‐dose aspirin for the prevention of pre‐eclampsia and intrauterine growth retardation. Proceedings of 7th World Congress of Hypertension in Pregnancy; 1990 October; Perugia, Italy. 1990:32. ParazziniF , BortolusR , ChatenoudL , RestelliS , BenedettoC . Follow‐up of children in the Italian Study of Aspirin in Pregnancy. Lancet1994;343:1235. ParazziniF , BortolusR , ChatenoudL , RestelliS , RicciE , MarozioL , et al. Risk factors for pregnancy‐induced hypertension in women at high risk for the condition. Epidemiology1996;7(3):306‐8. ">Italy 1993</a> suggested that antiplatelet agents may lower the risk of gross or fine motor problems at 18 months compared with control (15/427 versus 26/361, RR 0.49, 95% CI 0.26 to 0.91; <a href="./references#CD004659-fig-0086" title="">Analysis 5.31</a>), but suggested no difference in any of the other reported outcomes at 18 months (<a href="./references#CD004659-fig-0086" title="">Analysis 5.31</a>; <a href="./references#CD004659-fig-0088" title="">Analysis 5.33</a>; <a href="./references#CD004659-fig-0089" title="">Analysis 5.34</a>). This result should be interpreted with caution, however, as the trial was not placebo controlled and so assessment was unblinded, and 27% of children were lost to follow‐up </p> </section> <section id="CD004659-sec-0134"> <h6 class="title">Other secondary outcomes</h6> <p>There was a slight reduction for the treatment group in <b>birthweight less than 2500g</b> (31,522 babies, 32 trials; RR 0.92, 95% CI 0.88 to 0.97; <a href="./references#CD004659-fig-0076" title="">Analysis 5.21</a>; <a href="#CD004659-fig-0025">Figure 25</a>), and also in the risk of any baby requiring assisted ventilation (RR 0.80, 95% CI 0.66 to 0.97; 7383 mothers; 15 trials; <a href="./references#CD004659-fig-0083" title="">Analysis 5.28</a>; <a href="#CD004659-fig-0026">Figure 26</a>). </p> <div class="figure" id="CD004659-fig-0025"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 25</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.21 Birthweight &lt; 2500 g." data-id="CD004659-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG25.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.21 Birthweight &lt; 2500 g. </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0026"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 26</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.28 Any baby required assisted ventilation." data-id="CD004659-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG26.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.28 Any baby required assisted ventilation. </p> </div> </div> </div> <p>The evidence suggested that antiplatelet agents make little or no difference to <b>hospital admission for women during pregnancy</b> (AD trials only; 12,964 women, 3 trials; RR 1.03, 95% CI 0.97 to 1.09; <a href="./references#CD004659-fig-0078" title="">Analysis 5.23</a>), <b>non‐spontaneous labour</b> (induced labour or pre‐labour caesarean) (IPD trials only; 29,838 women, 24 trials; RR 1.02, 95% CI 0.98 to 1.05; <a href="./references#CD004659-fig-0079" title="">Analysis 5.24</a>; <a href="#CD004659-fig-0027">Figure 27</a>), <b>gestation at onset proteinuria</b> (IPD trials only; 3442 women; 14 trials; mean difference (MD) ‐0.42 weeks, 95% CI ‐1.40 to 0.56; <a href="./references#CD004659-fig-0066" title="">Analysis 5.11</a>; <a href="#CD004659-fig-0028">Figure 28</a>), <b>gestation at birth</b> (MD 0.02 weeks, 95% CI ‐0.04 to 0.09; 31,669 mothers; 34 trials; <a href="./references#CD004659-fig-0069" title="">Analysis 5.14</a>; <a href="#CD004659-fig-0029">Figure 29</a>), antepartum haemorrhage (IPD trials only; RR 1.04, 95% CI 0.92 to 1.17; 30,513 mothers, 25 trials; <a href="./references#CD004659-fig-0080" title="">Analysis 5.25</a>; <a href="#CD004659-fig-0030">Figure 30</a>), or <b>caesarean section</b> (32,698 women, 36 trials; RR 1.03, 95% CI 0.99 to 1.07; <a href="./references#CD004659-fig-0095" title="">Analysis 5.40</a>; <a href="#CD004659-fig-0031">Figure 31</a>), Antiplatelet agents probably make little or no difference to the risk of <b>HELLP syndrome</b> (20,130 women, 16 trials; RR 0.77, 95% CI 0.44 to 1.36; <a href="./references#CD004659-fig-0057" title="">Analysis 5.2</a>) and <b>severe maternal morbidity</b> (28,065 women; 15 trials; RR 1.00, 95% CI 0.72 to 1.39; <a href="./references#CD004659-fig-0056" title="">Analysis 5.1</a>; <a href="#CD004659-fig-0032">Figure 32</a>), although for these outcome the 95% CIs are wide, possibly due to the sample size being underpowered given the rarity of these events. In terms of outcomes for the baby, there was probably little or no difference in the risk of <b>intraventricular haemorrhage</b> (32,224 babies, 20 trials; RR 0.99, 95% CI 0.72 to 1.36; <a href="./references#CD004659-fig-0084" title="">Analysis 5.29</a>; <a href="#CD004659-fig-0033">Figure 33</a>), other <b>neonatal bleeding</b> (30,715 babies, 20 trials; RR 0.90, 95% CI 0.75 to 1.08; <a href="./references#CD004659-fig-0085" title="">Analysis 5.30</a>; <a href="#CD004659-fig-0034">Figure 34</a>), or in <b>admission to special care baby unit</b> (32,808 babies, 29 trials; RR 0.95, 95% CI 0.90 to 1.00; <a href="./references#CD004659-fig-0090" title="">Analysis 5.35</a>; <a href="#CD004659-fig-0035">Figure 35</a>). </p> <div class="figure" id="CD004659-fig-0027"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 27</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.24 Non spontaneous labour (induced labour or pre‐labour caesarean) ‐ IPD only." data-id="CD004659-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG27.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.24 Non spontaneous labour (induced labour or pre‐labour caesarean) ‐ IPD only. </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0028"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 28</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.11 Gestation at onset proteinuria by best definition ‐ IPD only." data-id="CD004659-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG28.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.11 Gestation at onset proteinuria by best definition ‐ IPD only. </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0029"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 29</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.14 Gestation at birth (mean, weeks)." data-id="CD004659-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG29.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.14 Gestation at birth (mean, weeks). </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0030"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 30</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.25 Antepartum haemorrhage ‐ IPD only." data-id="CD004659-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG30.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.25 Antepartum haemorrhage ‐ IPD only. </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0031"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 31</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.40 Caesarean section." data-id="CD004659-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG31.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.40 Caesarean section. </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0032"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 32</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.1 Severe maternal morbidity (eclampsia, renal failure, liver failure, HELLP syndrome, stroke ‐ IPD only)." data-id="CD004659-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG32.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.1 Severe maternal morbidity (eclampsia, renal failure, liver failure, HELLP syndrome, stroke ‐ IPD only). </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0033"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 33</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.29 Intraventricular haemorrhage." data-id="CD004659-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG33.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.29 Intraventricular haemorrhage. </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0034"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 34</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.30 Other neonatal bleed." data-id="CD004659-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG34.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.30 Other neonatal bleed. </p> </div> </div> </div> <div class="figure" id="CD004659-fig-0035"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 35</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.35 Admission to a special care baby unit." data-id="CD004659-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG35.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.35 Admission to a special care baby unit. </p> </div> </div> </div> <p>It was unclear whether there was a difference between treatment and control groups in the risk for the mother of <b>disseminated intravascular coagulation</b> (10,828 women; 9 trials; RR 0.32, 95% CI 0.01 to 7.57; <a href="./references#CD004659-fig-0058" title="">Analysis 5.3</a>), stroke (IPD trials only; 10,828 mothers; 9 trials; RR 2.99, 95% CI 0.12 to 73.40; <a href="./references#CD004659-fig-0059" title="">Analysis 5.4</a>), <b>renal failure</b> (IPD trials only; 16,502 mothers; 11 trials; RR 1.29, 95% CI 0.35 to 4.79; <a href="./references#CD004659-fig-0060" title="">Analysis 5.5</a>), <b>liver failure</b> (IPD trials only; 10838 women, 9 trials; not estimable due to no reported events; <a href="./references#CD004659-fig-0061" title="">Analysis 5.6</a>), pulmonary oedema (IPD trials only; 16,732 mothers, 12 trials; RR 0.84, 95% CI 0.37 to 1.89; <a href="./references#CD004659-fig-0062" title="">Analysis 5.7</a>), <b>eclampsia</b> (24,947 women, 17 trials; RR 1.03, 95% CI 0.66 to 1.60; <a href="./references#CD004659-fig-0093" title="">Analysis 5.38</a>), or <b>maternal death</b> (IPD trials only; 28,675 women, 18 trials; RR 1.75, 95% CI 0.51 to 5.96; <a href="./references#CD004659-fig-0094" title="">Analysis 5.39</a>). </p> <p>Two trials assessed the children in early childhood (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004659.pub2/references#CD004659-bbs2-0015" target="_blank">CLASP 1994</a>; <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004659.pub2/references#CD004659-bbs2-0034" target="_blank">Italy 1993</a>). In one, (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004659.pub2/references#CD004659-bbs2-0015" target="_blank">CLASP 1994</a>), no difference was apparent between treatment and control groups in any measure of health and development at 12 to 18 months. The other (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004659.pub2/references#CD004659-bbs2-0034" target="_blank">Italy 1993</a>) reported a higher risk of <b>gross and fine motor problems at 18 months</b> in treatment compared with control children (15/427 versus 26/361, RR 0.49, 95% CI 0.26 to 0.91), and there was also the possibility of a higher risk of <b>respiratory problems</b> in children of mothers who had received aspirin (56/427 versus 32/361; RR 1.48, 95% CI 0.98 to 2.23) (<a href="./references#CD004659-fig-0086" title="">Analysis 5.31</a>). These results should be interpreted with caution, however, as the trial was not placebo controlled and so assessment was unblinded, and 27% of children were lost to follow‐up. </p> </section> </section> </section> <section id="CD004659-sec-0135"> <h4 class="title">2. Antiplatelet agents versus placebo or no treatment for secondary prevention of pre‐eclampsia and its complications in women with gestational hypertension </h4> <section id="CD004659-sec-0136"> <h5 class="title">Primary outcomes</h5> <section id="CD004659-sec-0137"> <h6 class="title">Proteinuric pre‐eclampsia</h6> <p>Combined evidence from IPD and AD trials suggested that antiplatelet agents reduced the risk of pre‐eclampsia when administered to women who already have gestational hypertension (secondary prevention), compared with administration of placebo/no treatment (1813 women, 7 trials; average RR 0.67, 95% CI 0.47 to 0.95; <a href="./references#CD004659-fig-0097" title="">Analysis 6.2</a>). </p> </section> <section id="CD004659-sec-0138"> <h6 class="title">Any reported death: fetal, neonatal or before hospital discharge</h6> <p>In the seven trials with IPD available, there was evidence that antiplatelet agents may make little or no difference to fetal or neonatal death where mothers were treated who already had gestational hypertension (1950 women, 7 trials; RR 1.00, 95% CI 0.68 to 1.47; <a href="./references#CD004659-fig-0104" title="">Analysis 6.9</a>). In the two small AD trials, there appears to have been a reduction in the relative risk of any reported death (fetal, neonatal or infant) for the treatment group (260 women, 2 trials; RR 0.36, 95% CI 0.15 to 0.84; <a href="./references#CD004659-fig-0103" title="">Analysis 6.8</a>). </p> </section> <section id="CD004659-sec-0139"> <h6 class="title">Preterm birth</h6> <p>Administration of antiplatelet agents for secondary prevention appeared to slightly reduce the incidence of preterm birth, but the 95% just crossed the line of no effect (&lt; 37 weeks) (IPD and AD trials; 2070 women, 9 trials; RR 0.89, 95% CI 0.78 to 1.01; <a href="./references#CD004659-fig-0105" title="">Analysis 6.10</a>). </p> </section> <section id="CD004659-sec-0140"> <h6 class="title">Small‐for‐gestational age</h6> <p>It is unclear whether antiplatelet agents reduce the risk of babies being born small‐for‐gestational age when given to women for secondary prevention (1791 babies; 6 trials; average RR 0.76, 95% CI 0.54 to 1.09; <a href="./references#CD004659-fig-0106" title="">Analysis 6.11</a>). </p> </section> </section> <section id="CD004659-sec-0141"> <h5 class="title">Secondary outcomes</h5> <p>For secondary prevention, antiplatelet agents appeared to make little or no difference to the risk of: <b>caesarean section</b> (2327 women, 9 trials; RR 1.04, 95% CI 0.94 to 1.16; <a href="./references#CD004659-fig-0107" title="">Analysis 6.12</a>); <b>non‐spontaneous labour</b> (IPD trials only: RR 0.96, 95% CI 0.77 to 1.18; 1540 women; 5 trials; <a href="./references#CD004659-fig-0108" title="">Analysis 6.13</a>); <b>severe hypertension using trialists' definition</b> (IPD trials only; RR 0.94, 95% CI 0.83 to 1.07; 1834 mothers; 5 trials; <a href="./references#CD004659-fig-0099" title="">Analysis 6.4</a>); <b>pregnancy with severe adverse outcome</b> (IPD trials only; 1970 mothers, 8 trials; RR 0.95, 95% CI 0.84 to 1.06; <a href="./references#CD004659-fig-0114" title="">Analysis 6.19</a>); and they also appeared to make little difference to <b>gestation at birth</b> (IPD trials only: 1927 mothers, 8 trials; MD 0.15 weeks, 95% CI ‐0.12 to 0.41; <a href="./references#CD004659-fig-0115" title="">Analysis 6.20</a>). </p> <p>In terms of outcomes for the baby, the results suggested that antiplatelet agents are associated with a reduction in the risk of babies having <b>birthweight less than 2500g</b> (IPD and AD trials; 1966 babies, 9 trials; average RR 0.76, 95% CI 0.59 to 0.97; <a href="./references#CD004659-fig-0116" title="">Analysis 6.21</a>). However they make little or no difference to <b>admission to a special care baby unit</b> (IPD trials only; RR 0.97, 95% CI 0.86 to 1.10; 1910 babies, 6 trials; <a href="./references#CD004659-fig-0117" title="">Analysis 6.22</a>), while it is unclear whether they have an impact on the need for <b>assisted ventilation</b> (IPD trials only: 542 babies, 5 trials; RR 0.50, 95% CI 0.20 to 1.22; <a href="./references#CD004659-fig-0118" title="">Analysis 6.23</a>). </p> <p>It was unclear whether antiplatelet agents make a difference to secondary prevention of all the other secondary outcomes. In these cases the point estimates suggested a clinically important effect, but were accompanied by wide confidence intervals substantially crossing the line of no effect: <b>severe pre‐eclampsia</b> (1509 women; 3 trials; RR 0.78, 95% CI 0.48 to 1.26; <a href="./references#CD004659-fig-0096" title="">Analysis 6.1</a>), <b>gestation at onset proteinuria</b> (IPD trials only; 410 women, 2 trials; MD ‐1.05 weeks, 95% CI ‐3.70 to 1.59; <a href="./references#CD004659-fig-0102" title="">Analysis 6.7</a>), <b>antepartum haemorrhage</b> (IPD trials only; RR 1.11, 95% CI 0.75 to 1.64; 1606 women, 5 trials; <a href="./references#CD004659-fig-0109" title="">Analysis 6.14</a>), <b>postpartum haemorrhage &gt; 500 mL</b> (IPD trials only; 1573 women; 5 trials; RR 1.09, 95% CI 0.85 to 1.40; <a href="./references#CD004659-fig-0111" title="">Analysis 6.16</a>), <b>HELLP syndrome</b> (IPD trials only, not estimable due to no reported events; <a href="./references#CD004659-fig-0112" title="">Analysis 6.17</a>), <b>severe maternal morbidity</b> (IPD trials only: RR 0.72, 95% CI 0.14 to 3.61; 1483 women; 3 trials; <a href="./references#CD004659-fig-0113" title="">Analysis 6.18</a>) . The effects were also unclear for <b>eclampsia</b> (1743 women, 5 trials; RR 0.47, 95% CI 0.13 to 1.67; <a href="./references#CD004659-fig-0098" title="">Analysis 6.3</a>), and <b>placental abruption</b> (IPD trials only; 1606 women, 5 trials; RR 1.39, 95% CI 0.63 to 3.05; <a href="./references#CD004659-fig-0110" title="">Analysis 6.15</a>), probably due to there being very few events for both outcomes. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004659-sec-0142" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004659-sec-0142"></div> <section id="CD004659-sec-0143"> <h3 class="title" id="CD004659-sec-0143">Summary of main results</h3> <p>This review of randomised trials evaluating antiplatelet agents for prevention of pre‐eclampsia and its complications demonstrates that these agents, in particular low‐dose aspirin, have small‐to‐moderate benefits. For the first time, this update incorporates the individual participant data (IPD) analysis published by the PARIS collaborative group (<a href="./references#CD004659-bbs2-0211" title="AskieLM , DuleyL , Henderson‐SmartDJ , StewartLA . Antiplatelet agents for prevention of pre‐eclampsia: a meta‐analysis of individual patient data. Lancet2007;369:1791‐8. ">Askie 2007</a>). Methods for the two reviews have now been merged, and this Cochrane Review includes IPD wherever these are available. IPD are available from 36 trials including 34,514 women (80% of the total number of women included in this review). </p> <p>We found high‐quality evidence that the use of antiplatelet agents reduces the risk of pre‐eclampsia (where most women in the included trials were given low‐dose aspirin). This reduction in pre‐eclampsia is reflected in modest improvement in outcomes for the baby: antiplatelet agents slightly reduce the risk for preterm birth before 37 completed weeks, and they reduce fetal or neonatal deaths, and small‐for‐gestational‐age babies. For this Cochrane Review the outcome included any preterm birth before 37 weeks' gestation. A separate analysis using IPD for the 17 trials (28,797 women) that supplied data on whether onset of labour was spontaneous or indicated (induced or elective caesarean) in the PARIS dataset concluded that antiplatelet agents are associated with a reduction in spontaneous preterm birth (<a href="./references#CD004659-bbs2-0270" title="vanVlietEO , AskieLA , MolBW , OudijkMA . Antiplatelet agents and the prevention of spontaneous preterm birth: a systematic review and meta‐analysis. Obstetrics &amp; Gynecology2017;129(2):327‐36. ">van Vliet 2017</a>). The effect size of a 7% reduction was similar to that report here. </p> <p>There was a slight increase in postpartum blood loss of &gt; 500 mL associated with the use of antiplatelet agents. This result should be interpreted cautiously, however, given the well‐known difficulties of accurately estimating blood loss after birth, and because the outcome does not take into account mode of birth (for caesarean births, clinically important postpartum haemorrhage is usually considered to be more than 1000 mL). If true, this slight increase would lead to 9 more women having blood loss &gt; 500 mL per 1000 women giving birth, relative to an assumed baseline risk of 143 women per 1000. It should be noted that although the 95% confidence interval is narrow, it does include the possibility of no effect (1.00 to 1.12). Blood loss &gt; 500 mL is the traditional definition of postpartum haemorrhage, but in terms of clinical importance postpartum haemorrhage of 500 mL to 1000 mL is considered relatively minor, with 1001 mL to 2000 mL considered moderate loss and &gt; 2000 mL major postpartum haemorrhage. Hence the clinical relevance of this slight increase in minor postpartum haemorrhage is unclear. </p> <p>Exploratory analyses in the PARIS analysis found the overall results to be sensitive to even small changes in the cut‐off used to define postpartum blood loss. When the definition was changed from ‘greater than' to 'greater than or equal to' 500 mL, the change in definition had up to a four‐fold effect on the estimated effect size, and influenced statistical significance (<a href="./references#CD004659-bbs2-0211" title="AskieLM , DuleyL , Henderson‐SmartDJ , StewartLA . Antiplatelet agents for prevention of pre‐eclampsia: a meta‐analysis of individual patient data. Lancet2007;369:1791‐8. ">Askie 2007</a>). This underlines further the importance of interpreting the results for this outcome with caution. Data presented here are based on the pre‐specified definition for this Cochrane Review, which was ‘postpartum haemorrhage as defined in the trial’. </p> <p>Antiplatelet agents probably marginally increase the risk of placental abruption, whilst they make little or no difference to gestational hypertension. There was a 10% reduction in the overall risk of having a pregnancy with a serious adverse outcome (defined as pregnancy where the mother dies or develops pre‐eclampsia or if any baby is preterm, small‐for‐gestational age, or does not survive to discharge from hospital). </p> <p>The results for secondary prevention were less clear. Fewer trials involving a much smaller number of women reported on secondary prevention, compared with primary prevention. While the analyses suggested that antiplatelet agents probably lower the risk of proteinuric pre‐eclampsia for women with gestational hypertension, for other primary outcomes the results suggested either that antiplatelet agents may make little or no difference (preterm birth), or were too imprecise to support firm conclusions (fetal and neonatal death; small‐for‐gestational age). Overall, for secondary prevention, the available evidence did not consistently indicate that antiplatelet agents confer a benefit for women and their babies. </p> <p>The overall results of the review have not changed significantly after incorporation of IPD. Nevertheless, for several main outcomes IPD show more conservative estimates of the treatment effect than AD. It is not plausible that treatment effects really are bigger if IPD were not available. There are several possible explanations for this systematic difference between results based on IPD and AD. The first is that this is related to lower methodological quality, for trials which were eligible for the PARIS analysis, but for which IPD were not available (i.e. availability of IPD may be a marker for higher methodological quality). For example, a significant proportion of studies with only AD available were of uncertain risk of bias. Another possibility is publication bias; as shown in <a href="#CD004659-fig-0006">Figure 6</a>, smaller AD studies tended to report larger effects of antiplatelet agents for pre‐eclampsia, leading to a skewed funnel plot. However, the effects remain stable (whilst slightly more conservative) when only including IPD, with no indication of publication bias. Other possible explanations are that the difference in treatment effect is due to differences in the populations in the trials with IPD and those with AD, or a difference in dose of the intervention. For example, two thirds of the women in trials with AD were in trials evaluating the higher does (75 mg or more) of aspirin, compared with less that one third of the women in trials with IPD. As discussed below, trials with the higher dose tended to report a bigger effect. </p> <p>Incorporating IPD has allowed more accurate classification of risk for individual women included in many of the trials. This improves the precision of the subgroup analyses. For a small number of trials only AD are available, and so for these studies the subgroup analysis by baseline risk is classified at trial level. The differences between the subgroups by maternal risk were not significant, so any individual subgroup result should be interpreted with caution. Because of the different baseline levels, and slightly different risk reduction rate (albeit not significant), the results suggest seven fewer cases of pre‐eclampsia per 1000 low‐risk women, with a range from 12 fewer to one fewer, and 27 fewer cases per 1000 high‐risk women, with a range from 36 fewer to 16 fewer. </p> <p>It is possible that starting antiplatelet agents before implantation and trophoblast invasion are complete may increase the reduction in relative risk of pre‐eclampsia. In this review, data are presented by before and after 20 weeks' gestation, and we have added figures with the pre‐specified analyses by gestation at trial entry in the PARIS IPD dataset. There is no clear evidence that antiplatelet agents are more effective if given early in pregnancy (<a href="./references#CD004659-bbs2-0239" title="MeherS , DuleyL , HunterK , AskieL . Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta‐analysis. American Journal of Obstetrics and Gynecology2017;216:121‐8.e2. ">Meher 2017</a>). This differs from analysis based on AD only (<a href="./references#CD004659-bbs2-0216" title="BujoldE , RobergeS , LacasseY , Bureau M, AudibertF , MarcouxS , et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta‐analysis. Obstetrics and Gynecology2010;116:402‐14. ">Bujold 2010</a>; <a href="./references#CD004659-bbs2-0251" title="RobergeS , NicolaidesK , DemersS , HyettJ , ChailletN , BujoldE . The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta‐analysis. American Journal of Obstetrics and Gynecology2017;216:110‐20.e6. ">Roberge 2017</a>; <a href="./references#CD004659-bbs2-0275" title="XuTT , ZhouF , DengCY , HuangGQ , LiJK , WangXU . Low‐dose aspirin for preventing preeclampsia and its complications: a meta‐analysis. Journal of Clinical Hypertension2015;17(7):567‐73. ">Xu 2015</a>), as gestation at trial entry is based on data from individual women, rather than being determined at trial level and power is greater as far greater numbers of women are included in the analysis (<a href="./references#CD004659-bbs2-0264" title="TongS , MolBW , WalkerSP . Preventing preeclampsia with aspirin: does dose or timing matter?. American Journal of Obstetrics and Gynecology2017;216:95‐7. ">Tong 2017</a>). </p> <p>There is some evidence that a higher dose of aspirin (75 mg or more) may be more effective than a low dose (less than 75 mg), but this requires further evaluation (<a href="./references#CD004659-bbs2-0261" title="SeidlerAL , RayJ , AskieL . Optimal aspirin dosing for preeclampsia prevention. American Journal of Obstetrics and Gynecology2018;219(1):117‐8. ">Seidler 2018</a>), ideally in trials comparing alternative dose regimens. Higher doses may also have higher risk, and the current reassurance about safety applies only to lower doses. There was no significant difference between trials with placebo and without placebo. </p> <p>Although the subgroups presented in this review were all prespecified, their results should be interpreted with caution. As with all subgroup analyses, comparisons between subgroups are observational and so prone to all the limitations of observational analyses. Emphasis on the differences between subgroups is potentially misleading; provided the direction of effect is likely to be the same across subgroups, the best guide for clinical practice is the overall effect across all subgroups. </p> </section> <section id="CD004659-sec-0144"> <h3 class="title" id="CD004659-sec-0144">Overall completeness and applicability of evidence</h3> <p>It has been suggested that the promising early systematic reviews of antiplatelet therapy may have reflected publication bias (<a href="./references#CD004659-bbs2-0215" title="Broughton PipkinF , CrowtherC , deSwietM , DuleyL , JuddA , LilfordRJ , et al. Where next for prophylaxis against pre‐eclampsia?. British Journal of Obstetrics and Gynaecology1996;103:603‐7. ">Broughton Pipkin 1996</a>). Graphs (called funnel plots) of the effect size against sample size for each trial have been consistently asymmetric, suggesting that small negative trials may be missing. In this review, most of the small positive trials were published in the 1980s and early 1990s. It remains possible that small negative trials conducted at that time have still not been published. Interestingly, the recently conducted small studies added in this update are also largely positive. The funnel plot of the data for pre‐eclampsia therefore continues to be asymmetric (<a href="#CD004659-fig-0006">Figure 6</a>). However, as discussed above, this asymmetry largely disappears (while the effect remains stable) when only trials with IPD are included. The funnel plot for data on fetal deaths and neonatal deaths is more symmetric (<a href="#CD004659-fig-0009">Figure 9</a>). Publication bias is not the only cause of funnel plot asymmetry, and in this review it may also be due to differences in maternal characteristics between the small studies and the large trials. </p> </section> <section id="CD004659-sec-0145"> <h3 class="title" id="CD004659-sec-0145">Quality of the evidence</h3> <p>As summarised in the <a href="./full#CD004659-tbl-0001">summary of findings Table for the main comparison</a>, we assessed the quality of the evidence for the seven key outcomes using GRADE. Overall, the results for pre‐eclampsia, fetal or neonatal death, preterm birth, small‐for‐gestational age, and pregnancy with serious adverse outcome (composite including maternal death, baby death, pre‐eclampsia, small‐for‐gestational age, preterm birth) were rated as high‐quality evidence, while postpartum haemorrhage (&lt; 500 mL) and placental abruption were rated as moderate‐quality evidence. </p> <p>We did not downgrade any of the outcomes for risk of bias, since the majority of studies were of low risk of bias, and in particular, the large trials that had the largest influence on the results were low risk of bias for most domains. There was substantial clinical heterogeneity in the measurement of postpartum haemorrhage, due to the well‐known difficulties of accurately estimating blood loss after birth, we thus downgraded the quality of the evidence by one level for inconsistency. There was little heterogeneity for any of the other outcomes. Since the populations, settings, and treatments were representative for the question of interest for all rated outcomes, none of the outcomes were downgraded for indirectness. Generally, the results for our primary outcomes were precise due to the high number of included trials and women, whereas many trials did not report on our secondary outcomes so many of those results were imprecise. Of our primary outcomes, the only outcome that had to be downgraded for imprecision was placental abruption, where the confidence interval was wide due to the low number of events. </p> <p>For some of our secondary outcomes and for the subgroup analyses, future evidence may still change our conclusions. Similarly, the quality of the evidence for secondary prevention settings (i.e. women with gestational hypertension at trial entry) was not sufficient to derive final conclusions, and future research may change the conclusions drawn from this moderate‐ to‐low‐quality evidence. Also, the large number of subgroups and outcomes means that at least a few of the statistically significant results may merely reflect the play of chance (with a P value of 0.05, one in 20 can be expected to be positive, purely by chance). Where only a proportion of eligible trials reported a particular outcome and large numbers of women are missing, there is also the potential to be misled by bias. </p> </section> <section id="CD004659-sec-0146"> <h3 class="title" id="CD004659-sec-0146">Potential biases in the review process</h3> <p>This review is based on an extensive search strategy. It includes studies from a wide range of countries, and those published in languages other than English. Nevertheless, it remains possible that studies have been missed, but should that be the case they will be included in future updates once they become available. </p> </section> <section id="CD004659-sec-0147"> <h3 class="title" id="CD004659-sec-0147">Agreements and disagreements with other studies or reviews</h3> <p>Systematic reviews evaluating antiplatelet agents for prevention of pre‐eclampsia published elsewhere have focused on specific subgroups of women, for example, based on specific risk factors for developing pre‐eclampsia (<a href="./references#CD004659-bbs2-0219" title="CoomarasamyA , PapaioannouS , GeeH , KhanKS . Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta‐analysis. Obstetrics and Gynecology2001;98:861‐6. ">Coomarasamy 2001</a>; <a href="./references#CD004659-bbs2-0220" title="CoomarasamyA , HonestH , PapaioannouS , GeeH , KhanK . Aspirin for prevention of preeclampsia in women with historical risk factors : a systematic review. Obstetrics and Gynecology2003;101(6):1319–332. ">Coomarasamy 2003</a>; <a href="./references#CD004659-bbs2-0255" title="RossiAC , MullinPM . Prevention of pre‐eclampsia with low‐dose aspirin or vitamins C and E in women at high or low risk: a systematic review with meta‐analysis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2011;158:9‐16. ">Rossi 2011</a>; <a href="./references#CD004659-bbs2-0256" title="RuanoR , FontesRS , ZugaibM . Prevention of preeclampsia with low‐dose aspirin ‐‐ a systematic review and meta‐analysis of the main randomized controlled trials. Clinics2005;60:407–14. ">Ruano 2005</a>; <a href="./references#CD004659-bbs2-0266" title="TrivediNA . A meta‐analysis of low‐dose aspirin for prevention of preeclampsia. Journal of Postgraduate Medicine2011;57:91‐5. ">Trivedi 2011</a>), or gestation at randomisation (<a href="./references#CD004659-bbs2-0216" title="BujoldE , RobergeS , LacasseY , Bureau M, AudibertF , MarcouxS , et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta‐analysis. Obstetrics and Gynecology2010;116:402‐14. ">Bujold 2010</a>; <a href="./references#CD004659-bbs2-0250" title="RobergeS , NicolaidesKH , DemersS , VillaP , BujoldE . Prevention of perinatal death and adverse perinatal outcome using low‐dose aspirin: a meta‐analysis. Ultrasound in Obstetrics and Gynecology2013;41(5):491‐9. ">Roberge 2013</a>; <a href="./references#CD004659-bbs2-0275" title="XuTT , ZhouF , DengCY , HuangGQ , LiJK , WangXU . Low‐dose aspirin for preventing preeclampsia and its complications: a meta‐analysis. Journal of Clinical Hypertension2015;17(7):567‐73. ">Xu 2015</a>), or dose and gestation (<a href="./references#CD004659-bbs2-0251" title="RobergeS , NicolaidesK , DemersS , HyettJ , ChailletN , BujoldE . The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta‐analysis. American Journal of Obstetrics and Gynecology2017;216:110‐20.e6. ">Roberge 2017</a>). Most systematic reviews evaluating low‐dose aspirin for high‐risk and low‐risk women (mainly based on medical and obstetric history, obstetric factors, and ultrasound) show similar small‐to‐moderate benefits for prevention of pre‐eclampsia (<a href="./references#CD004659-bbs2-0238" title="MeherS , AlfirevicZ . Aspirin for pre‐eclampsia: beware of subgroup meta‐analysis. Ultrasound in Obstetrics and Gynecology2013;41(5):479‐85. ">Meher 2013</a>) as this Cochrane Review. Using IPD, the Paris Collaborative Group found no clear evidence that antiplatelet agents are any more or less effective in reducing the relative risk of pre‐eclampsia and its consequences for any particular subgroup of women (<a href="./references#CD004659-bbs2-0211" title="AskieLM , DuleyL , Henderson‐SmartDJ , StewartLA . Antiplatelet agents for prevention of pre‐eclampsia: a meta‐analysis of individual patient data. Lancet2007;369:1791‐8. ">Askie 2007</a>). Current research is focusing on biomarkers to identify women at risk of pre‐eclampsia (<a href="./references#CD004659-bbs2-0208" title="AkolekarR , SyngelakiA , PoonL , WrightD , NicolaidesKH . Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagnosis and Therapy2013;33(1):8‐15. ">Akolekar 2013</a>). Whether this will help identify women most likely to benefit from aspirin remains to be seen. </p> <p>Early and late administration of low‐dose aspirin has been compared in several systematic reviews (<a href="./references#CD004659-bbs2-0216" title="BujoldE , RobergeS , LacasseY , Bureau M, AudibertF , MarcouxS , et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta‐analysis. Obstetrics and Gynecology2010;116:402‐14. ">Bujold 2010</a>; <a href="./references#CD004659-bbs2-0250" title="RobergeS , NicolaidesKH , DemersS , VillaP , BujoldE . Prevention of perinatal death and adverse perinatal outcome using low‐dose aspirin: a meta‐analysis. Ultrasound in Obstetrics and Gynecology2013;41(5):491‐9. ">Roberge 2013</a>; <a href="./references#CD004659-bbs2-0275" title="XuTT , ZhouF , DengCY , HuangGQ , LiJK , WangXU . Low‐dose aspirin for preventing preeclampsia and its complications: a meta‐analysis. Journal of Clinical Hypertension2015;17(7):567‐73. ">Xu 2015</a>). All defined early administration as 16 weeks or earlier, and late as 16 weeks or after. The first review concluded that early administration of aspirin is associated with a reduction in pre‐eclampsia and intrauterine growth restriction, whereas late administration is not (<a href="./references#CD004659-bbs2-0216" title="BujoldE , RobergeS , LacasseY , Bureau M, AudibertF , MarcouxS , et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta‐analysis. Obstetrics and Gynecology2010;116:402‐14. ">Bujold 2010</a>). The second review concluded that early administration was associated with a reduction in perinatal death and other adverse perinatal outcomes (<a href="./references#CD004659-bbs2-0250" title="RobergeS , NicolaidesKH , DemersS , VillaP , BujoldE . Prevention of perinatal death and adverse perinatal outcome using low‐dose aspirin: a meta‐analysis. Ultrasound in Obstetrics and Gynecology2013;41(5):491‐9. ">Roberge 2013</a>). The third review concluded that early administration was associated with a greater reduction in pre‐eclampsia, perinatal death, fetal growth restriction, and preterm birth (<a href="./references#CD004659-bbs2-0275" title="XuTT , ZhouF , DengCY , HuangGQ , LiJK , WangXU . Low‐dose aspirin for preventing preeclampsia and its complications: a meta‐analysis. Journal of Clinical Hypertension2015;17(7):567‐73. ">Xu 2015</a>) In these trials women were not randomised to whether they had early or late administration of low‐dose aspirin. A fourth review looked at dose and gestation, and concluded there is a dose‐response effect (<a href="./references#CD004659-bbs2-0251" title="RobergeS , NicolaidesK , DemersS , HyettJ , ChailletN , BujoldE . The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta‐analysis. American Journal of Obstetrics and Gynecology2017;216:110‐20.e6. ">Roberge 2017</a>). As with all subgroup analyses, any comparison is therefore observational. Even if there is a statistically significant difference between subgroups, this may be due to confounding, rather than any real difference in effect. For example, in these reviews, the control event rate for pre‐eclampsia was high for women having early administration of low‐dose aspirin (8.1% in <a href="./references#CD004659-bbs2-0216" title="BujoldE , RobergeS , LacasseY , Bureau M, AudibertF , MarcouxS , et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta‐analysis. Obstetrics and Gynecology2010;116:402‐14. ">Bujold 2010</a> and 8.4% in <a href="./references#CD004659-bbs2-0250" title="RobergeS , NicolaidesKH , DemersS , VillaP , BujoldE . Prevention of perinatal death and adverse perinatal outcome using low‐dose aspirin: a meta‐analysis. Ultrasound in Obstetrics and Gynecology2013;41(5):491‐9. ">Roberge 2013</a>). Also, all three reviews were based on AD and so some women in the analyses will have been incorrectly classified. Our IPD analysis demonstrates no clear difference in the relative risk of pre‐eclampsia based on whether gestation at trial entry was before or after 16 weeks' gestation (<a href="./references#CD004659-bbs2-0239" title="MeherS , DuleyL , HunterK , AskieL . Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta‐analysis. American Journal of Obstetrics and Gynecology2017;216:121‐8.e2. ">Meher 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004659-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD004659-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004659-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph for the nine large trials: review authors' judgements about each risk of bias item presented as percentages across all studies." data-id="CD004659-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph for the nine large trials: review authors' judgements about each risk of bias item presented as percentages across all studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias, summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004659-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias, summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary for the nine large trials: review authors' judgements about each risk of bias item for each study" data-id="CD004659-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>'Risk of bias' summary for the nine large trials: review authors' judgements about each risk of bias item for each study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), outcome: 1.1 Pre‐eclampsia (IPD vs AD)." data-id="CD004659-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), outcome: 1.1 Pre‐eclampsia (IPD vs AD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Pre‐specified subgroup analysis using PARIS IPD" data-id="CD004659-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Pre‐specified subgroup analysis using PARIS IPD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Condensed version of (2 subgroups only) using PARIS IPD" data-id="CD004659-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Condensed version of <a href="#CD004659-fig-0004">Figure 4</a> (2 subgroups only) using PARIS IPD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (subgrouped by maternal risk), outcome: 1.4 Fetal and neonatal deaths." data-id="CD004659-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (subgrouped by maternal risk), outcome: 1.4 Fetal and neonatal deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.12 Fetal, neonatal, infant and childhood deaths (subgroups by time of death)." data-id="CD004659-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.12 Fetal, neonatal, infant and childhood deaths (subgroups by time of death). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), outcome: 1.3 Preterm birth (IPD vs AD)." data-id="CD004659-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), outcome: 1.3 Preterm birth (IPD vs AD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.15 Preterm birth (&lt; 34 weeks)." data-id="CD004659-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.15 Preterm birth (&lt; 34 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG13.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.16 Preterm birth (&lt; 32 weeks)." data-id="CD004659-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.16 Preterm birth (&lt; 32 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG14.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.17 Preterm birth (&lt; 28 weeks)." data-id="CD004659-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.17 Preterm birth (&lt; 28 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG15.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.18 Preterm birth (mutually exclusive subgroups) ‐ IPD only." data-id="CD004659-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.18 Preterm birth (mutually exclusive subgroups) ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG16.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), outcome: 1.4 Small‐for‐gestational age (IPD vs AD)." data-id="CD004659-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), outcome: 1.4 Small‐for‐gestational age (IPD vs AD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG17.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.19 Small‐for‐gestational age (subgrouped by severity) ‐ AD only, trial definition." data-id="CD004659-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 17</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.19 Small‐for‐gestational age (subgrouped by severity) ‐ AD only, trial definition. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG18.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.20 Any baby SGA &lt; 3rd centile or as reported ‐ IPD only." data-id="CD004659-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 18</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.20 Any baby SGA &lt; 3rd centile or as reported ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG19.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.8 Gestational hypertension using best available definition ‐ IPD only." data-id="CD004659-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 19</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.8 Gestational hypertension using best available definition ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG20.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.9 Gestational hypertension using trialists own definition ‐ IPD only." data-id="CD004659-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 20</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.9 Gestational hypertension using trialists own definition ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG21.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.10 Gestational hypertension PARIS definition ‐ IPD only." data-id="CD004659-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 21</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.10 Gestational hypertension PARIS definition ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG22.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.27 Postpartum haemorrhage &gt; 500 mL." data-id="CD004659-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 22</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.27 Postpartum haemorrhage &gt; 500 mL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG23.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.22 Pregnancy with SAO (including maternal death, baby death, PE, SGA, preterm) ‐ IPD only." data-id="CD004659-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 23</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.22 Pregnancy with SAO (including maternal death, baby death, PE, SGA, preterm) ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG24.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.26 Placental abruption." data-id="CD004659-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 24</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.26 Placental abruption. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG25.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.21 Birthweight &lt; 2500 g." data-id="CD004659-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 25</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.21 Birthweight &lt; 2500 g. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG26.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.28 Any baby required assisted ventilation." data-id="CD004659-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 26</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.28 Any baby required assisted ventilation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG27.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.24 Non spontaneous labour (induced labour or pre‐labour caesarean) ‐ IPD only." data-id="CD004659-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 27</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.24 Non spontaneous labour (induced labour or pre‐labour caesarean) ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG28.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.11 Gestation at onset proteinuria by best definition ‐ IPD only." data-id="CD004659-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 28</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.11 Gestation at onset proteinuria by best definition ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG29.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.14 Gestation at birth (mean, weeks)." data-id="CD004659-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 29</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.14 Gestation at birth (mean, weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG30.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.25 Antepartum haemorrhage ‐ IPD only." data-id="CD004659-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 30</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.25 Antepartum haemorrhage ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG31.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.40 Caesarean section." data-id="CD004659-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 31</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.40 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG32.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.1 Severe maternal morbidity (eclampsia, renal failure, liver failure, HELLP syndrome, stroke ‐ IPD only)." data-id="CD004659-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 32</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.1 Severe maternal morbidity (eclampsia, renal failure, liver failure, HELLP syndrome, stroke ‐ IPD only). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG33.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.29 Intraventricular haemorrhage." data-id="CD004659-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 33</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.29 Intraventricular haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG34.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.30 Other neonatal bleed." data-id="CD004659-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 34</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.30 Other neonatal bleed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-AFig-FIG35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-AFig-FIG35.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.35 Admission to a special care baby unit." data-id="CD004659-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 35</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), outcome: 5.35 Admission to a special care baby unit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-AFig-FIG35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 1 Pre‐eclampsia (IPD vs AD)." data-id="CD004659-fig-0036" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 1 Pre‐eclampsia (IPD vs AD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 2 Fetal death, neonatal death, or death before hospital discharge (IPD vs AD)." data-id="CD004659-fig-0037" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 2 Fetal death, neonatal death, or death before hospital discharge (IPD vs AD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 3 Preterm birth (IPD vs AD)." data-id="CD004659-fig-0038" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 3 Preterm birth (IPD vs AD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 4 Small‐for‐gestational age (IPD vs AD)." data-id="CD004659-fig-0039" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 4 Small‐for‐gestational age (IPD vs AD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 5 Pre‐eclampsia (IPD/AD combined)." data-id="CD004659-fig-0040" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 5 Pre‐eclampsia (IPD/AD combined). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 6 Fetal death, neonatal death, or death before hospital discharge (IPD/AD combined)." data-id="CD004659-fig-0041" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 6 Fetal death, neonatal death, or death before hospital discharge (IPD/AD combined). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 7 Preterm birth (IPD/AD combined)." data-id="CD004659-fig-0042" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 7 Preterm birth (IPD/AD combined). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 8 Small‐for‐gestational age (IPD/AD combined)." data-id="CD004659-fig-0043" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk), Outcome 8 Small‐for‐gestational age (IPD/AD combined). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by gestation at entry), Outcome 1 Pre‐eclampsia." data-id="CD004659-fig-0044" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by gestation at entry), Outcome 1 Pre‐eclampsia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by gestation at entry), Outcome 2 Fetal death, neonatal death, or death before hospital discharge." data-id="CD004659-fig-0045" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by gestation at entry), Outcome 2 Fetal death, neonatal death, or death before hospital discharge. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by gestation at entry), Outcome 3 Preterm birth." data-id="CD004659-fig-0046" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by gestation at entry), Outcome 3 Preterm birth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by gestation at entry), Outcome 4 Small‐for‐gestational age." data-id="CD004659-fig-0047" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by gestation at entry), Outcome 4 Small‐for‐gestational age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antiplatelet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by use of placebo), Outcome 1 Pre‐eclampsia." data-id="CD004659-fig-0048" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Antiplatelet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by use of placebo), Outcome 1 Pre‐eclampsia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antiplatelet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by use of placebo), Outcome 2 Fetal death, neonatal death, or death before hospital discharge." data-id="CD004659-fig-0049" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Antiplatelet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by use of placebo), Outcome 2 Fetal death, neonatal death, or death before hospital discharge. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antiplatelet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by use of placebo), Outcome 3 Preterm birth." data-id="CD004659-fig-0050" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Antiplatelet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by use of placebo), Outcome 3 Preterm birth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antiplatelet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by use of placebo), Outcome 4 Small‐for‐gestational age." data-id="CD004659-fig-0051" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Antiplatelet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by use of placebo), Outcome 4 Small‐for‐gestational age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antiplatet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by dose), Outcome 1 Pre‐eclampsia." data-id="CD004659-fig-0052" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Antiplatet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by dose), Outcome 1 Pre‐eclampsia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antiplatet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by dose), Outcome 2 Fetal death, neonatal death, or death before hospital discharge." data-id="CD004659-fig-0053" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Antiplatet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by dose), Outcome 2 Fetal death, neonatal death, or death before hospital discharge. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antiplatet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by dose), Outcome 3 Preterm birth." data-id="CD004659-fig-0054" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Antiplatet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by dose), Outcome 3 Preterm birth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antiplatet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by dose), Outcome 4 Small‐for‐gestational age." data-id="CD004659-fig-0055" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Antiplatet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by dose), Outcome 4 Small‐for‐gestational age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 1 Severe maternal morbidity (eclampsia, renal failure, liver failure, HELLP syndrome, stroke ‐ IPD only)." data-id="CD004659-fig-0056" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 1 Severe maternal morbidity (eclampsia, renal failure, liver failure, HELLP syndrome, stroke ‐ IPD only). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 2 HELLP syndrome." data-id="CD004659-fig-0057" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 2 HELLP syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 3 Disseminated intravascular coagulation ‐ IPD only." data-id="CD004659-fig-0058" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 3 Disseminated intravascular coagulation ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 4 Stroke ‐ IPD only." data-id="CD004659-fig-0059" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 4 Stroke ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 5 Renal failure ‐ IPD only." data-id="CD004659-fig-0060" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 5 Renal failure ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 6 Liver failure ‐ IPD only." data-id="CD004659-fig-0061" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 6 Liver failure ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 7 Pulmonary oedema ‐ IPD only." data-id="CD004659-fig-0062" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 7 Pulmonary oedema ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-08.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 8 Gestational hypertension using best available definition ‐ IPD only." data-id="CD004659-fig-0063" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 8 Gestational hypertension using best available definition ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-09.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 9 Gestational hypertension using trialists own definition ‐ IPD only." data-id="CD004659-fig-0064" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 9 Gestational hypertension using trialists own definition ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-10.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 10 Gestational hypertension PARIS definition ‐ IPD only." data-id="CD004659-fig-0065" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 10 Gestational hypertension PARIS definition ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-11.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 11 Gestation at onset proteinuria by best definition ‐ IPD only." data-id="CD004659-fig-0066" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 11 Gestation at onset proteinuria by best definition ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-12.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 12 Fetal, neonatal, infant and childhood deaths (subgroups by time of death)." data-id="CD004659-fig-0067" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 12 Fetal, neonatal, infant and childhood deaths (subgroups by time of death). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 13 Baby deaths after discharge from hospital ‐ AD only." data-id="CD004659-fig-0068" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 13 Baby deaths after discharge from hospital ‐ AD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-14.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 14 Gestation at birth (mean, weeks)." data-id="CD004659-fig-0069" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 14 Gestation at birth (mean, weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-15.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 15 Preterm birth (&lt; 34 weeks)." data-id="CD004659-fig-0070" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 15 Preterm birth (&lt; 34 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-16.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 16 Preterm birth (&lt; 32 weeks)." data-id="CD004659-fig-0071" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 16 Preterm birth (&lt; 32 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-17.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 17 Preterm birth (&lt; 28 weeks)." data-id="CD004659-fig-0072" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 17 Preterm birth (&lt; 28 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-18.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 18 Preterm birth (mutually exclusive subgroups) ‐ IPD only." data-id="CD004659-fig-0073" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 18 Preterm birth (mutually exclusive subgroups) ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-19.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 19 Small‐for‐gestational age (subgrouped by severity) ‐ AD only, trial definition." data-id="CD004659-fig-0074" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 19 Small‐for‐gestational age (subgrouped by severity) ‐ AD only, trial definition. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-20.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 20 Any baby SGA &lt; 3rd centile or as reported ‐ IPD only." data-id="CD004659-fig-0075" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.20</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 20 Any baby SGA &lt; 3rd centile or as reported ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-21.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 21 Birthweight &lt; 2500 g." data-id="CD004659-fig-0076" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.21</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 21 Birthweight &lt; 2500 g. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-22.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 22 Pregnancy with SAO (including maternal death, baby death, PE, SGA, preterm) ‐ IPD only." data-id="CD004659-fig-0077" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.22</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 22 Pregnancy with SAO (including maternal death, baby death, PE, SGA, preterm) ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 23 Hospital admission for the woman during pregnancy ‐ AD only." data-id="CD004659-fig-0078" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.23</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 23 Hospital admission for the woman during pregnancy ‐ AD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-24.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 24 Non spontaneous labour (induced labour or pre‐labour caesarean) ‐ IPD only." data-id="CD004659-fig-0079" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.24</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 24 Non spontaneous labour (induced labour or pre‐labour caesarean) ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-25.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 25 Antepartum haemorrhage ‐ IPD only." data-id="CD004659-fig-0080" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.25</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 25 Antepartum haemorrhage ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-26.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 26 Placental abruption." data-id="CD004659-fig-0081" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.26</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 26 Placental abruption. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-27.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 27 Postpartum haemorrhage &gt; 500 mL." data-id="CD004659-fig-0082" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.27</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 27 Postpartum haemorrhage &gt; 500 mL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-28.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 28 Any baby required assisted ventilation." data-id="CD004659-fig-0083" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.28</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 28 Any baby required assisted ventilation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-29.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 29 Intraventricular haemorrhage." data-id="CD004659-fig-0084" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.29</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 29 Intraventricular haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-30.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 30 Other neonatal bleed." data-id="CD004659-fig-0085" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.30</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 30 Other neonatal bleed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 31 Developmental problems at 18 months ‐ AD only." data-id="CD004659-fig-0086" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.31</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 31 Developmental problems at 18 months ‐ AD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 32 Behaviour problems at 18 months ‐ AD only." data-id="CD004659-fig-0087" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.32</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 32 Behaviour problems at 18 months ‐ AD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 33 Malformations at 18 months ‐ AD only." data-id="CD004659-fig-0088" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.33</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 33 Malformations at 18 months ‐ AD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 34 Growth at 18 months ‐ AD only." data-id="CD004659-fig-0089" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.34</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 34 Growth at 18 months ‐ AD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-35.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 35 Admission to a special care baby unit." data-id="CD004659-fig-0090" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.35</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 35 Admission to a special care baby unit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 36 Child admitted to hospital ‐ AD only." data-id="CD004659-fig-0091" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.36</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 36 Child admitted to hospital ‐ AD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 37 Non‐routine GP consultation for child ‐ AD only." data-id="CD004659-fig-0092" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.37</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 37 Non‐routine GP consultation for child ‐ AD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 38 Eclampsia." data-id="CD004659-fig-0093" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.38</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 38 Eclampsia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 39 Maternal death ‐ IPD only." data-id="CD004659-fig-0094" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.39</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 39 Maternal death ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-005-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-005-40.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 40 Caesarean section." data-id="CD004659-fig-0095" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.40</div> <div class="figure-caption"> <p>Comparison 5 Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes), Outcome 40 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-005-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 1 Severe pre‐eclampsia." data-id="CD004659-fig-0096" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 1 Severe pre‐eclampsia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 2 Pre‐eclampsia." data-id="CD004659-fig-0097" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 2 Pre‐eclampsia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 3 Eclampsia." data-id="CD004659-fig-0098" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 3 Eclampsia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 4 Severe hypertension using trialists own definition ‐ IPD only." data-id="CD004659-fig-0099" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 4 Severe hypertension using trialists own definition ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 5 Severe hypertension PARIS definition ‐ IPD only." data-id="CD004659-fig-0100" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 5 Severe hypertension PARIS definition ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 6 Severe hypertension using best available def ‐ IPD only." data-id="CD004659-fig-0101" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 6 Severe hypertension using best available def ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 7 Gestation at onset proteinuria by best definition ‐ IPD only." data-id="CD004659-fig-0102" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 7 Gestation at onset proteinuria by best definition ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 8 Fetal death, neonatal death, or death before hospital discharge ‐ AD only." data-id="CD004659-fig-0103" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 8 Fetal death, neonatal death, or death before hospital discharge ‐ AD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 9 Fetal and neonatal deaths ‐ IPD only." data-id="CD004659-fig-0104" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 9 Fetal and neonatal deaths ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 10 Preterm birth (&lt; 37 weeks)." data-id="CD004659-fig-0105" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 10 Preterm birth (&lt; 37 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 11 Small‐for‐gestational age." data-id="CD004659-fig-0106" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 11 Small‐for‐gestational age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 12 Caesarean section." data-id="CD004659-fig-0107" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 12 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 13 Non spontaneous labour IPD only." data-id="CD004659-fig-0108" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 13 Non spontaneous labour IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 14 Antepartum haemorrhage ‐ IPD only." data-id="CD004659-fig-0109" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 14 Antepartum haemorrhage ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 15 Placental abruption ‐ IPD only." data-id="CD004659-fig-0110" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 15 Placental abruption ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 16 Postpartum haemorrhage &gt; 500 mL ‐ IPD only." data-id="CD004659-fig-0111" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 16 Postpartum haemorrhage &gt; 500 mL ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 17 HELLP Syndrome ‐ IPD only." data-id="CD004659-fig-0112" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.17</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 17 HELLP Syndrome ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 18 Severe maternal morbidity ‐ IPD only." data-id="CD004659-fig-0113" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.18</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 18 Severe maternal morbidity ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 19 Pregnancy with SAO (including maternal death, baby death, PE, SGA, preterm) ‐ IPD only." data-id="CD004659-fig-0114" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.19</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 19 Pregnancy with SAO (including maternal death, baby death, PE, SGA, preterm) ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 20 Gestation at birth ‐ IPD only." data-id="CD004659-fig-0115" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.20</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 20 Gestation at birth ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 21 Birthweight &lt; 2500 g." data-id="CD004659-fig-0116" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.21</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 21 Birthweight &lt; 2500 g. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 22 Admission to a special care baby unit ‐ IPD only." data-id="CD004659-fig-0117" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.22</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 22 Admission to a special care baby unit ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004659-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/urn:x-wiley:14651858:media:CD004659:CD004659-CMP-006-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_t/tCD004659-CMP-006-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 23 Any baby required assisted ventilation ‐ IPD only." data-id="CD004659-fig-0118" src="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.23</div> <div class="figure-caption"> <p>Comparison 6 Antiplatelet agents versus placebo/no antiplatelet for secondary prevention, Outcome 23 Any baby required assisted ventilation ‐ IPD only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/media/CDSR/CD004659/image_n/nCD004659-CMP-006-23.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004659-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antiplatelet agents compared with no antiplatelet agents/placebo for pre‐eclampsia prevention</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> pregnant women <i>considered to be at risk of developing pre‐eclampsia</i> </p> <p><b>Settings:</b> maternity hospitals, recruitment usually in ante natal clinics </p> <p><b>Intervention:</b><i>any antiplatelet agent (such as low‐dose aspirin or dipyridamole)</i> </p> <p><b>Comparison:</b><i>no treatment with antiplatelet agents/placebo</i> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo/no antiplatelet</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antiplatelet agents</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proteinuric pre‐eclampsia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>16 fewer per 1000</b> </p> <p>(22 fewer to 11 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> </p> <p>(0.77 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36,716<br/> (60 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any reported infant death (fetal, neonatal, or before hospital discharge</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>5 fewer per 1000</b> </p> <p>(9 fewer to 1 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> </p> <p>(0.76 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,391</p> <p>(52 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Preterm birth</b> </p> <p>(before 37 weeks' gestation)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>175 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>16 fewer per 1000</b> </p> <p>(23 fewer to 9 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b> </p> <p>(0.87 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,212<br/> (47 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Small‐for‐gestational age</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>7 fewer per 1000</b> </p> <p>(11 fewer to 3 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b> </p> <p>(0.76 to 0.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,761<br/> (50 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy with serious adverse outcome (composite including maternal death, baby death, pre‐eclampsia, small‐for‐gestational age, preterm birth) ‐ only trials with individual participant data</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>197 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>20 fewer per 1000</b> </p> <p>(30 fewer to 8 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> </p> <p>(0.85 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,382</p> <p>(13 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Postpartum haemorrhage &gt; 500 mL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>9 more per 1000</b> </p> <p>(0 fewer to 19 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> </p> <p>(1.00 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,769</p> <p>(19 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placental abruption</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>2 more per 1000</b> </p> <p>(0 fewer to 4 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> </p> <p>(0.95 to 1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30,775</p> <p>(29 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Although this effect estimate did not meet our threshold for statistical heterogeneity (threshold i<sup>2</sup> = 40%), we downgraded due to concerns about clinical heterogeneity between trials in methods for measurement of blood loss (‐1). </p> <p>b. Wide confidence interval including appreciable harm for antiplatelet agents and crossing line of no effect (‐1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/full#CD004659-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004659-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pre‐eclampsia (IPD vs AD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.77, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low‐risk women (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.77, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Low‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.27, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Moderate‐risk women (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.47, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Moderate‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.42, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 High‐risk women (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11076</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.82, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 High‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.49, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Unclear‐/unspecified‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.03, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fetal death, neonatal death, or death before hospital discharge (IPD vs AD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.76, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Low‐risk women (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.79, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.07, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Moderate‐risk women (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.81, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Moderate‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.21, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 High‐risk women (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11076</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.66, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 High‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.40, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Unclear‐/unspecified‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.49, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Preterm birth (IPD vs AD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.87, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Low‐risk women (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.89, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Low‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.42, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Moderate‐risk women (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.94, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Moderate‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.60, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 High‐risk women (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11076</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 High‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.47, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Unclear‐/unspecified‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Small‐for‐gestational age (IPD vs AD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35761</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.76, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Low‐risk women (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.76, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Low‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.30, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Moderate‐risk women (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.70, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Moderate‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>883</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.33, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 High‐risk women (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11076</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 High‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.58, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Unclear‐/unspecified‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.16, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pre‐eclampsia (IPD/AD combined) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.77, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Low‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.75, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Moderate‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.49, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 High‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.77, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Unclear‐/unspecified‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.03, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Fetal death, neonatal death, or death before hospital discharge (IPD/AD combined) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.76, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Low‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.77, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Moderate‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>884</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.60, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 High‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.64, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Unclear‐/unspecified‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.49, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Preterm birth (IPD/AD combined) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.87, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Low‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.87, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Moderate‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.89, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 High‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.81, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Unclear‐/unspecified‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Small‐for‐gestational age (IPD/AD combined) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35761</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.76, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Low‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.76, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Moderate‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.55, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 High‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.73, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Unclear‐/unspecified‐risk women (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.16, 1.86]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by maternal risk)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004659-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by gestation at entry)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pre‐eclampsia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.77, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Entered into the study &lt; 20 weeks (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.78, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Entered into the study &lt; 20 weeks (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.51, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Entered into the study ≥ 20 weeks (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Entered into the study ≥ 20weeks (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.14, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Unclassified (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.04, 5.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Unclassified (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.41, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fetal death, neonatal death, or death before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.76, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Entered into the study &lt; 20 weeks (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Entered into the study &lt; 20 weeks (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.44, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Entered into the study ≥ 20 weeks (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.76, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Entered into the study ≥ 20 weeks (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.11, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Unclassified (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.04, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Unclassified (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.14, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Preterm birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.86, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Entered into the study &lt; 20 weeks (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.88, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Entered into the study &lt; 20 weeks (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.53, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Entered into the study ≥ 20 weeks (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.85, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Entered into the study ≥ 20 weeks (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.28, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Unclassified (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.1 [0.01, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Unclassified (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.07, 16.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Small‐for‐gestational age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35761</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.76, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Entered into the study &lt; 20 weeks (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.70, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Entered into the study &lt; 20 weeks (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.55, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Entered into the study ≥ 20 weeks (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.85, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Entered into the study ≥ 20 weeks (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.35, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Unclassified (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Unclassified (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.01, 5.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antiplatelet agents versus placebo/no antiplatelet for primary prevention (primary outcomes, subgroups by gestation at entry)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004659-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antiplatelet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by use of placebo)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pre‐eclampsia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36871</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.77, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Placebo (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.83, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Placebo (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.47, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 No placebo (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.37, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 No placebo (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.41, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fetal death, neonatal death, or death before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.76, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Placebo (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.79, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Placebo (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.47, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 No placebo (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.43, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 No placebo (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.23, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Unclear/unspecified (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.04, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Preterm birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.86, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Placebo (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.89, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Placebo (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.47, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 No placebo (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.72, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 No placebo (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.58, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Small‐for‐gestational age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.77, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Placebo (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Placebo (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.58, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 No Placebo (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.52, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 No placebo (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.33, 0.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antiplatelet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by use of placebo)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004659-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antiplatet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by dose)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pre‐eclampsia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.77, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 &lt; 75 mg aspirin (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.85, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 &lt; 75 mg aspirin (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.39, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 ≥ 75 mg aspirin (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.66, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 ≥ 75 mg aspirin (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.49, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Aspirin ≥ 75 mg + dipyridamole (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.26, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Aspirin ≥ 75 mg + dipyridamole (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.05, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fetal death, neonatal death, or death before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.76, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 &lt; 75 mg aspirin (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.78, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 &lt; 75 mg aspirin (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.45, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 ≥ 75 mg aspirin only (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.61, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 ≥ 75 mg aspirin only (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.34, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Aspirin ≥ 75 mg + dipyridamole (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.21, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Aspirin ≥ 75 mg + dipyridamole (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.23, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Preterm birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34778</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.78, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 &lt; 75 mg aspirin (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.89, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 &lt; 75 mg aspirin (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.08, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 ≥ 75 mg aspirin only (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.73, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 ≥ 75 mg aspirin only (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.50, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Aspirin ≥ 75 mg + dipyridamole (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.34, 5.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Aspirin ≥ 75 mg + dipyridamole (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.30, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Small‐for‐gestational age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.68, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 &lt; 75 mg aspirin (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.79, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 &lt; 75 mg aspirin (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.22, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 ≥ 75 mg aspirin only (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.53, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 ≥ 75 mg aspirin only (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.58, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Aspirin ≥ 75 mg + dipyridamole (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.40, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Aspirin ≥ 75 mg + dipyridamole (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.07, 1.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antiplatet agents versus placebo/no treatment for primary prevention (primary outcomes, subgroups by dose)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004659-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Severe maternal morbidity (eclampsia, renal failure, liver failure, HELLP syndrome, stroke ‐ IPD only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.72, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 HELLP syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.44, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.53, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.03, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Disseminated intravascular coagulation ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Stroke ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.99 [0.12, 73.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Renal failure ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.35, 4.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Liver failure ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Pulmonary oedema ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.37, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Gestational hypertension using best available definition ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.90, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Gestational hypertension using trialists own definition ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.89, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Gestational hypertension PARIS definition ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.90, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Gestation at onset proteinuria by best definition ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐1.40, 0.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Fetal, neonatal, infant and childhood deaths (subgroups by time of death) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Fetal death (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.80, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Fetal death (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>903</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.44, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Death in first week of life (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.68, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Death in first week of life (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.23, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 Late death (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.30, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 Perinatal deaths (AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.19, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.7 Death status unknown (IPD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.80, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Baby deaths after discharge from hospital ‐ AD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5886</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.21, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Deaths 8 days to 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.15, 18.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Hospital discharge ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.08, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Hospital discharge ‐ 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.20, 23.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Gestation at birth (mean, weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.04, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.05, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [‐0.33, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Preterm birth (&lt; 34 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.83, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.83, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.07, 16.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Preterm birth (&lt; 32 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.83, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [0.01, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Preterm birth (&lt; 28 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.74, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.74, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Preterm birth (mutually exclusive subgroups) ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 &lt; 28 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.74, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 28‐31 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.85, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 32‐33 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.73, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 34‐36 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5 Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.96, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Small‐for‐gestational age (subgrouped by severity) ‐ AD only, trial definition <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Birthweight &lt; 10th centile</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.75, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Birthweight &lt; 5th centile</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Birthweight &lt; 3rd centile</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.69, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 Definition not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.18, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Any baby SGA &lt; 3rd centile or as reported ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Birthweight &lt; 2500 g <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.88, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.88, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.25, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Pregnancy with SAO (including maternal death, baby death, PE, SGA, preterm) ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.85, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Hospital admission for the woman during pregnancy ‐ AD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.97, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Non spontaneous labour (induced labour or pre‐labour caesarean) ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.98, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Antepartum haemorrhage ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.92, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Placental abruption <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.95, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.95, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.26, 3.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Postpartum haemorrhage &gt; 500 mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [1.00, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [1.00, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.17, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Any baby required assisted ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.66, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.67, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 7.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Intraventricular haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.72, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.70, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.19, 22.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Other neonatal bleed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.75, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.75, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.13, 5.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Developmental problems at 18 months ‐ AD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 Poor gross motor function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.57, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2 Poor fine motor function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.84, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.3 Poor gross or fine motor function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.26, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.4 Respiratory problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.98, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.5 Poor language expression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.74, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.6 Poor language comprehension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.80, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.7 Language problems ‐ undefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.69, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.8 Hearing problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [0.10, 62.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.9 Sight problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.25, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Behaviour problems at 18 months ‐ AD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 Poor sleep pattern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Malformations at 18 months ‐ AD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.27, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Growth at 18 months ‐ AD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 Height &lt; 3rd or 10th centile</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.80, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 Weight &lt; 3rd or 10th centile</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.79, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Admission to a special care baby unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.91, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.91, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.60, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Child admitted to hospital ‐ AD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.2 At 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.89, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Non‐routine GP consultation for child ‐ AD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.99, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.2 At 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.96, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Eclampsia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.66, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.69, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 Maternal death ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.51, 5.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.99, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.99, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.72, 1.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Antiplatelet agents versus placebo/no antiplatelet for primary prevention (secondary outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004659-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Antiplatelet agents versus placebo/no antiplatelet for secondary prevention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Severe pre‐eclampsia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.48, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.48, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pre‐eclampsia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.47, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.60, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.23, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Eclampsia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.13, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.14, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Severe hypertension using trialists own definition ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Severe hypertension PARIS definition ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.51, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Severe hypertension using best available def ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Gestation at onset proteinuria by best definition ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.05 [‐3.70, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Fetal death, neonatal death, or death before hospital discharge ‐ AD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.15, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Fetal and neonatal deaths ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Preterm birth (&lt; 37 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.78, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.78, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Small‐for‐gestational age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.54, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.59, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.33, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.94, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.94, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.31, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Non spontaneous labour IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.77, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Antepartum haemorrhage ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.75, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Placental abruption ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.63, 3.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Postpartum haemorrhage &gt; 500 mL ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.85, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 HELLP Syndrome ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Severe maternal morbidity ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.14, 3.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Pregnancy with SAO (including maternal death, baby death, PE, SGA, preterm) ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Gestation at birth ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1927</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.12, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Birthweight &lt; 2500 g <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.59, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 IPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1866</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.66, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.09, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Admission to a special care baby unit ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.86, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Any baby required assisted ventilation ‐ IPD only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.20, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Antiplatelet agents versus placebo/no antiplatelet for secondary prevention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004659.pub3/references#CD004659-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004659.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD004659-note-0013">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD004659-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004659-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004659-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD004659-note-0017">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD004659-note-0015">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD004659-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD004659-note-0016">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD004659-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD004659-note-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004659-note-0012">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD004659-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004659\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004659\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004659\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004659\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004659\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004659.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004659.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004659.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004659.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004659.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714507564"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004659.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714507567"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004659.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d705bdd699377',t:'MTc0MDcxNDUwOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 